{"5231e9f8a2d263bddba5abe34ad434b730da0e33": [["Choi, H.R., Batsakis, J.G., Callender, D.L., Prieto, V.G., Luna, M.A., El-Naggar, A.K. (2002) .", [["Luna", "ANATOMY", 59, 63]]], ["Molecular analysis of chromosome 16q regions in dermal analogue tumors of salivary glands: a genetic link to dermal cylindroma?", [["chromosome 16q regions", "ANATOMY", 22, 44], ["dermal analogue tumors", "ANATOMY", 48, 70], ["salivary glands", "ANATOMY", 74, 89], ["dermal cylindroma", "ANATOMY", 109, 126], ["tumors", "DISEASE", 64, 70], ["dermal cylindroma", "DISEASE", 109, 126], ["chromosome 16q", "CELLULAR_COMPONENT", 22, 36], ["dermal analogue tumors", "CANCER", 48, 70], ["salivary glands", "ORGAN", 74, 89], ["dermal cylindroma", "CANCER", 109, 126], ["chromosome 16q regions", "DNA", 22, 44], ["Molecular analysis", "TEST", 0, 18], ["chromosome 16q regions", "PROBLEM", 22, 44], ["dermal analogue tumors of salivary glands", "PROBLEM", 48, 89], ["dermal cylindroma", "PROBLEM", 109, 126], ["dermal", "ANATOMY", 48, 54], ["analogue tumors", "OBSERVATION", 55, 70], ["salivary glands", "ANATOMY", 74, 89], ["cylindroma", "OBSERVATION", 116, 126]]], ["Spiradenocylindroma of the kidney: clinical and genetic findings suggesting a role of somatic mutation of the CYLD1 gene in the oncogenesis of an unusual renal neoplasm.", [["kidney", "ANATOMY", 27, 33], ["renal neoplasm", "ANATOMY", 154, 168], ["renal neoplasm", "DISEASE", 154, 168], ["kidney", "ORGAN", 27, 33], ["CYLD1", "GENE_OR_GENE_PRODUCT", 110, 115], ["renal neoplasm", "CANCER", 154, 168], ["CYLD1 gene", "DNA", 110, 120], ["somatic mutation", "PROBLEM", 86, 102], ["an unusual renal neoplasm", "PROBLEM", 143, 168], ["kidney", "ANATOMY", 27, 33], ["unusual", "OBSERVATION_MODIFIER", 146, 153], ["renal", "ANATOMY", 154, 159], ["neoplasm", "OBSERVATION", 160, 168]]]], "PMC7498918": [["Characteristic of At-Rest StateFigure 12.1, 12.2, 12.3, 12.4, 12.5, and 12.6 can be obtained with the analysis of the steady-state formula when particle concentration is uniformly distributed.", [["Rest StateFigure", "TEST", 21, 37], ["the analysis", "TEST", 98, 110], ["uniformly", "OBSERVATION_MODIFIER", 170, 179], ["distributed", "OBSERVATION_MODIFIER", 180, 191]]], ["During the plot of the curve, suppose 1 \u2212 S = 0.3, according to the test data at home and abroad.", [["the curve", "TEST", 19, 28], ["the test data", "TEST", 64, 77]]], ["Prefilters, placed before the final filter, contain primary filter (often the coarse filter, the efficiency for particles with diameter \u22650.5 \u03bcm is taken as 0.15) and intermediate filter (often the medium-efficiency filter, the efficiency for particles with diameter \u22650.5 \u03bcm is taken as 0.4).", [["Prefilters", "TREATMENT", 0, 10], ["the final filter", "TREATMENT", 26, 42], ["primary filter", "TREATMENT", 52, 66], ["the coarse filter", "TREATMENT", 74, 91], ["particles with diameter \u2265", "TREATMENT", 112, 137], ["intermediate filter", "TREATMENT", 166, 185], ["the medium-efficiency filter", "TREATMENT", 193, 221], ["diameter", "TEST", 257, 265], ["primary filter", "OBSERVATION", 52, 66], ["intermediate filter", "OBSERVATION", 166, 185], ["efficiency filter", "OBSERVATION", 204, 221]]], ["Its overall efficiency is about 0.5, which can be calculated through 1\u2212(1\u22120.15)(1\u22120.4) = 0.49.", [["overall", "OBSERVATION_MODIFIER", 4, 11], ["efficiency", "OBSERVATION_MODIFIER", 12, 22]]]], "fc2e04d73da71497d4bfa77786e469693caf6fb4": [["Reply by GattinoniFrom the Authors:The strong controversies raised by our 400-word letter (1) reflect the underlying conflict through which medical knowledge and science proceed: on one side, the need for evidence regarding a treatment, for which the apex is randomized trials, and on the other side, the need for evidence to elucidate the mechanisms of disease, for which the apex is the reproducible observation of phenomena and their interactions (2) .", [["a treatment", "TREATMENT", 224, 235], ["disease", "PROBLEM", 354, 361], ["phenomena", "PROBLEM", 417, 426], ["apex", "ANATOMY_MODIFIER", 251, 255], ["disease", "OBSERVATION", 354, 361], ["apex", "ANATOMY_MODIFIER", 377, 381], ["reproducible", "OBSERVATION_MODIFIER", 389, 401]]], ["As suggested by Fowler and colleagues, in a pandemic the real problem is to \"balance the tradeoff between learning (evidence of mechanism) and doing (evidence of response to treatment).\"", [["treatment", "TREATMENT", 174, 183]]], ["In any case, the process of acquiring knowledge about a novel disease or treatment ideally begins with observations (generating the hypothesis) and ends with the experiments (to prove or disprove the hypothesis).From the Authors:However, as evidenced by this correspondence, our scientific community seems divided into two broad categories: On one side are the believers that coronavirus disease (COVID-19) pneumonia must be defined as acute respiratory distress syndrome (ARDS)-and that is it.", [["respiratory", "ANATOMY", 442, 453], ["coronavirus disease", "DISEASE", 376, 395], ["pneumonia", "DISEASE", 407, 416], ["acute respiratory distress syndrome", "DISEASE", 436, 471], ["ARDS", "DISEASE", 473, 477], ["coronavirus", "ORGANISM", 376, 387], ["a novel disease", "PROBLEM", 54, 69], ["treatment", "TREATMENT", 73, 82], ["coronavirus disease", "PROBLEM", 376, 395], ["COVID", "TEST", 397, 402], ["pneumonia", "PROBLEM", 407, 416], ["acute respiratory distress syndrome", "PROBLEM", 436, 471], ["ARDS", "PROBLEM", 473, 477], ["coronavirus disease", "OBSERVATION", 376, 395], ["pneumonia", "OBSERVATION", 407, 416], ["acute", "OBSERVATION_MODIFIER", 436, 441], ["respiratory distress", "OBSERVATION", 442, 462]]], ["If so, we have nothing to learn about its respiratory treatment, just to do (lung-protective strategy, positive end-expiratory pressure [PEEP]-FI O2 table, etc.) (3) .", [["respiratory", "ANATOMY", 42, 53], ["lung", "ANATOMY", 77, 81], ["O2", "CHEMICAL", 146, 148], ["lung", "ORGAN", 77, 81], ["its respiratory treatment", "TREATMENT", 38, 63], ["lung-protective strategy", "TREATMENT", 77, 101], ["expiratory pressure", "TEST", 116, 135], ["PEEP", "TREATMENT", 137, 141], ["FI O2 table", "TREATMENT", 143, 154], ["lung", "ANATOMY", 77, 81]]], ["On the other side are the believers that COVID-19 is a specific disease that is somehow different from ARDS, with manifestations that may change over time.", [["ARDS", "DISEASE", 103, 107], ["COVID", "TEST", 41, 46], ["a specific disease", "PROBLEM", 53, 71], ["ARDS", "PROBLEM", 103, 107], ["disease", "OBSERVATION", 64, 71], ["different", "OBSERVATION_MODIFIER", 88, 97], ["ARDS", "OBSERVATION", 103, 107]]], ["As such, we have much to learn regarding mechanisms and what a \"lungprotective\" approach should mean in this setting (4) .From the Authors:It is from collecting hundreds of consistent observations (the sodespised anecdotes) from Milan, Parma, Turin, and London that we proposed two phenotypes, which represent the extremes of a broad spectrum of the respiratory manifestations in COVID-19 pneumonia: an early phenotype, L (i.e., the \"atypical\" ARDS of our letter, characterized by lower elastance, lower _ VA/ _ Q, lower recruitability, and lower lung weight), and a late phenotype, H (i.e., the typical ARDS, characterized by higher lung elastance, higher right-to-left shunt, higher recruitability, and higher lung weight) (5) .From the Authors:Dr. Bos, Dr. Maley and colleagues, and Dr. Haouzi and colleagues in their letters conclude, as do many others in our scientific community, that COVID-19 pneumonia is not atypical but fits the conventional ARDS definition and that higher respiratory system compliance (Crs) may be a normal finding in the syndrome.", [["respiratory", "ANATOMY", 350, 361], ["lung", "ANATOMY", 547, 551], ["lung", "ANATOMY", 634, 638], ["lung", "ANATOMY", 712, 716], ["respiratory system", "ANATOMY", 984, 1002], ["pneumonia", "DISEASE", 389, 398], ["ARDS", "DISEASE", 444, 448], ["ARDS", "DISEASE", 604, 608], ["pneumonia", "DISEASE", 900, 909], ["ARDS", "DISEASE", 952, 956], ["lung", "ORGAN", 547, 551], ["lung", "ORGAN", 634, 638], ["lung", "ORGAN", 712, 716], ["COVID-19", "ORGANISM", 891, 899], ["a \"lungprotective\" approach", "TREATMENT", 61, 88], ["the respiratory manifestations", "PROBLEM", 346, 376], ["COVID", "TEST", 380, 385], ["pneumonia", "PROBLEM", 389, 398], ["an early phenotype", "PROBLEM", 400, 418], ["lower elastance, lower _ VA/ _ Q", "PROBLEM", 481, 513], ["lower recruitability", "PROBLEM", 515, 535], ["lower lung weight)", "PROBLEM", 541, 559], ["a late phenotype", "PROBLEM", 565, 581], ["the typical ARDS", "PROBLEM", 592, 608], ["higher lung elastance", "PROBLEM", 627, 648], ["higher recruitability", "PROBLEM", 678, 699], ["pneumonia", "PROBLEM", 900, 909], ["the conventional ARDS definition", "PROBLEM", 935, 967], ["higher respiratory system compliance", "PROBLEM", 977, 1013], ["the syndrome", "PROBLEM", 1047, 1059], ["respiratory manifestations", "OBSERVATION", 350, 376], ["pneumonia", "OBSERVATION", 389, 398], ["early", "OBSERVATION_MODIFIER", 403, 408], ["phenotype", "OBSERVATION", 409, 418], ["ARDS", "OBSERVATION", 444, 448], ["lower elastance", "OBSERVATION_MODIFIER", 481, 496], ["lower", "ANATOMY_MODIFIER", 498, 503], ["lower", "ANATOMY_MODIFIER", 541, 546], ["lung", "ANATOMY", 547, 551], ["ARDS", "OBSERVATION", 604, 608], ["lung", "ANATOMY", 634, 638], ["elastance", "OBSERVATION", 639, 648], ["right", "ANATOMY_MODIFIER", 657, 662], ["left", "ANATOMY_MODIFIER", 666, 670], ["shunt", "OBSERVATION", 671, 676], ["higher", "OBSERVATION_MODIFIER", 678, 684], ["lung", "ANATOMY", 712, 716], ["pneumonia", "OBSERVATION", 900, 909], ["ARDS", "OBSERVATION", 952, 956], ["normal", "OBSERVATION", 1029, 1035]]], ["Dr. Bos, in particular, reports a \"striking similarity\" between the common presentation of patients with severe COVID-19 pneumonia and the ARDS originally described by Ashbaugh in 1967, namely, \"acute onset of tachypnea, hypoxemia and loss of compliance.\"", [["COVID", "DISEASE", 112, 117], ["pneumonia", "DISEASE", 121, 130], ["ARDS", "DISEASE", 139, 143], ["tachypnea", "DISEASE", 210, 219], ["hypoxemia", "DISEASE", 221, 230], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["severe COVID-19 pneumonia", "PROBLEM", 105, 130], ["the ARDS", "PROBLEM", 135, 143], ["tachypnea", "PROBLEM", 210, 219], ["hypoxemia", "PROBLEM", 221, 230], ["loss of compliance", "PROBLEM", 235, 253], ["pneumonia", "OBSERVATION", 121, 130], ["ARDS", "OBSERVATION", 139, 143], ["acute", "OBSERVATION_MODIFIER", 195, 200], ["tachypnea", "OBSERVATION", 210, 219], ["hypoxemia", "OBSERVATION", 221, 230]]], ["Actually, the L patients presenting to the hospital are in 50% of the cases eupneic, with a respiratory rate of approximately 20 breaths/min (approximately 40 breaths/min in the Ashbaugh paper [6] ) with near a normal Crs of .50 ml/cm H 2 O (,20 ml/cm H 2 in Ashbaugh [6] ).From the Authors:Maley and colleagues suggest that our small cohort (16 patients with a mean Crs of 50.", [["respiratory", "ANATOMY", 92, 103], ["eupneic", "DISEASE", 76, 83], ["H 2 O", "CHEMICAL", 235, 240], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 346, 354], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 346, 354], ["a respiratory rate", "TEST", 90, 108], ["a mean Crs", "TEST", 360, 370], ["small", "OBSERVATION_MODIFIER", 329, 334]]], ["Because the disease is the same all around the world, the observations also should be similar.", [["the disease", "PROBLEM", 8, 19], ["disease", "OBSERVATION", 12, 19]]], ["Actually, we believe that the apparent contradictory results stem from the time of observation, with type L being more likely early on and type H being more likely in the late phase.", [["late phase", "OBSERVATION_MODIFIER", 171, 181]]], ["We suspect that many ICUs are treating patients at a more advanced H stage.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47]]], ["The pivotal role of time is demonstrated in Figure 1 , in which we show, in a series of 28 patients, that Crs, measured at 5 cm H 2 O of PEEP is a function of the days elapsed from the initial symptoms ( Figure 1A) , regardless the venous admixture ( Figure 1B) .From the Authors:The striking feature of the COVID-19 pneumonia in the L state is not the Crs per se but the remarkable hypoxemia associated with a lung gas volume far greater than what is found in the ARDS \"baby lung.\"", [["venous", "ANATOMY", 232, 238], ["lung", "ANATOMY", 411, 415], ["lung", "ANATOMY", 476, 480], ["pneumonia", "DISEASE", 317, 326], ["hypoxemia", "DISEASE", 383, 392], ["ARDS", "DISEASE", 465, 469], ["patients", "ORGANISM", 91, 99], ["Crs", "GENE_OR_GENE_PRODUCT", 106, 109], ["venous", "MULTI-TISSUE_STRUCTURE", 232, 238], ["COVID-19", "ORGANISM", 308, 316], ["lung", "ORGAN", 411, 415], ["lung", "ORGAN", 476, 480], ["patients", "SPECIES", 91, 99], ["Crs", "TEST", 106, 109], ["PEEP", "TREATMENT", 137, 141], ["the initial symptoms", "PROBLEM", 181, 201], ["the venous admixture", "TEST", 228, 248], ["the COVID", "TEST", 304, 313], ["pneumonia", "PROBLEM", 317, 326], ["the remarkable hypoxemia", "PROBLEM", 368, 392], ["a lung gas volume", "TEST", 409, 426], ["venous", "ANATOMY", 232, 238], ["pneumonia", "OBSERVATION", 317, 326], ["L", "ANATOMY_MODIFIER", 334, 335], ["remarkable", "OBSERVATION_MODIFIER", 372, 382], ["hypoxemia", "OBSERVATION", 383, 392], ["lung", "ANATOMY", 411, 415], ["gas volume", "OBSERVATION", 416, 426], ["ARDS", "OBSERVATION", 465, 469], ["lung", "ANATOMY", 476, 480]]], ["Because the gas and ventilation side are relatively preserved, the hypoxemia must primarily derive from the perfusion side (7) .", [["hypoxemia", "DISEASE", 67, 76], ["the gas", "TEST", 8, 15], ["the hypoxemia", "PROBLEM", 63, 76], ["gas", "OBSERVATION", 12, 15], ["relatively", "OBSERVATION_MODIFIER", 41, 51], ["preserved", "OBSERVATION", 52, 61], ["hypoxemia", "OBSERVATION", 67, 76]]], ["Indeed, a growing number of observations show endothelial involvement (8) , which initiates hypercoagulability (9) , and the lung perfusion dysregulation that causes severe hypoxemia because of _ VA/ _ Q mismatch.", [["endothelial", "ANATOMY", 46, 57], ["lung", "ANATOMY", 125, 129], ["hypercoagulability", "DISEASE", 92, 110], ["hypoxemia", "DISEASE", 173, 182], ["endothelial", "CELL", 46, 57], ["lung", "ORGAN", 125, 129], ["endothelial involvement", "PROBLEM", 46, 69], ["hypercoagulability", "PROBLEM", 92, 110], ["the lung perfusion dysregulation", "PROBLEM", 121, 153], ["severe hypoxemia", "PROBLEM", 166, 182], ["_ VA/ _ Q mismatch", "PROBLEM", 194, 212], ["endothelial", "ANATOMY", 46, 57], ["hypercoagulability", "OBSERVATION", 92, 110], ["lung", "ANATOMY", 125, 129], ["perfusion dysregulation", "OBSERVATION", 130, 153], ["severe", "OBSERVATION_MODIFIER", 166, 172], ["hypoxemia", "OBSERVATION", 173, 182], ["mismatch", "OBSERVATION", 204, 212]]], ["However, as pointed out by Bhatia and Mohammed, microthrombosis are likely part of this phenomenon.", [["microthrombosis", "DISEASE", 48, 63], ["microthrombosis", "PROBLEM", 48, 63], ["this phenomenon", "PROBLEM", 83, 98], ["microthrombosis", "OBSERVATION", 48, 63], ["likely part", "UNCERTAINTY", 68, 79], ["phenomenon", "OBSERVATION", 88, 98]]], ["In this context, Hedenstierna and colleagues suggested that inhaled nitric oxide could be of interest to correct hypoxemia.", [["nitric oxide", "CHEMICAL", 68, 80], ["hypoxemia", "DISEASE", 113, 122], ["nitric oxide", "CHEMICAL", 68, 80], ["inhaled nitric oxide", "SIMPLE_CHEMICAL", 60, 80], ["inhaled nitric oxide", "TREATMENT", 60, 80], ["hypoxemia", "PROBLEM", 113, 122], ["hypoxemia", "OBSERVATION", 113, 122]]], ["This is rational and certainly possible, but only further observations may tell us the value of inhaled nitric oxide in the different stages of the disease.", [["nitric oxide", "CHEMICAL", 104, 116], ["nitric oxide", "CHEMICAL", 104, 116], ["nitric oxide", "SIMPLE_CHEMICAL", 104, 116], ["inhaled nitric oxide", "TREATMENT", 96, 116], ["the disease", "PROBLEM", 144, 155], ["disease", "OBSERVATION", 148, 155]]], ["Given that the hypoxemia is mainly determined by a pathology on the endothelial side of the alveolar membrane, the use of exogenous surfactant suggested by Koumbourlis and Motoyama lacks physiological rationale.From the Authors:Thus, so far, we have learned that COVID-19 is a systemic disease in which the viral assault is primarily focused on the endothelium, which accounts for both the pulmonary vascular dysregulation and the hypercoagulable state.", [["endothelial", "ANATOMY", 68, 79], ["alveolar membrane", "ANATOMY", 92, 109], ["endothelium", "ANATOMY", 349, 360], ["pulmonary vascular", "ANATOMY", 390, 408], ["hypoxemia", "DISEASE", 15, 24], ["endothelial", "CELLULAR_COMPONENT", 68, 79], ["alveolar membrane", "MULTI-TISSUE_STRUCTURE", 92, 109], ["Koumbourlis", "SIMPLE_CHEMICAL", 156, 167], ["COVID-19", "CELL", 263, 271], ["endothelium", "TISSUE", 349, 360], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 390, 408], ["the hypoxemia", "PROBLEM", 11, 24], ["exogenous surfactant", "TREATMENT", 122, 142], ["COVID", "TEST", 263, 268], ["a systemic disease", "PROBLEM", 275, 293], ["the viral assault", "PROBLEM", 303, 320], ["the pulmonary vascular dysregulation", "PROBLEM", 386, 422], ["the hypercoagulable state", "PROBLEM", 427, 452], ["hypoxemia", "OBSERVATION", 15, 24], ["pathology", "OBSERVATION", 51, 60], ["endothelial", "ANATOMY_MODIFIER", 68, 79], ["alveolar membrane", "ANATOMY", 92, 109], ["systemic", "OBSERVATION_MODIFIER", 277, 285], ["disease", "OBSERVATION", 286, 293], ["viral assault", "OBSERVATION", 307, 320], ["endothelium", "ANATOMY", 349, 360], ["pulmonary vascular", "ANATOMY", 390, 408], ["dysregulation", "OBSERVATION", 409, 422], ["hypercoagulable state", "OBSERVATION", 431, 452]]], ["Fowler and colleagues, recognizing the difficulties of promptly organizing randomized controlled trials, propose a direct acyclic graph to evaluate the hypothetical risks and benefits of conventional therapies for the two extreme phenotypes.", [["a direct acyclic graph", "TREATMENT", 113, 135], ["conventional therapies", "TREATMENT", 187, 209], ["the two extreme phenotypes", "PROBLEM", 214, 240]]], ["In the meantime, how should we manage type L patients?", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["The transition from L to H status, in which the ARDS criteria and therapies fully apply, may be due both to the natural course of the disease and to the patient self-induced lung injury (10) .", [["lung", "ANATOMY", 174, 178], ["ARDS", "DISEASE", 48, 52], ["lung injury", "DISEASE", 174, 185], ["patient", "ORGANISM", 153, 160], ["lung", "ORGAN", 174, 178], ["patient", "SPECIES", 153, 160], ["the ARDS criteria", "TEST", 44, 61], ["therapies", "TREATMENT", 66, 75], ["the disease", "PROBLEM", 130, 141], ["lung injury", "PROBLEM", 174, 185], ["ARDS", "OBSERVATION", 48, 52], ["disease", "OBSERVATION", 134, 141], ["lung", "ANATOMY", 174, 178], ["injury", "OBSERVATION", 179, 185]]], ["There is little that can be done to alleviate the first factor, but we can certainly intervene to prevent patient self-induced lung injury.", [["lung", "ANATOMY", 127, 131], ["lung injury", "DISEASE", 127, 138], ["patient", "ORGANISM", 106, 113], ["lung", "ORGAN", 127, 131], ["patient", "SPECIES", 106, 113], ["patient self-induced lung injury", "PROBLEM", 106, 138], ["lung", "ANATOMY", 127, 131], ["injury", "OBSERVATION", 132, 138]]], ["If, despite noninvasive support, the patient continues to make vigorous inspiratory efforts, we believe that mechanical ventilation should be applied without delay.", [["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44], ["noninvasive support", "TREATMENT", 12, 31], ["mechanical ventilation", "TREATMENT", 109, 131], ["delay", "PROBLEM", 158, 163], ["mechanical ventilation", "OBSERVATION", 109, 131]]], ["During the mechanical ventilation of these early phase L patients, higher PEEP is not advisable despite the severe hypoxemia because recruitability is relatively low, the lung is already full of gas, and the consequences on hemodynamics may be remarkable.", [["lung", "ANATOMY", 171, 175], ["hypoxemia", "DISEASE", 115, 124], ["patients", "ORGANISM", 57, 65], ["lung", "ORGAN", 171, 175], ["patients", "SPECIES", 57, 65], ["the mechanical ventilation", "TREATMENT", 7, 33], ["higher PEEP", "TREATMENT", 67, 78], ["the severe hypoxemia", "PROBLEM", 104, 124], ["recruitability", "PROBLEM", 133, 147], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["hypoxemia", "OBSERVATION", 115, 124], ["relatively", "OBSERVATION_MODIFIER", 151, 161], ["low", "OBSERVATION_MODIFIER", 162, 165], ["lung", "ANATOMY", 171, 175], ["gas", "OBSERVATION", 195, 198]]], ["We also proposed in these L patients a VT higher than 6 ml/kg, provoking a strong disagreement by Maley and colleagues, for whom the conventionally low VT ventilation is the precise strategy for gentle lung ventilation.", [["lung", "ANATOMY", 202, 206], ["patients", "ORGANISM", 28, 36], ["lung", "ORGAN", 202, 206], ["patients", "SPECIES", 28, 36], ["the conventionally low VT ventilation", "TREATMENT", 129, 166], ["gentle lung ventilation", "TREATMENT", 195, 218], ["lung", "ANATOMY", 202, 206], ["ventilation", "OBSERVATION", 207, 218]]], ["However, in those patients with higher Crs, the tradeoff is between possible ventilator-induced lung injury and possible hypoventilation, with an increased need for sedation and risk of atelectasis.", [["lung", "ANATOMY", 96, 100], ["lung injury", "DISEASE", 96, 107], ["hypoventilation", "DISEASE", 121, 136], ["atelectasis", "DISEASE", 186, 197], ["patients", "ORGANISM", 18, 26], ["lung", "ORGAN", 96, 100], ["patients", "SPECIES", 18, 26], ["higher Crs", "PROBLEM", 32, 42], ["ventilator", "TREATMENT", 77, 87], ["lung injury", "PROBLEM", 96, 107], ["hypoventilation", "PROBLEM", 121, 136], ["sedation", "TREATMENT", 165, 173], ["atelectasis", "PROBLEM", 186, 197], ["lung", "ANATOMY", 96, 100], ["injury", "OBSERVATION", 101, 107], ["possible", "UNCERTAINTY", 112, 120], ["hypoventilation", "OBSERVATION", 121, 136], ["increased", "OBSERVATION_MODIFIER", 146, 155], ["atelectasis", "OBSERVATION", 186, 197]]], ["We believe that in the L patients the risk of ventilatorinduced lung injury is minimized, as plateau, driving pressure, and mechanical power are far from their conventionally accepted thresholds.", [["lung", "ANATOMY", 64, 68], ["lung injury", "DISEASE", 64, 75], ["patients", "ORGANISM", 25, 33], ["lung", "ORGAN", 64, 68], ["patients", "SPECIES", 25, 33], ["ventilatorinduced lung injury", "PROBLEM", 46, 75], ["driving pressure", "TREATMENT", 102, 118], ["mechanical power", "TREATMENT", 124, 140], ["lung", "ANATOMY", 64, 68], ["injury", "OBSERVATION", 69, 75]]], ["In addition, we would like to respectfully remind our correspondents that in three large randomized controlled trials, no differences were found between patients treated with 7.1 ml/kg versus 10.3 ml/kg ideal body weight (IBW) (11), 7.2 ml/kg versus 10.8 ml/kg IBW (12), 7.3 ml/kg versus 10.2 ml/kg IBW (13) .From the Authors:ARDS is of fundamental importance in the ICU community, which developed in parallel to the understanding of the syndrome (14) .", [["body", "ANATOMY", 209, 213], ["ARDS", "DISEASE", 326, 330], ["patients", "ORGANISM", 153, 161], ["body", "ORGANISM_SUBDIVISION", 209, 213], ["patients", "SPECIES", 153, 161], ["ARDS", "PROBLEM", 326, 330], ["the syndrome", "PROBLEM", 434, 446], ["ARDS", "OBSERVATION", 326, 330]]], ["Many people have argued that the term \"ARDS\" is too generic because it encompasses too many conditions and etiologies to have any credible diagnostic and prognostic validity.", [["ARDS", "DISEASE", 39, 43], ["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11], ["ARDS", "PROBLEM", 39, 43]]], ["It is therefore ironic to see how many try to turn strongly in favor of preserving the diagnosis of ARDS in COVID-19 disease, particularly because COVID-19 is a single-etiology disease (unlike ARDS), and the ventilatory management is independent from the degree of hypoxemia (unlike ARDS).", [["ARDS", "DISEASE", 100, 104], ["ARDS", "DISEASE", 193, 197], ["hypoxemia", "DISEASE", 265, 274], ["ARDS", "DISEASE", 283, 287], ["COVID-19", "CANCER", 108, 116], ["ARDS in COVID-19 disease", "PROBLEM", 100, 124], ["COVID", "TEST", 147, 152], ["a single-etiology disease", "PROBLEM", 159, 184], ["ARDS", "PROBLEM", 193, 197], ["the ventilatory management", "TREATMENT", 204, 230], ["hypoxemia", "PROBLEM", 265, 274], ["ARDS", "PROBLEM", 283, 287], ["ARDS", "OBSERVATION", 100, 104], ["ARDS", "OBSERVATION", 193, 197], ["ventilatory management", "OBSERVATION", 208, 230], ["hypoxemia", "OBSERVATION", 265, 274], ["ARDS", "OBSERVATION", 283, 287]]], ["Standard ARDS treatment in such cases should be deeply reconsidered, taking also in account that the mortality rate in different ICUs around the world ranges from 10% to 90% (personal communications).", [["ARDS", "DISEASE", 9, 13], ["Standard ARDS treatment", "TREATMENT", 0, 23], ["the mortality rate", "TEST", 97, 115], ["ARDS", "OBSERVATION", 9, 13]]], ["Because the disease is the same, this disparity underlines the impact of treatment. n", [["the disease", "PROBLEM", 8, 19], ["treatment", "TREATMENT", 73, 82], ["disease", "OBSERVATION", 12, 19]]]], "PMC7408563": [], "28369dd227b442c7387ce6901bbc4b5d11b7733c": [["IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) initially spread widely in China, then in Italy, and, now in other parts of the world, causing coronavirus disease 2019 (COVID-19) [1] .", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["SARS-CoV-2", "CHEMICAL", 61, 71], ["coronavirus disease", "DISEASE", 168, 187], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-CoV-2", "ORGANISM", 61, 71], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2", "SPECIES", 61, 71], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["SARS", "TEST", 61, 65], ["coronavirus disease", "PROBLEM", 168, 187], ["COVID", "TEST", 194, 199], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["coronavirus disease", "OBSERVATION", 168, 187]]], ["SARS-CoV-2 is the novel coronavirus that causes the alarming pandemic of COVID-19 since February 2020 [2] .", [["SARS", "DISEASE", 0, 4], ["coronavirus", "DISEASE", 24, 35], ["SARS-CoV-2", "ORGANISM", 0, 10], ["coronavirus", "ORGANISM", 24, 35], ["coronavirus", "SPECIES", 24, 35], ["SARS-CoV-2", "SPECIES", 0, 10], ["the novel coronavirus", "PROBLEM", 14, 35]]], ["While the novel coronaviruses (SARS-CoV-2) have gained enormous attention and grave concern as a consequence of the current worldwide COVID-19 pandemic situation, other known human coronaviruses, beta coronaviruses (SARS-CoV, MERS, OC43, HKU1) and alpha coronaviruses (229E, NL63), historically, caused a significant level of public-health concerns and resulted in severe respiratory syndrome for the patients as well [3, 4] .", [["SARS", "DISEASE", 216, 220], ["respiratory syndrome", "DISEASE", 372, 392], ["coronaviruses", "ORGANISM", 16, 29], ["SARS-CoV-2", "ORGANISM", 31, 41], ["COVID-19", "ORGANISM", 134, 142], ["human", "ORGANISM", 175, 180], ["coronaviruses", "ORGANISM", 181, 194], ["beta coronaviruses", "ORGANISM", 196, 214], ["SARS-CoV", "ORGANISM", 216, 224], ["MERS", "GENE_OR_GENE_PRODUCT", 226, 230], ["OC43", "GENE_OR_GENE_PRODUCT", 232, 236], ["HKU1", "GENE_OR_GENE_PRODUCT", 238, 242], ["alpha coronaviruses", "ORGANISM", 248, 267], ["patients", "ORGANISM", 401, 409], ["human", "SPECIES", 175, 180], ["patients", "SPECIES", 401, 409], ["SARS-CoV", "SPECIES", 31, 39], ["human coronaviruses", "SPECIES", 175, 194], ["SARS-CoV", "SPECIES", 216, 224], ["known human coronaviruses", "PROBLEM", 169, 194], ["beta coronaviruses", "PROBLEM", 196, 214], ["SARS", "PROBLEM", 216, 220], ["CoV", "TEST", 221, 224], ["MERS", "PROBLEM", 226, 230], ["OC43", "TEST", 232, 236], ["HKU1", "TEST", 238, 242], ["alpha coronaviruses", "PROBLEM", 248, 267], ["severe respiratory syndrome", "PROBLEM", 365, 392], ["human coronaviruses", "OBSERVATION", 175, 194], ["alpha coronaviruses", "ANATOMY", 248, 267], ["severe", "OBSERVATION_MODIFIER", 365, 371], ["respiratory syndrome", "OBSERVATION", 372, 392]]], ["To combat the global lethality of COVID-19, it demands an urgent solution for the detection and therapeutic treatment, which requires a comprehensive experimental elucidation of biomedical entities (e.g., genes, non-coding RNAs (ncRNA), viruses, drugs, etc.) [5] that are involved in this disease.", [["non-coding RNAs", "DNA", 212, 227], ["ncRNA", "DNA", 229, 234], ["COVID", "TEST", 34, 39], ["an urgent solution", "TREATMENT", 55, 73], ["the detection", "TEST", 78, 91], ["therapeutic treatment", "TREATMENT", 96, 117], ["biomedical entities (e.g., genes, non-coding RNAs (ncRNA)", "PROBLEM", 178, 235], ["viruses", "PROBLEM", 237, 244], ["this disease", "PROBLEM", 284, 296]]], ["But this is a relatively slow process due to the inherent nature of the experimental validation.", [["a relatively slow process", "PROBLEM", 12, 37]]], ["Still, it is also a daunting task due to a large number of possible combinations of biomedical entities that need to be examined [8] .", [["biomedical entities", "PROBLEM", 84, 103], ["large", "OBSERVATION_MODIFIER", 43, 48]]], ["To mediate these two extreme experimental setups, and at the same time, to enable a comprehensive exploration of potential therapeutic treatments, knowledgebase based solutions are proposed, as part of this study, for the scientific community to focus on a smaller number of biomedical entities that may guide to the discovery of a novel solution of the COVID-19 treatment.IntroductionThere exist databases that focused on the virus-related diseases for multiple hosts.", [["COVID-19", "CHEMICAL", 354, 362], ["COVID-19", "CHEMICAL", 354, 362], ["a comprehensive exploration", "TEST", 82, 109], ["potential therapeutic treatments", "TREATMENT", 113, 145], ["knowledgebase based solutions", "TREATMENT", 147, 176], ["this study", "TEST", 202, 212], ["the COVID-19 treatment", "TREATMENT", 350, 372], ["the virus", "PROBLEM", 423, 432]]], ["For example, in ViRBase [9] , the authors highlighted the association between non-coding RNAs (ncRNAs) and viruses in 20 hosts.", [["non-coding RNAs", "RNA", 78, 93], ["ncRNAs", "DNA", 95, 101], ["non-coding RNAs (ncRNAs", "PROBLEM", 78, 101], ["non-coding RNAs", "OBSERVATION", 78, 93]]], ["VISDB database, based on literature mining, integrated the virus interaction site in humans for five DNA oncoviruses and four RNA retroviruses [10] .", [["humans", "ORGANISM", 85, 91], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["VISDB database", "DNA", 0, 14], ["virus interaction site", "DNA", 59, 81], ["DNA oncoviruses", "DNA", 101, 116], ["humans", "SPECIES", 85, 91], ["humans", "SPECIES", 85, 91], ["the virus interaction site", "PROBLEM", 55, 81], ["five DNA oncoviruses", "TREATMENT", 96, 116], ["four RNA retroviruses", "TREATMENT", 121, 142], ["RNA retroviruses", "OBSERVATION", 126, 142]]], ["The Virus Pathogen Resources (VIPR), developed a portal collecting a comprehensive set of information related to coronavirus and hepatitis C virus (HCV), other viruses [11, 12] .", [["coronavirus and hepatitis C", "DISEASE", 113, 140], ["coronavirus", "ORGANISM", 113, 124], ["hepatitis C virus", "ORGANISM", 129, 146], ["HCV", "ORGANISM", 148, 151], ["hepatitis C virus", "SPECIES", 129, 146], ["hepatitis C virus", "SPECIES", 129, 146], ["HCV", "SPECIES", 148, 151], ["coronavirus", "PROBLEM", 113, 124], ["hepatitis C virus (HCV)", "PROBLEM", 129, 152], ["other viruses", "PROBLEM", 154, 167], ["portal", "ANATOMY", 49, 55], ["coronavirus", "OBSERVATION", 113, 124]]], ["But none of the mentioned databases are much useful for COVID-19/SARS-CoV-2, as those databases were not specific to novel coronavirus, or they provide very limited information about the associated genes, ncRNA or do not cover other associated factors that are involved in coronavirus-related diseases, drugs and their side effects.", [["coronavirus", "DISEASE", 273, 284], ["SARS-CoV-2", "ORGANISM", 65, 75], ["coronavirus", "ORGANISM", 123, 134], ["coronavirus", "ORGANISM", 273, 284], ["ncRNA", "DNA", 205, 210], ["SARS-CoV", "SPECIES", 65, 73], ["COVID", "TEST", 56, 61], ["CoV", "TEST", 70, 73], ["novel coronavirus", "PROBLEM", 117, 134], ["coronavirus", "PROBLEM", 273, 284], ["related diseases", "PROBLEM", 285, 301], ["drugs", "TREATMENT", 303, 308], ["their side effects", "PROBLEM", 313, 331]]], ["Moreover, there exists no such knowledgebase that has integrated all biomedical entities specific to COVID-19/SARS-CoV-2.", [["COVID-19", "ORGANISM", 101, 109], ["SARS-CoV-2", "ORGANISM", 110, 120], ["COVID", "TEST", 101, 106], ["CoV", "TEST", 115, 118], ["no", "UNCERTAINTY", 23, 25]]], ["To fill this gap, we develop the first comprehensive knowledgebase, COVID-19Base, that integrates several biomedical entities that are associated with COVID-19/SARS-CoV-2 from the scientific literature.IntroductionIn COVID-19Base, we use a dictionary-based approach to find the association of seven different thematic areas related to COVID-19/SARS-CoV-2 and other coronavirus-related diseases in humans.", [["coronavirus-related diseases", "DISEASE", 365, 393], ["SARS-CoV-2", "ORGANISM", 160, 170], ["SARS-CoV-2", "ORGANISM", 344, 354], ["coronavirus", "ORGANISM", 365, 376], ["humans", "ORGANISM", 397, 403], ["COVID-19Base", "DNA", 217, 229], ["humans", "SPECIES", 397, 403], ["SARS-CoV", "SPECIES", 344, 352], ["humans", "SPECIES", 397, 403], ["COVID", "TEST", 68, 73], ["COVID", "TEST", 151, 156], ["CoV", "TEST", 165, 168], ["a dictionary-based approach", "TREATMENT", 238, 265], ["seven different thematic areas", "PROBLEM", 293, 323], ["COVID", "TEST", 335, 340], ["SARS", "TEST", 344, 348], ["CoV", "TEST", 349, 352], ["other coronavirus-related diseases in humans", "PROBLEM", 359, 403], ["coronavirus", "OBSERVATION", 365, 376], ["diseases", "OBSERVATION", 385, 393]]], ["In COVID-19Base, we not only highlight the biomedical terms that are mentioned in the literature, but we also identify \"term pairs\" based on their co-occurrence, which will allow the scientific community to investigate in depth the association between term pairs like disease-gene, disease-drug, disease-ncRNA, etc. While careful manual curation of the identified associations is the ultimate goal, in COVID-19Base, we propose and implement a novel approach to estimate the effectiveness of drug for diseases based on natural language processing, sentiment analysis, and deep learning.", [["COVID-19Base", "CELL", 402, 414], ["disease-gene", "DNA", 268, 280], ["ncRNA", "DNA", 304, 309], ["term pairs like disease", "PROBLEM", 252, 275], ["disease", "PROBLEM", 282, 289], ["disease", "PROBLEM", 296, 303], ["ncRNA", "PROBLEM", 304, 309], ["a novel approach", "TREATMENT", 441, 457], ["diseases", "PROBLEM", 500, 508], ["sentiment analysis", "TEST", 547, 565], ["deep", "ANATOMY_MODIFIER", 571, 575]]], ["We also apply the concept of cosine similarity [36] to confidently infer the associations between diseases and genes, lncRNAs, miRNAs.", [["lncRNAs", "DNA", 118, 125], ["miRNAs", "DNA", 127, 133], ["miRNAs", "ANATOMY", 127, 133]]], ["The knowledgebase, we developed, will support the researcher around the world to discover the existing knowledge and find a solution for this pandemic.Materials and MethodsFor this study, we considered COVID-19 Open Research Dataset (CORD-19), generated by Allen Institute of AI (publicly available at https://pages.semanticscholar.org/coronavirus-research) .", [["a solution", "TREATMENT", 122, 132], ["this pandemic", "PROBLEM", 137, 150], ["this study", "TEST", 176, 186], ["COVID", "TEST", 202, 207], ["CORD", "ANATOMY", 234, 238]]], ["The dataset contains over 44K scholarly articles, related to COVID-19 and the coronavirus family of viruses.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 61, 69], ["coronavirus", "ORGANISM", 78, 89], ["COVID-19", "DNA", 61, 69], ["COVID", "TEST", 61, 66], ["viruses", "OBSERVATION", 100, 107]]], ["The dataset was collected using query: \"COVID-19\" OR Coronavirus OR \"Corona virus\" OR \"2019-nCoV\" OR \"SARS-CoV\" OR \"MERS-CoV\" OR \"Severe Acute Respiratory Syndrome\" OR \"Middle East Respiratory Syndrome\" against PubMed, PubMed Central (PMC), bioRxiv and medRxiv pre-prints and it covers major part of all research articles related to COVID-19 and other coronavirus (e.g. MERS, SARS, etc.) till 27-03-2020.", [["SARS", "DISEASE", 102, 106], ["Acute Respiratory Syndrome", "DISEASE", 137, 163], ["Respiratory Syndrome", "DISEASE", 181, 201], ["SARS", "DISEASE", 376, 380], ["coronavirus", "ORGANISM", 352, 363], ["SARS-CoV", "SPECIES", 102, 110], ["Coronavirus", "PROBLEM", 53, 64], ["Severe Acute Respiratory Syndrome", "PROBLEM", 130, 163], ["Middle East Respiratory Syndrome", "PROBLEM", 169, 201], ["bioRxiv", "TREATMENT", 241, 248], ["medRxiv pre-prints", "TREATMENT", 253, 271], ["COVID", "TEST", 333, 338], ["other coronavirus", "PROBLEM", 346, 363], ["SARS", "PROBLEM", 376, 380], ["Severe", "OBSERVATION_MODIFIER", 130, 136], ["Acute", "OBSERVATION_MODIFIER", 137, 142], ["Respiratory Syndrome", "OBSERVATION", 143, 163]]], ["We considered the abstract and full body from the research articles for downstream analysis.Extracting Disease-Drug InteractionsWe extract disease-drug interactions from the CORD-19 literature and classify them in two categories (labels): Positive and Negative.", [["body", "ANATOMY", 36, 40], ["body", "ORGANISM_SUBDIVISION", 36, 40], ["downstream analysis", "TEST", 72, 91], ["Extracting Disease", "PROBLEM", 92, 110], ["extract disease", "PROBLEM", 131, 146], ["Disease", "OBSERVATION", 103, 110], ["extract disease", "OBSERVATION", 131, 146], ["CORD", "ANATOMY", 174, 178], ["Negative", "OBSERVATION", 252, 260]]], ["The positive label means the drug is somewhat effective for curing the disease, and the negative label means the opposite.", [["the disease", "PROBLEM", 67, 78], ["disease", "OBSERVATION", 71, 78]]], ["We also determine a confidence score which indicates our level of confidence for that automatic label.", [["a confidence score", "TEST", 18, 36]]], ["Fig. 1 shows the workflow of extracting disease-drug interactions and predicting the effectiveness of drugs against diseases with confidence scores.Disease and Drug Names ExtractionTo extract relevant disease-drug pairs from the CORD-19 literature, we employ a dictionary-based approach to detect mentions of diseases and drugs in the literature.", [["extracting disease", "PROBLEM", 29, 47], ["drug interactions", "PROBLEM", 48, 65], ["drugs", "TREATMENT", 102, 107], ["diseases", "PROBLEM", 116, 124], ["Disease", "PROBLEM", 148, 155], ["relevant disease", "PROBLEM", 192, 208], ["diseases", "PROBLEM", 309, 317], ["drugs", "TREATMENT", 322, 327], ["CORD", "ANATOMY", 229, 233], ["diseases", "OBSERVATION", 309, 317]]], ["We use Disease Ontology [13] and DrugBank [14] to prepare the disease and drug dictionaries.", [["the disease", "PROBLEM", 58, 69], ["disease", "OBSERVATION", 62, 69]]], ["We leverage the Aho-Corasick algorithm [15] to search the drug and disease names considering the large size of drug and disease dictionaries and the corpus itself.", [["corpus", "ANATOMY", 149, 155], ["corpus", "ORGAN", 149, 155], ["disease", "PROBLEM", 67, 74], ["drug and disease dictionaries", "PROBLEM", 111, 140], ["large", "OBSERVATION_MODIFIER", 97, 102], ["size", "OBSERVATION_MODIFIER", 103, 107], ["corpus", "ANATOMY_MODIFIER", 149, 155]]], ["The Aho-Corasick algorithm is a string searching algorithm that efficiently locates multiple patterns in a large blob of text.", [["a string searching algorithm", "PROBLEM", 30, 58], ["multiple", "OBSERVATION_MODIFIER", 84, 92], ["patterns", "OBSERVATION_MODIFIER", 93, 101], ["large", "OBSERVATION_MODIFIER", 107, 112], ["blob", "OBSERVATION", 113, 117]]], ["The time complexity of the algorithm is O(n + m + z), where n is the length of the text, m is the total length of all the patterns to be searched, and z is the total number of occurrences of the patterns in the text.Disease-Drug Pairs ExtractionAfter extracting the disease and drug names separately, we want to mine the literature and identify the sentences that contain the disease and drug pairs to semantically evaluate their interactions.", [["the algorithm", "TEST", 23, 36], ["Disease", "PROBLEM", 216, 223], ["the disease", "PROBLEM", 262, 273], ["the disease and drug pairs", "PROBLEM", 372, 398]]], ["For this purpose, we search for every disease-drug pair from our disease and drug list in the CORD-19 literature and collect every sentence where a co-occurrence is found.", [["every disease", "PROBLEM", 32, 45], ["CORD", "ANATOMY", 94, 98]]], ["Then we create a document for every disease-drug pair combining all extracted sentences.", [["every disease", "PROBLEM", 30, 43]]], ["Thus we build a disease-drug pair to document mapping.", [["a disease-drug pair", "PROBLEM", 14, 33], ["disease", "OBSERVATION", 16, 23]]], ["We do not use any pattern-based approach here as done in the paper [16] as this could result in missing a good number of sentences containing disease-drug pairs.Anomaly RemovalAs we automatically extract the sentences containing the disease-drug pairs, there is a possibility of aberration in our extracted data.", [["drug pairs", "PROBLEM", 150, 160], ["Anomaly RemovalAs", "PROBLEM", 161, 178], ["the disease-drug pairs", "PROBLEM", 229, 251], ["aberration in our extracted data", "PROBLEM", 279, 311], ["possibility of", "UNCERTAINTY", 264, 278], ["aberration", "OBSERVATION", 279, 289]]], ["So we decide to check and remove any abnormality from our collected data before going into the next stage of the pipeline.", [["any abnormality", "PROBLEM", 33, 48]]], ["Unsupervised anomaly detection technique detects anomalies in an unlabeled dataset by looking for instances that seem to fit the least to the remainder of the dataset under the assumption that the majority of the instances in the dataset are 'normal'.", [["Unsupervised anomaly detection technique", "PROBLEM", 0, 40], ["anomalies", "PROBLEM", 49, 58], ["anomaly", "OBSERVATION", 13, 20], ["normal", "OBSERVATION", 243, 249]]], ["We use K-Means clustering algorithm [18] as it has been used for anomaly detection in several studies [19, 20, 21, 22, 23] .", [["K-Means clustering algorithm", "TREATMENT", 7, 35], ["anomaly detection", "PROBLEM", 65, 82], ["several studies", "TEST", 86, 101]]], ["First, we use Doc2Vec [24] to create a numeric representation of each document associated with each disease-drug pair.", [["each disease", "PROBLEM", 95, 107]]], ["Then we fit these representations into our Kmeans model and observe two clear clusters of easily discriminable sizes, where the smaller one consists of only 161 instances.", [["our Kmeans model", "TEST", 39, 55], ["sizes", "OBSERVATION_MODIFIER", 111, 116], ["smaller", "OBSERVATION_MODIFIER", 128, 135]]], ["As we know that anomalies differ from the normal instances significantly and occur very rarely in the data, we can assume that the instances of the smaller cluster are indeed anomalies.", [["anomalies", "PROBLEM", 16, 25], ["indeed anomalies", "PROBLEM", 168, 184], ["smaller", "OBSERVATION_MODIFIER", 148, 155], ["anomalies", "OBSERVATION", 175, 184]]], ["We discard these 161 instances from any further consideration.Sentiment AnalysisWe apply sentiment analysis to automatically assess the effectiveness of a drug to treat a particular disease in the context of each extracted drug-disease pair.", [["sentiment analysis", "TEST", 89, 107], ["a drug", "TREATMENT", 153, 159], ["a particular disease", "PROBLEM", 169, 189]]], ["However, it shows some inconsistency in some cases as expected from a pre-trained model and we feel the necessity of unsupervised sentiment analysis which is the second model of our pipeline.", [["unsupervised sentiment analysis", "TEST", 117, 148], ["some", "OBSERVATION_MODIFIER", 18, 22], ["inconsistency", "OBSERVATION", 23, 36]]], ["We get a polarity score from the TextBlob model and a sentiment rate from our unsupervised model for each disease-drug pair which are subsequently fed to our Neural Network model to predict the final label.Sentiment AnalysisTextBlob model: TextBlob is a Python library that is widely used in natural language processing tasks such as POS tagging, noun phrase extraction, sentiment analysis, classification, translation, and more.", [["TextBlob", "DNA", 240, 248], ["a polarity score", "TEST", 7, 23], ["each disease", "PROBLEM", 101, 113], ["drug pair", "TREATMENT", 114, 123], ["POS tagging", "TEST", 334, 345], ["noun phrase extraction", "TREATMENT", 347, 369], ["sentiment analysis", "TEST", 371, 389]]], ["Given the sentences that we mined for each disease-drug pair as input, TextBlob gives a polarity score in the range between -1 and 1.", [["TextBlob", "DNA", 71, 79], ["each disease", "PROBLEM", 38, 50], ["a polarity score", "TEST", 86, 102]]], ["We record the polarity scores for each disease-drug to use it as a feature for our Neural Network model.Unsupervised model:We use the concept of K-means clustering again for unsupervised sentiment analysis.", [["each disease", "PROBLEM", 34, 46], ["unsupervised sentiment analysis", "TEST", 174, 205]]], ["The positive cluster is decided on the basis of the presence of several positive words (in the context of a disease-rug pair) in it such as 'cure', 'preclude', 'inhibit', 'prescribe', 'reduce', 'modest', etc. On the other hand, the negative cluster contains words like 'risky', 'kill', 'danger', etc. Then we assign each word a sentiment value, either +1 or -1, based on the cluster (positive or negative) they belong to.", [["+1 or -1", "DNA", 352, 360], ["several positive words", "PROBLEM", 64, 86], ["a disease-rug pair)", "TREATMENT", 106, 125], ["positive cluster", "OBSERVATION_MODIFIER", 4, 20]]], ["Then we calculate the tf-idf score [27, 28] of each word in the sentence collection to consider the significance of the unique words.", [["tf", "PROTEIN", 22, 24], ["idf score", "TEST", 25, 34]]], ["Next, we build a tf-idf representation, T, for each disease-drug pair by replacing each word of the corresponding sentences with its tf-idf score and a sentiment value representation, S, by replacing each word with its sentiment value.", [["tf", "DNA", 17, 19], ["each disease", "PROBLEM", 47, 59], ["drug pair", "TREATMENT", 60, 69]]], ["Finally, we take their dot product (T\u25cbS) as the final sentiment rate of our unsupervised model.Neural Network Model for Automatic Label and Confidence ScoreWe use a Deep Neural Network (DNN) model to automatically predict the label and confidence score for our disease-drug pairs.", [["our disease-drug pairs", "PROBLEM", 257, 279]]], ["Earlier studies [29, 30] also used DNN models on small labeled data and achieved promising results.Neural Network Model for Automatic Label and Confidence ScoreTraining data: We manually labeled 200 disease-drug pairs to train our Neural Network model.", [["Earlier studies", "TEST", 0, 15], ["small labeled data", "TEST", 49, 67]]], ["Among them, there were 110 positive instances and the rest were negative.Neural Network Model for Automatic Label and Confidence ScoreInput features: We use the polarity or sentiment score given by the TextBlob and unsupervised models as the input features for our Neural Network model along with the minimum distance between the disease and drug term in the corresponding document.Model setup and output:The DNN structure used in this study is similar to that shown in Fig. 2 .", [["110 positive instances", "PROBLEM", 23, 45], ["sentiment score", "TEST", 173, 188], ["the disease and drug term", "PROBLEM", 326, 351], ["Model setup and output", "TEST", 382, 404], ["The DNN structure", "TREATMENT", 405, 422], ["this study", "TEST", 431, 441], ["disease", "OBSERVATION", 330, 337], ["output", "OBSERVATION_MODIFIER", 398, 404]]], ["It consists of 1 input layer with 3 neurons (each neuron corresponds to one input feature), 2 hidden layers with 8 and 4 neurons respectively, and 1 output layer containing 1 neuron for binary classification (positive or negative).", [["neurons", "ANATOMY", 36, 43], ["neuron", "ANATOMY", 50, 56], ["neurons", "ANATOMY", 121, 128], ["neuron", "ANATOMY", 175, 181], ["neurons", "CELL", 36, 43], ["layers", "TISSUE", 101, 107], ["neurons", "CELL", 121, 128], ["binary classification", "TEST", 186, 207], ["layer", "OBSERVATION_MODIFIER", 23, 28]]], ["The transfer functions of the first and second hidden layers are Rectified Linear Unit (ReLU) [31] and Hyperbolic Tangent function (tanh) [32] respectively.", [["Hyperbolic Tangent function", "TEST", 103, 130]]], ["The transfer function of the output layer is a Sigmoid function [33] .", [["Sigmoid", "ANATOMY", 47, 54]]], ["We use Adam optimizer [35] and the maximum training epoch is set to 500.", [["the maximum training epoch", "TREATMENT", 31, 57]]], ["We split our labeled data into training and test sets on an 80:20 ratio.", [["test sets", "TEST", 44, 53]]], ["We train our model on the training data and achieve 75% accuracy on the test set.", [["the training data", "TEST", 22, 39], ["the test set", "TEST", 68, 80]]], ["Fig. 3 shows the workflow of extracting disease-gene associations.", [["extracting disease", "PROBLEM", 29, 47]]], ["We extract gene names along with lncRNAs and miRNAs from the CORD-19 literature in a dictionary-based approach using HGNC [40] , LNCipedia [41] , and miRBase [42] .", [["lncRNAs", "DNA", 33, 40], ["miRNAs", "DNA", 45, 51], ["CORD", "DNA", 61, 65], ["CORD", "ANATOMY", 61, 65]]], ["Then we extract their associations with diseases in a similar process that we have used to extract the disease-drug pairs and collected all the abstracts where a co-occurrence was found.", [["diseases", "PROBLEM", 40, 48], ["the disease-drug pairs", "PROBLEM", 99, 121]]], ["We transformed each disease into vector V1, each gene (and lncRNA, miRNA) into vector V2, and then calculated the cosine similarity of V1 and V2 for each pair.", [["vector V1", "DNA", 33, 42], ["lncRNA", "DNA", 59, 65], ["miRNA", "DNA", 67, 72], ["vector V2", "DNA", 79, 88], ["V1", "DNA", 135, 137], ["V2", "DNA", 142, 144], ["each disease into vector V1", "PROBLEM", 15, 42], ["disease", "OBSERVATION", 20, 27], ["vector V1", "ANATOMY", 33, 42]]], ["To create the vector representations, we train a Word2Vec model with all the collected abstracts.", [["a Word2Vec model", "TREATMENT", 47, 63]]], ["We use the DisGeNET [37] database as the gold standard to evaluate the performance of cosine similarity in predicting the gene-disease linkage.", [["DisGeNET [37] database", "DNA", 11, 33], ["the gene-disease linkage", "PROBLEM", 118, 142], ["disease", "OBSERVATION", 127, 134]]], ["Moreover, pairs that are also found in the DisGeNET database are labeled as verified associations.Extracting Drug-Protein AssociationsWe also extract drug-protein associations from the CORD-19 literature applying the same cooccurrence based approach as mentioned above.", [["DisGeNET database", "DNA", 43, 60], ["Extracting Drug-Protein AssociationsWe", "PROBLEM", 98, 136], ["Drug-Protein", "OBSERVATION", 109, 121], ["CORD", "ANATOMY", 185, 189]]], ["We use PDB Ids from the Protein Data Bank [38] for extracting protein names.", [["PDB Ids", "PROTEIN", 7, 14], ["protein names", "PROTEIN", 62, 75]]], ["Unlike the disease-gene associations, we do not apply the concept of cosine similarity here as we do not find any suitable dataset that can be used as the gold standard in this case.Extracting Side-effects of DrugsThe drugs we are suggesting through this literature mining may come with different side-effects.", [["the disease", "PROBLEM", 7, 18], ["Drugs", "TREATMENT", 209, 214], ["The drugs", "TREATMENT", 214, 223], ["disease", "OBSERVATION", 11, 18]]], ["Therefore, we also explore the possible side-effects of the drugs.", [["the drugs", "TREATMENT", 56, 65]]], ["We collect the drugs with the corresponding side-effects from SIDER [39] and map the drug names with the drugs mentioned in the CORD-19 literature to extract the possible side-effects.Association between pair of terms in COVID-19BaseWe have mined 1811 drugs, 1219 diseases, 1703 genes, 11 lncRNAs, 9 miRNAs, and 70 PDBs from the CORD-19 literature.", [["COVID-19BaseWe", "GENE_OR_GENE_PRODUCT", 221, 235], ["lncRNAs", "DNA", 289, 296], ["CORD", "DNA", 329, 333], ["the drugs", "TREATMENT", 11, 20], ["the drugs", "TREATMENT", 101, 110], ["miRNAs", "TEST", 300, 306], ["CORD", "ANATOMY", 128, 132], ["CORD", "ANATOMY", 329, 333]]], ["Majority share of the data is labeled automatically following the methodology reported in the Methods section and complete manual curation is planned in subsequent versions.", [["the Methods section", "TREATMENT", 90, 109]]], ["Notably, a tiny part (1.5%) of the findings have already been manually curated.", [["a tiny part (1.5%) of the findings", "PROBLEM", 9, 43], ["tiny", "OBSERVATION_MODIFIER", 11, 15], ["part", "OBSERVATION_MODIFIER", 16, 20]]], ["In the rest of this section, we discuss two of the interesting and useful findings using COVID-19Base in the context of drug exploration for COVID-19.Remdesivir as the top ranked drug for COVID-19 in COVID-19BaseAs a case study, we find Remdesivir as a positive (i.e., effective) drug for COVID-19, automatically labeled as such through our pipeline with a confidence score of 75.86%.", [["COVID-19Base", "CHEMICAL", 89, 101], ["Remdesivir", "CHEMICAL", 150, 160], ["COVID-19", "CHEMICAL", 188, 196], ["Remdesivir", "CHEMICAL", 237, 247], ["COVID-19", "CHEMICAL", 141, 149], ["Remdesivir", "CHEMICAL", 150, 160], ["COVID-19", "CHEMICAL", 188, 196], ["Remdesivir", "CHEMICAL", 237, 247], ["COVID-19Base", "SIMPLE_CHEMICAL", 89, 101], ["Remdesivir", "SIMPLE_CHEMICAL", 150, 160], ["COVID-19BaseAs", "SIMPLE_CHEMICAL", 200, 214], ["Remdesivir", "SIMPLE_CHEMICAL", 237, 247], ["COVID-19Base", "TREATMENT", 89, 101], ["drug exploration", "TEST", 120, 136], ["COVID", "TEST", 141, 146], ["Remdesivir", "TREATMENT", 150, 160], ["COVID", "TEST", 188, 193], ["COVID", "TEST", 289, 294], ["a confidence score", "TEST", 355, 373]]], ["Thus COVID-19Base suggests Remdesivir as a promising drug for further investigation for treating COVID-19.", [["COVID-19Base", "CHEMICAL", 5, 17], ["Remdesivir", "CHEMICAL", 27, 37], ["Remdesivir", "CHEMICAL", 27, 37], ["COVID-19", "CHEMICAL", 97, 105], ["COVID-19Base", "GENE_OR_GENE_PRODUCT", 5, 17], ["Remdesivir", "SIMPLE_CHEMICAL", 27, 37], ["COVID", "TEST", 5, 10], ["Remdesivir", "TREATMENT", 27, 37], ["further investigation", "TEST", 62, 83], ["COVID", "TEST", 97, 102]]], ["Interestingly, it is recently being considered as the most effective drug for treating COVID-19.Remdesivir as the top ranked drug for COVID-19 in COVID-19BaseNotably, Remdesivir is an antiviral drug originally developed for Ebola treatment.", [["Remdesivir", "CHEMICAL", 96, 106], ["COVID-19", "CHEMICAL", 134, 142], ["COVID-19BaseNotably", "CHEMICAL", 146, 165], ["Remdesivir", "CHEMICAL", 167, 177], ["Ebola", "DISEASE", 224, 229], ["COVID-19", "CHEMICAL", 87, 95], ["Remdesivir", "CHEMICAL", 96, 106], ["COVID-19", "CHEMICAL", 134, 142], ["Remdesivir", "CHEMICAL", 167, 177], ["Remdesivir", "SIMPLE_CHEMICAL", 96, 106], ["COVID-19BaseNotably", "SIMPLE_CHEMICAL", 146, 165], ["Remdesivir", "SIMPLE_CHEMICAL", 167, 177], ["Ebola", "ORGANISM", 224, 229], ["COVID", "TEST", 87, 92], ["Remdesivir", "TREATMENT", 96, 106], ["COVID", "TEST", 134, 139], ["Remdesivir", "TREATMENT", 167, 177], ["an antiviral drug", "TREATMENT", 181, 198], ["Ebola treatment", "TREATMENT", 224, 239]]], ["It prevents viral replication by blocking an enzyme called polymerase and thus limits the spread of the disease.", [["enzyme called polymerase", "PROTEIN", 45, 69], ["viral replication", "TREATMENT", 12, 29], ["an enzyme called polymerase", "TEST", 42, 69], ["the disease", "PROBLEM", 100, 111], ["viral replication", "OBSERVATION", 12, 29], ["disease", "OBSERVATION", 104, 111]]], ["A recent clinical trial conducted by the National Institute of Allergy and Infectious Diseases (NIAID)Remdesivir as the top ranked drug for COVID-19 in COVID-19Baseshows that Remdesivir helps COVID-19 patients recover faster and improves their survival rates.", [["Allergy and Infectious Diseases", "DISEASE", 63, 94], ["COVID-19Baseshows", "SIMPLE_CHEMICAL", 152, 169], ["Remdesivir", "SIMPLE_CHEMICAL", 175, 185], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 201, 209], ["Remdesivir", "TREATMENT", 102, 112], ["COVID", "TEST", 140, 145], ["Remdesivir", "TREATMENT", 175, 185], ["Infectious", "OBSERVATION_MODIFIER", 75, 85]]], ["Adult patients, treated with Remdesivir, were found to recover four days faster, an improvement of 31% compared to other patients and the overall death rate dropped from 11.6% to 8%.", [["Remdesivir", "CHEMICAL", 29, 39], ["death", "DISEASE", 146, 151], ["Remdesivir", "CHEMICAL", 29, 39], ["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 121, 129], ["Remdesivir", "TREATMENT", 29, 39], ["the overall death rate", "TEST", 134, 156], ["improvement", "OBSERVATION_MODIFIER", 84, 95]]], ["1Hydroxychloroquine as a possible treatment for COVID-19Anti-malaria drug Hydroxychloroquine, which is one of the most talked-about drugs for treating COVID-19, has also been found in our mining.", [["1Hydroxychloroquine", "CHEMICAL", 0, 19], ["malaria", "DISEASE", 61, 68], ["Hydroxychloroquine", "CHEMICAL", 74, 92], ["COVID-19", "CHEMICAL", 151, 159], ["1Hydroxychloroquine", "CHEMICAL", 0, 19], ["Hydroxychloroquine", "CHEMICAL", 74, 92], ["COVID-19", "CHEMICAL", 151, 159], ["1Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 19], ["COVID-19Anti-malaria", "SIMPLE_CHEMICAL", 48, 68], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 74, 92], ["1Hydroxychloroquine", "TREATMENT", 0, 19], ["treatment", "TREATMENT", 34, 43], ["COVID-19Anti-malaria drug Hydroxychloroquine", "TREATMENT", 48, 92], ["drugs", "TREATMENT", 132, 137]]], ["Our model finds it as a positive (i.e., effective) drug with 57.89% confidence (note the significantly lower confidence score than that of Remdesivir).", [["the significantly lower confidence score", "PROBLEM", 85, 125], ["Remdesivir", "TREATMENT", 139, 149]]], ["But it is also revealed from COVID-19Base that this drug has 111 side-effects including Anaemia, Haemorrhage, Liver disorder, Hepatitis fulminant, Cardiomyopathy, Cardiac failure, etc., which makes it a risky option especially for patients with heart and liver complications.", [["Liver", "ANATOMY", 110, 115], ["Cardiac", "ANATOMY", 163, 170], ["heart", "ANATOMY", 245, 250], ["liver", "ANATOMY", 255, 260], ["Anaemia", "DISEASE", 88, 95], ["Haemorrhage", "DISEASE", 97, 108], ["Liver disorder", "DISEASE", 110, 124], ["Hepatitis fulminant", "DISEASE", 126, 145], ["Cardiomyopathy", "DISEASE", 147, 161], ["Cardiac failure", "DISEASE", 163, 178], ["heart and liver complications", "DISEASE", 245, 274], ["Liver", "ORGAN", 110, 115], ["patients", "ORGANISM", 231, 239], ["heart", "ORGAN", 245, 250], ["liver", "ORGAN", 255, 260], ["patients", "SPECIES", 231, 239], ["COVID", "TEST", 29, 34], ["Anaemia", "PROBLEM", 88, 95], ["Haemorrhage", "PROBLEM", 97, 108], ["Liver disorder", "PROBLEM", 110, 124], ["Hepatitis fulminant", "PROBLEM", 126, 145], ["Cardiomyopathy", "PROBLEM", 147, 161], ["Cardiac failure", "PROBLEM", 163, 178], ["heart and liver complications", "PROBLEM", 245, 274], ["Anaemia", "OBSERVATION", 88, 95], ["Haemorrhage", "OBSERVATION", 97, 108], ["Liver", "ANATOMY", 110, 115], ["disorder", "OBSERVATION", 116, 124], ["Hepatitis", "OBSERVATION_MODIFIER", 126, 135], ["Cardiomyopathy", "OBSERVATION", 147, 161], ["Cardiac", "ANATOMY", 163, 170], ["failure", "OBSERVATION", 171, 178], ["heart", "ANATOMY", 245, 250], ["liver", "ANATOMY", 255, 260], ["complications", "OBSERVATION", 261, 274]]], ["Informatively, although the US Food and Drugs Administration (FDA) had previously granted authorization to use this drug for Covid-19, it recently cautions against its use outside of the hospital setting or a clinical trial due to its' side effects and risk factors.", [["Covid", "TEST", 125, 130], ["its' side effects", "PROBLEM", 231, 248], ["risk factors", "PROBLEM", 253, 265]]], ["2AvailabilityCOVID-19Base is available at: http://77.68.43.135:96/ .", [["2AvailabilityCOVID", "TEST", 0, 18]]], ["Additionally, a manually curation drive is underway and to facilitate that a limited sentence-wise feedback mechanism (from the esteemed users) is also incorporated in the software.LimitationsWhile complete manual curation is the ideal goal, due to time and cost constraints we have employed a novel sophisticated automated approach to prepare COVID-19Base and make it available for the scientific community.", [["COVID-19Base", "CHEMICAL", 344, 356], ["COVID-19Base", "CHEMICAL", 344, 356], ["COVID-19Base", "SIMPLE_CHEMICAL", 344, 356], ["COVID", "TREATMENT", 344, 349]]], ["However, this comes naturally with some errors due to inherent limitations of the methods and approaches adopted.", [["some errors", "PROBLEM", 35, 46]]], ["This is why the identified inferences/associations are made available to the users for review to facilitate a feedback mechanism (from the esteemed users) in the COVID-19Base.", [["COVID-19Base", "DNA", 162, 174]]]], "PMC7166540": [["INTRODUCTIONThe acute phase response (APR) is one of the main reactions of the innate host defence system (Baumann & Gauldie 1994, Paltrinieri 2008).", [["acute phase response", "PROBLEM", 16, 36], ["acute", "OBSERVATION_MODIFIER", 16, 21], ["phase", "OBSERVATION_MODIFIER", 22, 27]]], ["It refers to a non\u2010specific and complex phenomenon that occurs in the early stages of inflammation, preceding the development of the acquired immune response (Baumann & Gauldie 1994, Ceron et al. 2005).", [["inflammation", "DISEASE", 86, 98], ["a non\u2010specific and complex phenomenon", "PROBLEM", 13, 50], ["inflammation", "PROBLEM", 86, 98], ["complex", "OBSERVATION_MODIFIER", 32, 39], ["phenomenon", "OBSERVATION", 40, 50], ["early stages", "OBSERVATION_MODIFIER", 70, 82], ["inflammation", "OBSERVATION", 86, 98]]], ["The APR is a consequence of the production and release of several cytokines, of which interleukin (IL)\u20101, IL\u20106 and tumour necrosis factor (TNF)\u2010\u03b1 are the most relevant (Mart\u00ednez\u2010Subiela et al. 2001, Paltrinieri 2008).", [["necrosis", "DISEASE", 122, 130], ["interleukin (IL)\u20101", "GENE_OR_GENE_PRODUCT", 86, 104], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 106, 110], ["tumour necrosis factor (TNF)\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 115, 145], ["cytokines", "PROTEIN", 66, 75], ["interleukin (IL)\u20101", "PROTEIN", 86, 104], ["IL\u20106", "PROTEIN", 106, 110], ["tumour necrosis factor (TNF)\u2010\u03b1", "PROTEIN", 115, 145], ["several cytokines", "PROBLEM", 58, 75], ["interleukin (IL)", "TEST", 86, 102], ["IL\u2010", "TEST", 106, 109], ["tumour necrosis factor (TNF)", "PROBLEM", 115, 143], ["several", "OBSERVATION_MODIFIER", 58, 65], ["cytokines", "OBSERVATION", 66, 75], ["tumour", "OBSERVATION_MODIFIER", 115, 121], ["necrosis", "OBSERVATION", 122, 130]]], ["These mediators induce various changes in the body including fever, leucocytosis and a modulation of protein synthesis by hepatocytes (Baumann & Gauldie 1994, Ceciliani et al. 2002).INTRODUCTIONPositive acute phase proteins (APP), which increase during inflammation, are believed to act as immunomodulators, \u2010contributing in different ways to reinforce the body's innate defences during inflammation (Petersen et al. 2004, Eckersall & Bell 2010).", [["body", "ANATOMY", 46, 50], ["hepatocytes", "ANATOMY", 122, 133], ["body", "ANATOMY", 357, 361], ["fever", "DISEASE", 61, 66], ["leucocytosis", "DISEASE", 68, 80], ["inflammation", "DISEASE", 253, 265], ["inflammation", "DISEASE", 387, 399], ["body", "ORGANISM_SUBDIVISION", 46, 50], ["hepatocytes", "CELL", 122, 133], ["acute phase proteins", "GENE_OR_GENE_PRODUCT", 203, 223], ["APP", "GENE_OR_GENE_PRODUCT", 225, 228], ["body", "ORGANISM_SUBDIVISION", 357, 361], ["hepatocytes", "CELL_TYPE", 122, 133], ["INTRODUCTIONPositive acute phase proteins", "PROTEIN", 182, 223], ["APP", "PROTEIN", 225, 228], ["various changes in the body", "PROBLEM", 23, 50], ["fever", "PROBLEM", 61, 66], ["leucocytosis", "PROBLEM", 68, 80], ["a modulation of protein synthesis", "PROBLEM", 85, 118], ["INTRODUCTIONPositive acute phase proteins", "PROBLEM", 182, 223], ["inflammation", "PROBLEM", 253, 265], ["immunomodulators", "TREATMENT", 290, 306], ["inflammation", "PROBLEM", 387, 399], ["various", "OBSERVATION_MODIFIER", 23, 30], ["body", "ANATOMY", 46, 50], ["fever", "OBSERVATION", 61, 66], ["leucocytosis", "OBSERVATION", 68, 80], ["protein synthesis", "OBSERVATION", 101, 118], ["hepatocytes", "ANATOMY", 122, 133], ["acute", "OBSERVATION_MODIFIER", 203, 208], ["increase", "OBSERVATION_MODIFIER", 237, 245], ["inflammation", "OBSERVATION", 253, 265]]], ["The most relevant and well described positive APPs in cats are \u03b1\u20101\u2010glycoprotein (AGP) and serum amyloid\u2010A (SAA) (Petersen et al. 2004, Ceron et al. 2005, Paltrinieri 2008, Eckersall & Bell 2010).INTRODUCTIONAGP is believed to act as an immunomodulator and anti\u2010inflammatory protein because it down\u2010regulates the neutrophilic response secondary to inflammation, stimulates the production of IL\u20101R antagonists by macrophages, reduces platelet aggregation and lymphoid proliferation and modulates the production of anti\u2010inflammatory cytokines by the circulating lymphocytes (Hochepied et al. 2003).", [["serum", "ANATOMY", 90, 95], ["neutrophilic", "ANATOMY", 312, 324], ["macrophages", "ANATOMY", 411, 422], ["platelet", "ANATOMY", 432, 440], ["lymphoid", "ANATOMY", 457, 465], ["lymphocytes", "ANATOMY", 559, 570], ["inflammation", "DISEASE", 347, 359], ["platelet aggregation", "DISEASE", 432, 452], ["APPs", "GENE_OR_GENE_PRODUCT", 46, 50], ["cats", "ORGANISM", 54, 58], ["\u03b1\u20101\u2010glycoprotein", "GENE_OR_GENE_PRODUCT", 63, 79], ["AGP", "GENE_OR_GENE_PRODUCT", 81, 84], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["amyloid\u2010A", "GENE_OR_GENE_PRODUCT", 96, 105], ["SAA", "GENE_OR_GENE_PRODUCT", 107, 110], ["IL\u20101R antagonists", "GENE_OR_GENE_PRODUCT", 390, 407], ["macrophages", "CELL", 411, 422], ["platelet", "CELL", 432, 440], ["lymphoid", "CELL", 457, 465], ["lymphocytes", "CELL", 559, 570], ["APPs", "PROTEIN", 46, 50], ["\u03b1\u20101\u2010glycoprotein", "PROTEIN", 63, 79], ["AGP", "PROTEIN", 81, 84], ["SAA", "PROTEIN", 107, 110], ["anti\u2010inflammatory protein", "PROTEIN", 256, 281], ["macrophages", "CELL_TYPE", 411, 422], ["anti\u2010inflammatory cytokines", "PROTEIN", 512, 539], ["circulating lymphocytes", "CELL_TYPE", 547, 570], ["cats", "SPECIES", 54, 58], ["AGP", "TEST", 81, 84], ["serum amyloid", "TEST", 90, 103], ["an immunomodulator", "TREATMENT", 233, 251], ["anti\u2010inflammatory protein", "TREATMENT", 256, 281], ["the neutrophilic response", "PROBLEM", 308, 333], ["inflammation", "PROBLEM", 347, 359], ["IL\u20101R antagonists", "TREATMENT", 390, 407], ["macrophages", "PROBLEM", 411, 422], ["platelet aggregation", "PROBLEM", 432, 452], ["lymphoid proliferation", "PROBLEM", 457, 479], ["anti\u2010inflammatory cytokines", "PROBLEM", 512, 539], ["neutrophilic response", "OBSERVATION", 312, 333], ["inflammation", "OBSERVATION", 347, 359], ["platelet aggregation", "OBSERVATION", 432, 452], ["lymphoid proliferation", "OBSERVATION", 457, 479], ["circulating lymphocytes", "ANATOMY", 547, 570]]], ["Its increase in different cat infectious diseases has been described (Duthie et al. 1997, Paltrinieri et al. 2004, Paltrinieri et al. 2007a,2007b).", [["infectious diseases", "DISEASE", 30, 49], ["cat", "ORGANISM", 26, 29], ["Its increase in different cat infectious diseases", "PROBLEM", 0, 49], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["different", "OBSERVATION_MODIFIER", 16, 25], ["cat", "OBSERVATION_MODIFIER", 26, 29], ["infectious", "OBSERVATION", 30, 40]]], ["In retroviral infected cats, while a previous study reported its increase (Duthie et al. 1997), a more recent one found that FIV positive cats have lower concentrations of AGP than healthy ones (Korman et al. 2012).INTRODUCTIONSAA is a small protein that appears to be the precursor of amyloid protein A, a major protein of \u03b1\u2010amyloid which is potentially involved in a variety of chronic inflammatory diseases (Uhlar & Whitehead 1999).", [["retroviral infected", "DISEASE", 3, 22], ["retroviral", "ORGANISM", 3, 13], ["cats", "ORGANISM", 23, 27], ["FIV", "ORGANISM", 125, 128], ["cats", "ORGANISM", 138, 142], ["AGP", "GENE_OR_GENE_PRODUCT", 172, 175], ["amyloid protein A", "GENE_OR_GENE_PRODUCT", 286, 303], ["\u03b1\u2010amyloid", "GENE_OR_GENE_PRODUCT", 324, 333], ["AGP", "PROTEIN", 172, 175], ["amyloid protein A", "PROTEIN", 286, 303], ["cats", "SPECIES", 23, 27], ["cats", "SPECIES", 138, 142], ["FIV", "SPECIES", 125, 128], ["a previous study", "TEST", 35, 51], ["FIV positive cats", "PROBLEM", 125, 142], ["lower concentrations of AGP", "PROBLEM", 148, 175], ["a small protein", "PROBLEM", 234, 249], ["amyloid protein A", "PROBLEM", 286, 303], ["a major protein of \u03b1\u2010amyloid", "PROBLEM", 305, 333], ["chronic inflammatory diseases", "PROBLEM", 380, 409], ["retroviral", "OBSERVATION", 3, 13], ["infected cats", "OBSERVATION", 14, 27], ["increase", "OBSERVATION_MODIFIER", 65, 73], ["lower concentrations", "OBSERVATION_MODIFIER", 148, 168], ["small protein", "OBSERVATION_MODIFIER", 236, 249], ["appears to be", "UNCERTAINTY", 255, 268], ["amyloid protein", "OBSERVATION", 286, 301], ["variety", "OBSERVATION_MODIFIER", 369, 376], ["chronic", "OBSERVATION_MODIFIER", 380, 387], ["inflammatory", "OBSERVATION", 388, 400]]], ["Among its major functions, SAA acts as a scavenger of oxidised metabolites, protecting tissues from excessive damage induced by inflammation (He et al. 2006).", [["tissues", "ANATOMY", 87, 94], ["excessive damage", "DISEASE", 100, 116], ["inflammation", "DISEASE", 128, 140], ["SAA", "GENE_OR_GENE_PRODUCT", 27, 30], ["tissues", "TISSUE", 87, 94], ["SAA", "PROTEIN", 27, 30], ["oxidised metabolites", "PROBLEM", 54, 74], ["excessive damage", "PROBLEM", 100, 116], ["inflammation", "PROBLEM", 128, 140], ["excessive", "OBSERVATION_MODIFIER", 100, 109], ["damage", "OBSERVATION_MODIFIER", 110, 116], ["inflammation", "OBSERVATION", 128, 140]]], ["As with AGP, its measurement has been reported in different feline diseases (Kajikawa et al. 1999, Sasaki et al. 2001, 2003, Giordano et al. 2004, Tamamoto et al. 2008, 2009).INTRODUCTIONC\u2010reactive protein (CRP) was the first APP described and it is considered to be a major protein in different species such as humans and dogs (Ceron et al. 2005, Schultz & Arnold 1990).", [["feline diseases", "DISEASE", 60, 75], ["AGP", "GENE_OR_GENE_PRODUCT", 8, 11], ["feline", "ORGANISM", 60, 66], ["\u2010reactive protein", "GENE_OR_GENE_PRODUCT", 188, 205], ["CRP", "GENE_OR_GENE_PRODUCT", 207, 210], ["APP", "GENE_OR_GENE_PRODUCT", 226, 229], ["humans", "ORGANISM", 312, 318], ["dogs", "ORGANISM", 323, 327], ["AGP", "PROTEIN", 8, 11], ["\u2010reactive protein", "PROTEIN", 188, 205], ["CRP", "PROTEIN", 207, 210], ["APP", "PROTEIN", 226, 229], ["humans", "SPECIES", 312, 318], ["dogs", "SPECIES", 323, 327], ["humans", "SPECIES", 312, 318], ["AGP", "TEST", 8, 11], ["different feline diseases", "PROBLEM", 50, 75], ["CRP", "TEST", 207, 210], ["a major protein in different species", "PROBLEM", 267, 303], ["different feline", "OBSERVATION_MODIFIER", 50, 66], ["reactive protein", "OBSERVATION", 189, 205]]], ["Among the major functions in the immune system, CRP is involved in the activation of the classical complement pathway, the enhancement of phagocytosis or even the modulation of polymorphonuclear cells (Schultz & Arnold 1990).", [["immune system", "ANATOMY", 33, 46], ["polymorphonuclear cells", "ANATOMY", 177, 200], ["immune system", "ANATOMICAL_SYSTEM", 33, 46], ["CRP", "GENE_OR_GENE_PRODUCT", 48, 51], ["polymorphonuclear cells", "CELL", 177, 200], ["CRP", "PROTEIN", 48, 51], ["polymorphonuclear cells", "CELL_TYPE", 177, 200], ["CRP", "TEST", 48, 51], ["the enhancement of phagocytosis", "PROBLEM", 119, 150], ["polymorphonuclear cells", "OBSERVATION", 177, 200]]], ["Because CRP does not appear to be involved in the feline acute phase reaction, it has not been very well studied or documented in the cat (Ceron et al. 2005).", [["CRP", "GENE_OR_GENE_PRODUCT", 8, 11], ["feline", "ORGANISM", 50, 56], ["cat", "ORGANISM", 134, 137], ["CRP", "PROTEIN", 8, 11], ["CRP", "TEST", 8, 11], ["the feline acute phase reaction", "PROBLEM", 46, 77]]], ["In human medicine, several studies describe its increase in human immunodeficiency virus (HIV) positive patients (Jahoor et al. 1999, Treitinger et al. 2001), even after immunomodulation therapy with exogenous IL\u20102 (Barbai et al. 2010).", [["human immunodeficiency virus (HIV) positive", "DISEASE", 60, 103], ["human", "ORGANISM", 3, 8], ["human immunodeficiency virus", "ORGANISM", 60, 88], ["HIV", "ORGANISM", 90, 93], ["patients", "ORGANISM", 104, 112], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 210, 214], ["IL\u20102", "PROTEIN", 210, 214], ["human", "SPECIES", 3, 8], ["human immunodeficiency virus (HIV", "SPECIES", 60, 93], ["patients", "SPECIES", 104, 112], ["human", "SPECIES", 3, 8], ["human immunodeficiency virus", "SPECIES", 60, 88], ["HIV", "SPECIES", 90, 93], ["several studies", "TEST", 19, 34], ["human immunodeficiency virus", "PROBLEM", 60, 88], ["immunomodulation therapy", "TREATMENT", 170, 194], ["exogenous IL\u20102", "TREATMENT", 200, 214], ["increase", "OBSERVATION_MODIFIER", 48, 56]]], ["Despite the similarity between HIV and FIV (Hosie et al. 2009, Hartmann 2011), the CRP behaviour in FIV positive cats undergoing immunomodulating therapy remains unknown.INTRODUCTIONRecombinant feline interferon\u2010\u03c9 (rFeIFN\u2010\u03c9) therapy (Virbagen, Virbac) is an immunomodulating drug that plays an important role in the therapeutic approach for various feline diseases including cat retrovirus infections (Collado et al. 2006).", [["HIV and FIV", "DISEASE", 31, 42], ["Virbagen", "CHEMICAL", 234, 242], ["Virbac", "CHEMICAL", 244, 250], ["feline diseases", "DISEASE", 349, 364], ["cat retrovirus infections", "DISEASE", 375, 400], ["Virbagen", "CHEMICAL", 234, 242], ["HIV", "ORGANISM", 31, 34], ["FIV", "ORGANISM", 39, 42], ["CRP", "GENE_OR_GENE_PRODUCT", 83, 86], ["FIV", "ORGANISM", 100, 103], ["cats", "ORGANISM", 113, 117], ["feline", "ORGANISM", 194, 200], ["interferon\u2010\u03c9", "GENE_OR_GENE_PRODUCT", 201, 213], ["rFeIFN\u2010\u03c9", "GENE_OR_GENE_PRODUCT", 215, 223], ["Virbagen", "SIMPLE_CHEMICAL", 234, 242], ["Virbac", "SIMPLE_CHEMICAL", 244, 250], ["feline", "ORGANISM", 349, 355], ["cat retrovirus", "ORGANISM", 375, 389], ["CRP", "PROTEIN", 83, 86], ["HIV", "SPECIES", 31, 34], ["cats", "SPECIES", 113, 117], ["HIV", "SPECIES", 31, 34], ["FIV", "SPECIES", 39, 42], ["FIV", "SPECIES", 100, 103], ["HIV", "PROBLEM", 31, 34], ["the CRP behaviour", "TEST", 79, 96], ["FIV positive cats", "PROBLEM", 100, 117], ["immunomodulating therapy", "TREATMENT", 129, 153], ["INTRODUCTIONRecombinant feline interferon\u2010\u03c9 (rFeIFN\u2010\u03c9) therapy", "TREATMENT", 170, 232], ["an immunomodulating drug", "TREATMENT", 255, 279], ["the therapeutic approach", "TREATMENT", 312, 336], ["various feline diseases", "PROBLEM", 341, 364], ["cat retrovirus infections", "PROBLEM", 375, 400], ["immunomodulating therapy", "OBSERVATION", 129, 153]]], ["There are only a few studies describing the clinical improvement of retroviral infected cats with rFeIFN\u2010\u03c9 therapy (de Mari et al. 2004, Domenech et al. 2011, Gil et al. 2013) and little is known about the immunological bases that support these findings.", [["retroviral infected", "DISEASE", 68, 87], ["rFeIFN\u2010\u03c9", "CHEMICAL", 98, 106], ["retroviral", "ORGANISM", 68, 78], ["cats", "ORGANISM", 88, 92], ["rFeIFN\u2010\u03c9", "SIMPLE_CHEMICAL", 98, 106], ["cats", "SPECIES", 88, 92], ["a few studies", "TEST", 15, 28], ["retroviral infected cats", "TREATMENT", 68, 92], ["rFeIFN\u2010\u03c9 therapy", "TREATMENT", 98, 114], ["retroviral infected cats", "OBSERVATION", 68, 92]]], ["Because of reported clinical improvement, increased survival time and reduction of concurrent viral excretion, rFeIFN\u2010\u03c9 appears to be involved in the innate response (de Mari et al. 2004, Domenech et al. 2011, Gil et al. 2013).INTRODUCTIONStudies that describe the use of APPs as a clinical monitoring tool for the immune system in animals undergoing \u2010IFN\u2010therapy are scarce.", [["immune system", "ANATOMY", 315, 328], ["rFeIFN", "CHEMICAL", 111, 117], ["IFN", "CHEMICAL", 352, 355], ["rFeIFN\u2010\u03c9", "GENE_OR_GENE_PRODUCT", 111, 119], ["APPs", "GENE_OR_GENE_PRODUCT", 272, 276], ["immune system", "ANATOMICAL_SYSTEM", 315, 328], ["rFeIFN\u2010\u03c9", "PROTEIN", 111, 119], ["APPs", "PROTEIN", 272, 276], ["IFN", "PROTEIN", 352, 355], ["increased survival time", "TREATMENT", 42, 65], ["concurrent viral excretion", "PROBLEM", 83, 109], ["a clinical monitoring tool", "TEST", 280, 306], ["IFN\u2010therapy", "TREATMENT", 352, 363], ["viral excretion", "OBSERVATION", 94, 109]]], ["Therefore, the main objective of this study was to determine whether rFeIFN\u2010\u03c9 therapy influences APPs (namely SAA, AGP and CRP) in naturally retroviral infected cats and whether these parameters may be good predictors of innate\u2010immune stimulation.Animals ::: MATERIALS AND METHODSSixteen naturally retroviral infected cats living in an animal shelter (Uni\u00e3o Zo\u00f3fila, Lisbon) were selected for the study.", [["rFeIFN", "CHEMICAL", 69, 75], ["rFeIFN", "SIMPLE_CHEMICAL", 69, 75], ["\u03c9", "SIMPLE_CHEMICAL", 76, 77], ["APPs", "GENE_OR_GENE_PRODUCT", 97, 101], ["SAA", "GENE_OR_GENE_PRODUCT", 110, 113], ["AGP", "GENE_OR_GENE_PRODUCT", 115, 118], ["CRP", "GENE_OR_GENE_PRODUCT", 123, 126], ["retroviral", "ORGANISM", 141, 151], ["cats", "ORGANISM", 161, 165], ["retroviral", "ORGANISM", 298, 308], ["cats", "ORGANISM", 318, 322], ["APPs", "PROTEIN", 97, 101], ["SAA", "PROTEIN", 110, 113], ["AGP", "PROTEIN", 115, 118], ["CRP", "PROTEIN", 123, 126], ["cats", "SPECIES", 161, 165], ["cats", "SPECIES", 318, 322], ["this study", "TEST", 33, 43], ["therapy", "TREATMENT", 78, 85], ["APPs", "TEST", 97, 101], ["SAA", "TEST", 110, 113], ["AGP", "TEST", 115, 118], ["CRP", "TEST", 123, 126], ["naturally retroviral infected cats", "TREATMENT", 131, 165], ["innate\u2010immune stimulation", "TREATMENT", 221, 246], ["METHODSSixteen naturally retroviral infected cats", "TREATMENT", 273, 322], ["the study", "TEST", 393, 402], ["retroviral", "OBSERVATION_MODIFIER", 298, 308], ["infected", "OBSERVATION_MODIFIER", 309, 317]]], ["All the cats were accustomed to the shelter environment having lived there for at least 8 weeks before the start of the protocol.", [["cats", "ORGANISM", 8, 12], ["cats", "SPECIES", 8, 12], ["the protocol", "TREATMENT", 116, 128]]], ["In accordance with previous studies (de Mari et al. 2004; Gil et al. 2013), the inclusion criteria included the following: (1) cats of any age, breed or sex (heterogeneous population), (2) cats that showed at least one clinical sign potentially related to retroviral infections, (3) cats that had previously shown a positive rapid immuno\u2010migration FIV and/or FeLV test result.", [["retroviral infections", "DISEASE", 256, 277], ["cats", "ORGANISM", 127, 131], ["cats", "ORGANISM", 189, 193], ["retroviral", "ORGANISM", 256, 266], ["cats", "ORGANISM", 283, 287], ["FIV", "ORGANISM", 348, 351], ["FeLV", "ORGANISM", 359, 363], ["cats", "SPECIES", 127, 131], ["cats", "SPECIES", 189, 193], ["FIV", "SPECIES", 348, 351], ["FeLV", "SPECIES", 359, 363], ["previous studies", "TEST", 19, 35], ["retroviral infections", "PROBLEM", 256, 277], ["a positive rapid immuno\u2010migration FIV", "PROBLEM", 314, 351], ["FeLV test result", "TEST", 359, 375], ["potentially related to", "UNCERTAINTY", 233, 255], ["retroviral infections", "OBSERVATION", 256, 277]]], ["Exclusion criteria were (1) cats with any type of malignancy/neoplasia (such as lymphoma or lymphoid leukaemia), (2) cats having received immunomodulating drugs (such as corticosteroids) during the 4 weeks before the study, (3) cats having received antibiotics or non\u2010steroidal anti\u2010inflammatory drugs during the 2 weeks before the study and (4) cats that did not complete the therapeutic protocol.", [["malignancy", "ANATOMY", 50, 60], ["neoplasia", "ANATOMY", 61, 70], ["lymphoma", "ANATOMY", 80, 88], ["lymphoid leukaemia", "ANATOMY", 92, 110], ["malignancy", "DISEASE", 50, 60], ["neoplasia", "DISEASE", 61, 70], ["lymphoma", "DISEASE", 80, 88], ["lymphoid leukaemia", "DISEASE", 92, 110], ["corticosteroids", "CHEMICAL", 170, 185], ["cats", "ORGANISM", 28, 32], ["neoplasia", "CANCER", 61, 70], ["lymphoma", "CANCER", 80, 88], ["lymphoid leukaemia", "CANCER", 92, 110], ["cats", "ORGANISM", 117, 121], ["cats", "ORGANISM", 228, 232], ["cats", "ORGANISM", 346, 350], ["cats", "SPECIES", 28, 32], ["cats", "SPECIES", 117, 121], ["cats", "SPECIES", 228, 232], ["malignancy", "PROBLEM", 50, 60], ["neoplasia", "PROBLEM", 61, 70], ["lymphoma", "PROBLEM", 80, 88], ["lymphoid leukaemia", "PROBLEM", 92, 110], ["immunomodulating drugs", "TREATMENT", 138, 160], ["corticosteroids", "TREATMENT", 170, 185], ["the study", "TEST", 213, 222], ["antibiotics", "TREATMENT", 249, 260], ["non\u2010steroidal anti\u2010inflammatory drugs", "TREATMENT", 264, 301], ["the study", "TEST", 328, 337], ["the therapeutic protocol", "TREATMENT", 373, 397], ["malignancy", "OBSERVATION", 50, 60], ["neoplasia", "OBSERVATION", 61, 70], ["lymphoid leukaemia", "OBSERVATION", 92, 110]]], ["Initially, all cats were retested to confirm their FIV/FeLV infections by using commercially available enzyme\u2010linked immunoabsorbent assays (ELISA) (ViraCHEK/FIV and ViraCHEK/FeLV, Synbiotics).Animals ::: MATERIALS AND METHODSAnimals were housed in two different catteries, according to their FIV or FeLV status.", [["FeLV infections", "DISEASE", 55, 70], ["cats", "ORGANISM", 15, 19], ["FIV", "ORGANISM", 51, 54], ["FeLV", "ORGANISM", 55, 59], ["FIV", "ORGANISM", 158, 161], ["FeLV", "ORGANISM", 175, 179], ["FIV", "ORGANISM", 293, 296], ["FeLV", "ORGANISM", 300, 304], ["cats", "SPECIES", 15, 19], ["FIV", "SPECIES", 51, 54], ["FeLV", "SPECIES", 55, 59], ["FIV", "SPECIES", 158, 161], ["FIV", "SPECIES", 293, 296], ["their FIV/FeLV infections", "PROBLEM", 45, 70], ["immunoabsorbent assays", "TEST", 117, 139], ["ELISA", "TEST", 141, 146], ["ViraCHEK", "TEST", 149, 157], ["FIV", "TREATMENT", 158, 161], ["ViraCHEK/FeLV", "TREATMENT", 166, 179], ["Synbiotics", "TREATMENT", 181, 191], ["METHODSAnimals", "TREATMENT", 219, 233], ["FeLV infections", "OBSERVATION", 55, 70]]], ["Animals concurrently infected with FIV and FeLV were housed in the FeLV cattery.", [["Animals", "ORGANISM", 0, 7], ["FIV", "ORGANISM", 35, 38], ["FeLV", "ORGANISM", 43, 47], ["FeLV", "ORGANISM", 67, 71], ["FIV", "SPECIES", 35, 38], ["FeLV", "SPECIES", 43, 47], ["FIV and FeLV", "TREATMENT", 35, 47], ["infected", "OBSERVATION", 21, 29], ["FeLV cattery", "OBSERVATION", 67, 79]]], ["All the cats in each cattery were treated and during the study, no incoming animals were allowed.", [["cats", "ORGANISM", 8, 12], ["cats", "SPECIES", 8, 12], ["the study", "TEST", 53, 62]]], ["For the purposes of analysis, cats were divided into three different groups according to their retroviral status: FIV positive cats (n=7), FeLV positive cats (n=6) and co\u2010infected animals (n=3).Animals ::: MATERIALS AND METHODSThe cats were living in good conditions, in agreement with current ethical and European welfare standards.", [["cats", "ORGANISM", 30, 34], ["retroviral", "ORGANISM", 95, 105], ["FIV", "ORGANISM", 114, 117], ["cats", "ORGANISM", 127, 131], ["FeLV", "ORGANISM", 139, 143], ["cats", "ORGANISM", 153, 157], ["cats", "ORGANISM", 231, 235], ["cats", "SPECIES", 30, 34], ["cats", "SPECIES", 127, 131], ["cats", "SPECIES", 153, 157], ["cats", "SPECIES", 231, 235], ["FIV", "SPECIES", 114, 117], ["analysis", "TEST", 20, 28], ["FIV positive cats", "PROBLEM", 114, 131], ["FeLV positive cats", "PROBLEM", 139, 157], ["co\u2010infected animals", "PROBLEM", 168, 187]]], ["All the procedures involving the manipulation of these animals were consented and approved not only by the Local Committee for Ethics and Animal Welfare (CEBEA\u2010Faculty of Veterinary Medicine/Technical University of Lisbon) but also by the clinical director of the animal shelter.Treatment protocol ::: MATERIALS AND METHODSOn the basis of the assumptions derived from two previously published double arm trials with rFeIFN\u2010\u03c9 (de Mari et al. 2004, Domenech et al. 2011), a single\u2010arm study was performed.", [["double arm trials", "TREATMENT", 393, 410], ["a single\u2010arm study", "TEST", 470, 488]]], ["In this study model, a time point before therapy is considered to be the animal's own control.", [["therapy", "TREATMENT", 41, 48]]], ["In this study, assessments before therapy were designated as D0 and considered representative of the stage of each animal before treatment.Treatment protocol ::: MATERIALS AND METHODSAll the animals were treated with rFeIFN\u2010\u03c9, according to the licensed protocol (three cycles of injections at Day (D) 0, D14 and D60.", [["rFeIFN\u2010\u03c9", "CHEMICAL", 217, 225], ["animals", "ORGANISM", 191, 198], ["rFeIFN\u2010\u03c9", "SIMPLE_CHEMICAL", 217, 225], ["this study", "TEST", 3, 13], ["assessments", "TEST", 15, 26], ["therapy", "TREATMENT", 34, 41], ["treatment", "TREATMENT", 129, 138], ["rFeIFN\u2010\u03c9", "TREATMENT", 217, 225], ["the licensed protocol", "TREATMENT", 240, 261], ["D14", "TREATMENT", 304, 307], ["D60", "TREATMENT", 312, 315]]], ["Each treatment cycle consists of five subcutaneous (sc) injections: 1 \u00b5/kg once a day for 5 days).", [["subcutaneous", "ANATOMY", 38, 50], ["Each treatment cycle", "TREATMENT", 0, 20], ["five subcutaneous (sc) injections", "TREATMENT", 33, 66]]], ["Vials of rFeIFN\u2010\u03c9 (\u2010Virbagen Omega; Virbac) were reconstituted with the accompanying saline diluent according to the manufacturer's recommendations immediately before each treatment.Treatment protocol ::: MATERIALS AND METHODSTreatment was administered by two veterinary clinicians from the research team of the project where this study was conducted.Supportive treatment ::: MATERIALS AND METHODSDespite the exclusion criteria applied, some animals needed supportive treatment during therapy.", [["rFeIFN\u2010\u03c9", "SIMPLE_CHEMICAL", 9, 17], ["animals", "ORGANISM", 442, 449], ["rFeIFN\u2010\u03c9 (\u2010Virbagen Omega", "TREATMENT", 9, 34], ["the accompanying saline diluent", "TREATMENT", 68, 99], ["each treatment", "TREATMENT", 167, 181], ["Treatment protocol", "TREATMENT", 182, 200], ["this study", "TEST", 326, 336], ["supportive treatment", "TREATMENT", 457, 477], ["therapy", "TREATMENT", 485, 492]]], ["Consequently, potentiated amoxycillin, hepatic protectants (ursodeoxycholic acid, sylimarin or S\u2010adenylmethionine) and/or fluid therapy were allowed.", [["hepatic", "ANATOMY", 39, 46], ["amoxycillin", "CHEMICAL", 26, 37], ["ursodeoxycholic acid", "CHEMICAL", 60, 80], ["sylimarin", "CHEMICAL", 82, 91], ["S\u2010adenylmethionine", "CHEMICAL", 95, 113], ["amoxycillin", "CHEMICAL", 26, 37], ["ursodeoxycholic acid", "CHEMICAL", 60, 80], ["sylimarin", "CHEMICAL", 82, 91], ["S\u2010adenylmethionine", "CHEMICAL", 95, 113], ["amoxycillin", "SIMPLE_CHEMICAL", 26, 37], ["hepatic protectants", "SIMPLE_CHEMICAL", 39, 58], ["ursodeoxycholic acid", "SIMPLE_CHEMICAL", 60, 80], ["sylimarin", "SIMPLE_CHEMICAL", 82, 91], ["S\u2010adenylmethionine", "SIMPLE_CHEMICAL", 95, 113], ["amoxycillin", "TREATMENT", 26, 37], ["hepatic protectants", "TREATMENT", 39, 58], ["ursodeoxycholic acid", "TREATMENT", 60, 80], ["sylimarin", "TREATMENT", 82, 91], ["S\u2010adenylmethionine)", "TREATMENT", 95, 114], ["fluid therapy", "TREATMENT", 122, 135], ["hepatic", "ANATOMY", 39, 46], ["fluid therapy", "OBSERVATION", 122, 135]]], ["Although any antibiotic may have direct immunomodulator effects, potentiated amoxycillin was allowed taking into account its empirical use and frequent administration in retrovirus infected cats with suspected bacterial infections.", [["amoxycillin", "CHEMICAL", 77, 88], ["retrovirus infected", "DISEASE", 170, 189], ["bacterial infections", "DISEASE", 210, 230], ["amoxycillin", "CHEMICAL", 77, 88], ["amoxycillin", "SIMPLE_CHEMICAL", 77, 88], ["retrovirus", "ORGANISM", 170, 180], ["cats", "ORGANISM", 190, 194], ["cats", "SPECIES", 190, 194], ["any antibiotic", "TREATMENT", 9, 23], ["direct immunomodulator effects", "TREATMENT", 33, 63], ["amoxycillin", "TREATMENT", 77, 88], ["frequent administration", "TREATMENT", 143, 166], ["retrovirus infected cats", "TREATMENT", 170, 194], ["suspected bacterial infections", "PROBLEM", 200, 230], ["bacterial", "OBSERVATION_MODIFIER", 210, 219], ["infections", "OBSERVATION", 220, 230]]], ["Antibiotics (other than potentiated amoxycillin), corticosteroids and non\u2010steroidal anti\u2010inflammatory drugs were not permitted to avoid any possible immunomodulation effects.Blood collection and analysis ::: MATERIALS AND METHODSBlood samples were collected by venipuncture of the jugular vein at four specific time points namely: before (D0), during (D10 and D30) and after therapy (D65).Blood collection and analysis ::: MATERIALS AND METHODSTo allow a better evaluation and simpler blood sample collections, cats were subjected to mild sedation with 0\u00b72 to 0\u00b75 mg/kg butorphanol solution sc (Dolorex, Intervet Portugal).Blood collection and analysis ::: MATERIALS AND METHODSSerum samples were collected after clotting of the sample had occurred by centrifugation (5000g, 10 minutes), and were subsequently frozen at \u221220\u00b0C until analysed.Blood collection and analysis ::: MATERIALS AND METHODSSAA and CRP were measured by specific ELISA kits (Phase SAA Multispecies/Tridelta and Cat CRP ELISA/Kamiya Biomedical Company, respectively).", [["Blood", "ANATOMY", 174, 179], ["samples", "ANATOMY", 235, 242], ["jugular vein", "ANATOMY", 281, 293], ["Blood", "ANATOMY", 389, 394], ["blood sample", "ANATOMY", 485, 497], ["Blood", "ANATOMY", 623, 628], ["METHODSSerum samples", "ANATOMY", 671, 691], ["sample", "ANATOMY", 729, 735], ["Blood", "ANATOMY", 841, 846], ["amoxycillin", "CHEMICAL", 36, 47], ["butorphanol", "CHEMICAL", 570, 581], ["amoxycillin", "CHEMICAL", 36, 47], ["corticosteroids", "CHEMICAL", 50, 65], ["butorphanol", "CHEMICAL", 570, 581], ["amoxycillin", "SIMPLE_CHEMICAL", 36, 47], ["corticosteroids", "SIMPLE_CHEMICAL", 50, 65], ["Blood", "ORGANISM_SUBSTANCE", 174, 179], ["METHODSBlood samples", "CANCER", 222, 242], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 281, 293], ["Blood", "ORGANISM_SUBSTANCE", 389, 394], ["blood", "ORGANISM_SUBSTANCE", 485, 490], ["cats", "ORGANISM", 511, 515], ["butorphanol", "SIMPLE_CHEMICAL", 570, 581], ["Blood", "ORGANISM_SUBSTANCE", 623, 628], ["METHODSSerum samples", "CANCER", 671, 691], ["Blood", "ORGANISM_SUBSTANCE", 841, 846], ["CRP", "GENE_OR_GENE_PRODUCT", 904, 907], ["CRP", "PROTEIN", 904, 907], ["SAA", "PROTEIN", 952, 955], ["Antibiotics", "TREATMENT", 0, 11], ["amoxycillin", "TREATMENT", 36, 47], ["corticosteroids", "TREATMENT", 50, 65], ["non\u2010steroidal anti\u2010inflammatory drugs", "TREATMENT", 70, 107], ["immunomodulation effects", "PROBLEM", 149, 173], ["Blood collection", "TEST", 174, 190], ["METHODSBlood samples", "TEST", 222, 242], ["D30", "TREATMENT", 360, 363], ["therapy", "TREATMENT", 375, 382], ["Blood collection", "TEST", 389, 405], ["a better evaluation", "TEST", 453, 472], ["simpler blood sample collections", "PROBLEM", 477, 509], ["mild sedation", "TREATMENT", 534, 547], ["0\u00b72", "TREATMENT", 553, 556], ["butorphanol solution sc", "TREATMENT", 570, 593], ["Blood collection", "TEST", 623, 639], ["METHODSSerum samples", "TEST", 671, 691], ["Blood collection", "TEST", 841, 857], ["METHODSSAA", "TEST", 889, 899], ["CRP", "TEST", 904, 907], ["specific ELISA kits", "TEST", 925, 944], ["Phase SAA Multispecies", "TEST", 946, 968], ["Tridelta", "TREATMENT", 969, 977], ["Cat CRP ELISA", "TEST", 982, 995], ["jugular vein", "ANATOMY", 281, 293]]], ["AGP was determined by single radial immunodiffusion (Feline AGP, SRID, Tridelta).Blood collection and analysis ::: MATERIALS AND METHODSAll the measurements were performed according the manufacturer's instructions.Statistical analysis ::: MATERIALS AND METHODSStatistical evaluation was performed using R Statistical Software.", [["Blood", "ANATOMY", 81, 86], ["AGP", "GENE_OR_GENE_PRODUCT", 0, 3], ["Blood", "ORGANISM_SUBSTANCE", 81, 86], ["AGP", "PROTEIN", 0, 3], ["Feline AGP", "PROTEIN", 53, 63], ["SRID", "PROTEIN", 65, 69], ["AGP", "TEST", 0, 3], ["single radial immunodiffusion", "TEST", 22, 51], ["Blood collection", "TEST", 81, 97], ["METHODSAll the measurements", "TEST", 129, 156], ["METHODSStatistical evaluation", "TEST", 253, 282]]], ["Because of the small sample size, nonparametric statistical tests were used.", [["the small sample size", "PROBLEM", 11, 32], ["nonparametric statistical tests", "TEST", 34, 65], ["small", "OBSERVATION_MODIFIER", 15, 20], ["sample", "OBSERVATION_MODIFIER", 21, 27], ["size", "OBSERVATION_MODIFIER", 28, 32]]], ["Kruskall\u2013Wallis Tests were applied to assess differences among groups at each time point.", [["Kruskall\u2013Wallis Tests", "TEST", 0, 21]]], ["When differences were observed, a pairwise comparison was applied.", [["a pairwise comparison", "TEST", 32, 53]]], ["The nonparametric tests applied took into account not only the magnitude but also the predominant \u201csign\u201d (positive or negative) of the effect.", [["The nonparametric tests", "TEST", 0, 23]]], ["Significance was set at P<0\u00b705.RESULTSAll 16 cats completed the licensed therapeutic protocol.", [["cats", "ORGANISM", 45, 49], ["the licensed therapeutic protocol", "TREATMENT", 60, 93]]], ["No statistical differences between groups were observed apart from CRP on D65 and AGP on D30.RESULTSFor SAA, groups were similar at all time points and all the cats behaved similarly.", [["CRP", "GENE_OR_GENE_PRODUCT", 67, 70], ["D65", "SIMPLE_CHEMICAL", 74, 77], ["AGP", "GENE_OR_GENE_PRODUCT", 82, 85], ["SAA", "GENE_OR_GENE_PRODUCT", 104, 107], ["cats", "ORGANISM", 160, 164], ["CRP", "PROTEIN", 67, 70], ["D65", "PROTEIN", 74, 77], ["AGP", "PROTEIN", 82, 85], ["SAA", "PROTEIN", 104, 107], ["cats", "SPECIES", 160, 164], ["statistical differences between groups", "PROBLEM", 3, 41], ["CRP", "TEST", 67, 70], ["D65", "TREATMENT", 74, 77], ["AGP", "TREATMENT", 82, 85], ["D30", "TREATMENT", 89, 92]]], ["Therefore, for analysis over time, the groups were all considered together.", [["analysis", "TEST", 15, 23]]], ["A significant increase of SAA concentration was observed (P=0\u00b70005; increased SAA in 15 animals and decreased SAA in 1).", [["SAA", "GENE_OR_GENE_PRODUCT", 26, 29], ["SAA", "PROTEIN", 26, 29], ["SAA", "PROTEIN", 78, 81], ["SAA", "PROTEIN", 110, 113], ["A significant increase of SAA concentration", "PROBLEM", 0, 43], ["P", "TEST", 58, 59], ["increased SAA", "PROBLEM", 68, 81], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["SAA concentration", "OBSERVATION", 26, 43]]], ["On D65, mean SAA concentration was 1\u00b76 times higher than D0.", [["SAA", "GENE_OR_GENE_PRODUCT", 13, 16], ["SAA", "PROTEIN", 13, 16], ["D65", "TREATMENT", 3, 6], ["mean SAA concentration", "TEST", 8, 30]]], ["All values remained below the upper limit of the reference interval (RI) of 10 \u00b5g/mL.RESULTSFor AGP, the three groups were also similar at all time points, apart from D30 (P=0\u00b7016), where co\u2010infected and FeLV cats showed higher mean values than FIV cats (FIV versus \u2010co\u2010infected: P=0\u00b7029; FIV versus FeLV: P=0\u00b7067; FeLV versus \u2010co\u2010infected: P=0\u00b712) (Fig 2).", [["AGP", "GENE_OR_GENE_PRODUCT", 96, 99], ["FeLV", "ORGANISM", 204, 208], ["cats", "ORGANISM", 209, 213], ["FIV", "ORGANISM", 245, 248], ["cats", "ORGANISM", 249, 253], ["FIV", "ORGANISM", 255, 258], ["FIV", "ORGANISM", 289, 292], ["FeLV", "ORGANISM", 300, 304], ["FeLV", "ORGANISM", 315, 319], ["AGP", "PROTEIN", 96, 99], ["cats", "SPECIES", 209, 213], ["cats", "SPECIES", 249, 253], ["FeLV", "SPECIES", 204, 208], ["FIV", "SPECIES", 245, 248], ["All values", "TEST", 0, 10], ["AGP", "TEST", 96, 99], ["FeLV cats", "TEST", 204, 213], ["higher mean values", "PROBLEM", 221, 239], ["FIV cats", "TEST", 245, 253], ["P", "TEST", 280, 281], ["P", "TEST", 306, 307], ["FeLV", "PROBLEM", 315, 319], ["upper limit", "OBSERVATION_MODIFIER", 30, 41]]], ["There was a significant overall increase (1\u00b77 times) of AGP concentrations (P=0\u00b7012; AGP increased in 13 cats and decreased in 3) from D0 to D65.", [["AGP", "GENE_OR_GENE_PRODUCT", 56, 59], ["cats", "ORGANISM", 105, 109], ["AGP", "PROTEIN", 56, 59], ["AGP", "PROTEIN", 85, 88], ["AGP concentrations", "TEST", 56, 74], ["P", "TEST", 76, 77], ["AGP", "TEST", 85, 88], ["D65", "TREATMENT", 141, 144], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["overall", "OBSERVATION_MODIFIER", 24, 31], ["increase", "OBSERVATION_MODIFIER", 32, 40]]], ["Basal values were within the RI (260 to 580 \u00b5g/mL).", [["Basal values", "TEST", 0, 12]]], ["During therapy, mean values of FeLV and co\u2010infected cats exceeded the upper limit of the RI while for FIV, all the results remained within the RI.RESULTSFor CRP, the three groups were statistically indistinguishable during the study apart from D65 (P=0\u00b7019), where there was a statistically significant difference.", [["FeLV", "ORGANISM", 31, 35], ["cats", "ORGANISM", 52, 56], ["FIV", "ORGANISM", 102, 105], ["CRP", "GENE_OR_GENE_PRODUCT", 157, 160], ["CRP", "PROTEIN", 157, 160], ["cats", "SPECIES", 52, 56], ["FIV", "SPECIES", 102, 105], ["therapy", "TREATMENT", 7, 14], ["mean values", "TEST", 16, 27], ["FeLV and co\u2010infected cats", "PROBLEM", 31, 56], ["FIV", "TREATMENT", 102, 105], ["CRP", "TEST", 157, 160], ["the study", "TEST", 223, 232], ["a statistically significant difference", "PROBLEM", 275, 313], ["upper limit", "OBSERVATION_MODIFIER", 70, 81], ["significant", "OBSERVATION_MODIFIER", 291, 302], ["difference", "OBSERVATION", 303, 313]]], ["At this time point, co\u2010infected and FeLV cats had higher CRP concentrations than FIV cats (FIV versus co\u2010infected: P=0\u00b7009; FIV versus FeLV: P=0\u00b7052; FeLV versus co\u2010infected: P=0\u00b736).", [["FeLV", "ORGANISM", 36, 40], ["cats", "ORGANISM", 41, 45], ["CRP", "GENE_OR_GENE_PRODUCT", 57, 60], ["FIV cats", "ORGANISM", 81, 89], ["FIV", "ORGANISM", 91, 94], ["FIV", "ORGANISM", 124, 127], ["FeLV", "ORGANISM", 135, 139], ["FeLV", "ORGANISM", 150, 154], ["CRP", "PROTEIN", 57, 60], ["cats", "SPECIES", 41, 45], ["cats", "SPECIES", 85, 89], ["FeLV", "SPECIES", 36, 40], ["FIV", "SPECIES", 81, 84], ["FeLV cats", "TEST", 36, 45], ["higher CRP concentrations", "PROBLEM", 50, 75], ["FIV cats", "TEST", 81, 89], ["P", "TEST", 115, 116], ["FeLV", "PROBLEM", 150, 154]]], ["Results of CRP values are presented in Fig 3.", [["CRP", "GENE_OR_GENE_PRODUCT", 11, 14], ["CRP", "PROTEIN", 11, 14], ["CRP values", "TEST", 11, 21]]], ["From D0 to D65 there was an increase in CRP concentrations in all the cats (P=0\u00b70001; increased CRP in 16 cats).", [["CRP", "GENE_OR_GENE_PRODUCT", 40, 43], ["cats", "ORGANISM", 70, 74], ["CRP", "GENE_OR_GENE_PRODUCT", 96, 99], ["cats", "ORGANISM", 106, 110], ["CRP", "PROTEIN", 40, 43], ["CRP", "PROTEIN", 96, 99], ["cats", "SPECIES", 70, 74], ["D65", "TREATMENT", 11, 14], ["an increase in CRP concentrations", "TREATMENT", 25, 58], ["P", "TEST", 76, 77], ["CRP", "TEST", 96, 99], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["CRP concentrations", "OBSERVATION_MODIFIER", 40, 58]]], ["This increase was approximately 1\u00b78 times the baseline value.", [["increase", "OBSERVATION_MODIFIER", 5, 13]]], ["Values on D30 and D65 were above the upper limit of the RI (38 to 186 \u00b5g/mL) for FIV, FeLV and co\u2010infected cats,RESULTSOnly one cat of the FeLV group (cat 9) received supportive therapy at D65, namely intravenous fluids, because of suspected otitis/vestibular syndrome and mild\u2010dehydration.", [["intravenous", "ANATOMY", 201, 212], ["vestibular", "ANATOMY", 249, 259], ["otitis/vestibular syndrome", "DISEASE", 242, 268], ["mild\u2010dehydration", "DISEASE", 273, 289], ["D65", "SIMPLE_CHEMICAL", 18, 21], ["FIV", "ORGANISM", 81, 84], ["FeLV", "ORGANISM", 86, 90], ["cats", "ORGANISM", 107, 111], ["cat", "ORGANISM", 128, 131], ["FeLV", "ORGANISM", 139, 143], ["D65", "SIMPLE_CHEMICAL", 189, 192], ["vestibular", "ORGAN", 249, 259], ["cats", "SPECIES", 107, 111], ["FIV", "SPECIES", 81, 84], ["FeLV", "SPECIES", 86, 90], ["Values", "TEST", 0, 6], ["D30", "TREATMENT", 10, 13], ["D65", "TREATMENT", 18, 21], ["FIV", "TREATMENT", 81, 84], ["supportive therapy", "TREATMENT", 167, 185], ["D65", "TREATMENT", 189, 192], ["intravenous fluids", "TREATMENT", 201, 219], ["otitis", "PROBLEM", 242, 248], ["vestibular syndrome", "PROBLEM", 249, 268], ["mild\u2010dehydration", "PROBLEM", 273, 289], ["upper limit", "OBSERVATION_MODIFIER", 37, 48], ["otitis", "OBSERVATION", 242, 248], ["vestibular syndrome", "OBSERVATION", 249, 268]]], ["This fact was considered as a co\u2010morbidity factor and was included in the clinical\u2010evaluation and considered in the clinical score.", [["a co\u2010morbidity factor", "PROBLEM", 28, 49]]], ["This animal also received potentiated amoxycilin but after the end of the study.", [["amoxycilin", "CHEMICAL", 38, 48], ["amoxycilin", "CHEMICAL", 38, 48], ["amoxycilin", "SIMPLE_CHEMICAL", 38, 48], ["potentiated amoxycilin", "TREATMENT", 26, 48], ["the study", "TEST", 70, 79]]], ["The APP profile of this cat was similar to the wider group.RESULTSData related to clinical signs and concurrent viral loads (namely calicivirus, herpesvirus, coronavirus and parvovirus) in these cats over the same time period have been previously reported (Gil et al. 2013).", [["calicivirus, herpesvirus, coronavirus and parvovirus", "DISEASE", 132, 184], ["APP", "GENE_OR_GENE_PRODUCT", 4, 7], ["cat", "ORGANISM", 24, 27], ["calicivirus", "ORGANISM", 132, 143], ["herpesvirus", "ORGANISM", 145, 156], ["coronavirus", "ORGANISM", 158, 169], ["parvovirus", "ORGANISM", 174, 184], ["cats", "ORGANISM", 195, 199], ["APP", "PROTEIN", 4, 7], ["coronavirus and parvovirus", "SPECIES", 158, 184], ["cats", "SPECIES", 195, 199], ["The APP profile", "TEST", 0, 15], ["clinical signs", "TEST", 82, 96], ["concurrent viral loads", "PROBLEM", 101, 123], ["calicivirus", "PROBLEM", 132, 143], ["herpesvirus", "PROBLEM", 145, 156], ["coronavirus", "PROBLEM", 158, 169], ["parvovirus", "PROBLEM", 174, 184], ["viral loads", "OBSERVATION", 112, 123]]], ["Herpesvirus and coronavirus viral load were assessed by real\u2010time polymerase chain reaction (PCR), while calicivirus and parvovirus status were determined by conventional\u2010PCR (Gil et al. 2013).", [["Herpesvirus", "ORGANISM", 0, 11], ["coronavirus", "ORGANISM", 16, 27], ["calicivirus", "ORGANISM", 105, 116], ["parvovirus", "ORGANISM", 121, 131], ["Herpesvirus", "SPECIES", 0, 11], ["coronavirus", "SPECIES", 16, 27], ["Herpesvirus", "PROBLEM", 0, 11], ["coronavirus viral load", "PROBLEM", 16, 38], ["PCR", "TEST", 93, 96], ["calicivirus", "PROBLEM", 105, 116], ["parvovirus status", "PROBLEM", 121, 138], ["PCR", "TEST", 171, 174], ["coronavirus viral load", "OBSERVATION", 16, 38]]], ["These results are summarised in Table 1, which also includes the detailed APP results.", [["APP", "GENE_OR_GENE_PRODUCT", 74, 77], ["APP", "PROTEIN", 74, 77]]], ["Clinical signs improved and concurrent viral excretion decreased in the majority of the cats.", [["cats", "ORGANISM", 88, 92], ["cats", "SPECIES", 88, 92], ["Clinical signs", "TEST", 0, 14], ["concurrent viral excretion", "PROBLEM", 28, 54], ["improved", "OBSERVATION_MODIFIER", 15, 23], ["viral", "OBSERVATION_MODIFIER", 39, 44], ["excretion", "OBSERVATION_MODIFIER", 45, 54], ["decreased", "OBSERVATION_MODIFIER", 55, 64]]], ["Only two cats increased coronovirus excretion but they remained asymptomatic.", [["coronovirus", "CHEMICAL", 24, 35], ["coronovirus", "CHEMICAL", 24, 35], ["cats", "ORGANISM", 9, 13], ["coronovirus", "SIMPLE_CHEMICAL", 24, 35], ["cats", "SPECIES", 9, 13], ["two cats increased coronovirus excretion", "PROBLEM", 5, 45], ["asymptomatic", "PROBLEM", 64, 76], ["two", "OBSERVATION_MODIFIER", 5, 8], ["cats", "OBSERVATION_MODIFIER", 9, 13], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["coronovirus excretion", "OBSERVATION", 24, 45], ["asymptomatic", "OBSERVATION", 64, 76]]], ["All the cats that were positive for calicivirus and a single cat that was excreting parvovirus became negative at the end of the study meaning an overall significant decrease of concurrent viral infections.", [["calicivirus", "DISEASE", 36, 47], ["viral infections", "DISEASE", 189, 205], ["cats", "ORGANISM", 8, 12], ["calicivirus", "ORGANISM", 36, 47], ["cat", "ORGANISM", 61, 64], ["parvovirus", "ORGANISM", 84, 94], ["cats", "SPECIES", 8, 12], ["cat", "SPECIES", 61, 64], ["cat", "SPECIES", 61, 64], ["All the cats", "TEST", 0, 12], ["calicivirus", "PROBLEM", 36, 47], ["a single cat", "TEST", 52, 64], ["excreting parvovirus", "PROBLEM", 74, 94], ["the study", "TEST", 125, 134], ["concurrent viral infections", "PROBLEM", 178, 205], ["significant", "OBSERVATION_MODIFIER", 154, 165], ["decrease", "OBSERVATION_MODIFIER", 166, 174], ["viral infections", "OBSERVATION", 189, 205]]], ["Simultaneously, the majority of cats had increased APP concentrations.DISCUSSIONThis study describes the changes observed in serum concentrations of three different APPs in 16 cats naturally infected with retroviruses and undergoing rFeIFN\u2010\u03c9 therapy.", [["serum", "ANATOMY", 125, 130], ["rFeIFN", "CHEMICAL", 233, 239], ["cats", "ORGANISM", 32, 36], ["APP", "GENE_OR_GENE_PRODUCT", 51, 54], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["APPs", "GENE_OR_GENE_PRODUCT", 165, 169], ["cats", "ORGANISM", 176, 180], ["retroviruses", "ORGANISM", 205, 217], ["rFeIFN\u2010\u03c9", "SIMPLE_CHEMICAL", 233, 241], ["APP", "PROTEIN", 51, 54], ["APPs", "PROTEIN", 165, 169], ["cats", "SPECIES", 32, 36], ["cats", "SPECIES", 176, 180], ["the changes", "PROBLEM", 101, 112], ["serum concentrations", "TEST", 125, 145], ["retroviruses", "TREATMENT", 205, 217], ["rFeIFN\u2010\u03c9 therapy", "TREATMENT", 233, 249], ["retroviruses", "OBSERVATION", 205, 217]]], ["A single\u2010arm study was considered and performed as this is likely to be the most reliable approach when studying naturally infected \u2010animals, for which time of infection and sub\u2010types of the virus are uncertain.", [["naturally infected \u2010animals", "DISEASE", 113, 140], ["infection", "DISEASE", 160, 169], ["A single\u2010arm study", "TEST", 0, 18], ["infection", "PROBLEM", 160, 169], ["the virus", "PROBLEM", 187, 196], ["infection", "OBSERVATION", 160, 169]]], ["In this study, rFeIFN\u2010\u03c9 was used according to a licensed protocol, approved for veterinary use in feline retrovirus infections.", [["rFeIFN\u2010\u03c9", "CHEMICAL", 15, 23], ["feline retrovirus infections", "DISEASE", 98, 126], ["rFeIFN", "CHEMICAL", 15, 21], ["rFeIFN\u2010\u03c9", "SIMPLE_CHEMICAL", 15, 23], ["feline retrovirus", "ORGANISM", 98, 115], ["feline retrovirus", "SPECIES", 98, 115], ["this study", "TEST", 3, 13], ["rFeIFN\u2010\u03c9", "TREATMENT", 15, 23], ["a licensed protocol", "TREATMENT", 46, 65], ["feline retrovirus infections", "PROBLEM", 98, 126], ["feline retrovirus infections", "OBSERVATION", 98, 126]]], ["Although only a few studies have been published, clinical improvement of cats undergoing rFeIFN\u03c9 therapy has been well documented in double arm trials (de Mari et al. 2004, Domenech et al. 2011).", [["rFeIFN\u03c9", "CHEMICAL", 89, 96], ["cats", "ORGANISM", 73, 77], ["rFeIFN\u03c9", "SIMPLE_CHEMICAL", 89, 96], ["cats", "SPECIES", 73, 77], ["a few studies", "TEST", 14, 27], ["rFeIFN\u03c9 therapy", "TREATMENT", 89, 104], ["double arm trials", "TREATMENT", 133, 150]]], ["This study provides further information regarding parameters complementary to the main clinical signs and concurrent viral excretion data previously published (Gil et al. 2013), clarifying the pathophysiological phenomena behind immune stimulation.DISCUSSIONAs several authors have suggested (Ceron et al. 2005) the concentration of APPs may be within the RI even in animals with disease.", [["APPs", "GENE_OR_GENE_PRODUCT", 333, 337], ["APPs", "PROTEIN", 333, 337], ["This study", "TEST", 0, 10], ["concurrent viral excretion data", "TEST", 106, 137], ["the pathophysiological phenomena", "PROBLEM", 189, 221], ["immune stimulation", "TREATMENT", 229, 247], ["disease", "PROBLEM", 380, 387], ["immune stimulation", "OBSERVATION", 229, 247], ["disease", "OBSERVATION", 380, 387]]], ["As such measurement of these parameters for monitoring inflammation stimulus is not without difficulty.", [["inflammation", "DISEASE", 55, 67], ["these parameters", "TEST", 23, 39], ["monitoring inflammation stimulus", "TEST", 44, 76], ["difficulty", "PROBLEM", 92, 102]]], ["Using each individual animal as its own reference was considered to be a practical and reasonable approach to bypass this problem (Ceron et al. 2005).", [["bypass", "TREATMENT", 110, 116]]], ["Therefore, as in previous human studies that evaluated APPs (Wasunna et al. 1995, Barbai et al. 2010), animals acted as their own controls and the time point before therapy (D0) was considered the baseline value for each cat.", [["human", "ORGANISM", 26, 31], ["APPs", "GENE_OR_GENE_PRODUCT", 55, 59], ["cat", "ORGANISM", 221, 224], ["APPs", "PROTEIN", 55, 59], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["previous human studies", "TEST", 17, 39], ["APPs", "TEST", 55, 59]]], ["Subsequently, it was possible to study the individual trends during therapy.DISCUSSIONAlthough there is no consensus on upper and lower limit values for the measured APPs, the suggested ranges for each kit were used.", [["upper", "ORGANISM_SUBDIVISION", 120, 125], ["APPs", "GENE_OR_GENE_PRODUCT", 166, 170], ["APPs", "PROTEIN", 166, 170], ["no", "UNCERTAINTY", 104, 106]]], ["Particularly for AGP and CRP, cats had higher mean values than the upper limit at some time points.", [["AGP", "GENE_OR_GENE_PRODUCT", 17, 20], ["CRP", "GENE_OR_GENE_PRODUCT", 25, 28], ["cats", "ORGANISM", 30, 34], ["AGP", "PROTEIN", 17, 20], ["CRP", "PROTEIN", 25, 28], ["cats", "SPECIES", 30, 34], ["AGP", "TEST", 17, 20], ["CRP", "TEST", 25, 28], ["cats", "TEST", 30, 34], ["upper limit", "OBSERVATION_MODIFIER", 67, 78]]], ["However, previous studies describe higher values in healthy cats (Kajikawa et al. 1999, Selting et al. 2000), which if adapted would expand the recommended RI.", [["cats", "ORGANISM", 60, 64], ["cats", "SPECIES", 60, 64], ["previous studies", "TEST", 9, 25]]], ["Only the comparison between individual values before (D0), during and after therapy (D65) with particular relevance to differences between D0 and D65 were considered relevant for the study, whether or not they were above the RI.DISCUSSIONFor concentrations of SAA and AGP, the three groups studied (FIV, FeLV and co\u2010infected animals) behaved similarly, demonstrating increased values during rFeIFN\u2010\u03c9 therapy.", [["rFeIFN\u2010\u03c9", "CHEMICAL", 391, 399], ["SAA", "GENE_OR_GENE_PRODUCT", 260, 263], ["AGP", "GENE_OR_GENE_PRODUCT", 268, 271], ["FIV", "ORGANISM", 299, 302], ["FeLV", "ORGANISM", 304, 308], ["rFeIFN\u2010\u03c9", "SIMPLE_CHEMICAL", 391, 399], ["SAA", "PROTEIN", 260, 263], ["AGP", "PROTEIN", 268, 271], ["FIV", "SPECIES", 299, 302], ["therapy (D65", "TREATMENT", 76, 88], ["D65", "TREATMENT", 146, 149], ["the study", "TEST", 179, 188], ["SAA and AGP", "TREATMENT", 260, 271], ["increased values", "PROBLEM", 367, 383], ["rFeIFN\u2010\u03c9 therapy", "TREATMENT", 391, 407], ["increased", "OBSERVATION_MODIFIER", 367, 376]]], ["Groups were not statistically different with the exception of AGP on D30.", [["AGP", "GENE_OR_GENE_PRODUCT", 62, 65], ["AGP", "PROTEIN", 62, 65], ["D30", "TREATMENT", 69, 72]]], ["This particular variation is secondary to the fact that the FIV group demonstrated lower AGP values compared to FeLV and co\u2010infected cats.", [["FIV", "ORGANISM", 60, 63], ["AGP", "GENE_OR_GENE_PRODUCT", 89, 92], ["FeLV", "ORGANISM", 112, 116], ["cats", "ORGANISM", 133, 137], ["AGP", "PROTEIN", 89, 92], ["cats", "SPECIES", 133, 137], ["FeLV", "SPECIES", 112, 116], ["the FIV group", "TEST", 56, 69], ["lower AGP values", "PROBLEM", 83, 99]]], ["Despite the low number of animals a possible explanation may be sub\u2010clinical diseases leading to a particular alteration at this time point.", [["sub\u2010clinical diseases", "PROBLEM", 64, 85], ["a particular alteration", "PROBLEM", 97, 120], ["low number", "OBSERVATION_MODIFIER", 12, 22], ["possible explanation may be", "UNCERTAINTY", 36, 63]]], ["However, considering that the statistical difference was only evident at this particular time point, this finding was not considered biologically significant.", [["not considered", "UNCERTAINTY", 118, 132]]], ["According to previous studies which reported that AGP and SAA are good predictors of immunomodulation (Kajikawa et al. 1999, Hochepied et al. 2003), these results support the hypothesis that rFeIFN\u2010\u03c9 therapy may modulate pro\u2010inflammatory innate mechanisms.", [["rFeIFN", "CHEMICAL", 191, 197], ["AGP", "GENE_OR_GENE_PRODUCT", 50, 53], ["SAA", "GENE_OR_GENE_PRODUCT", 58, 61], ["rFeIFN\u2010\u03c9", "GENE_OR_GENE_PRODUCT", 191, 199], ["AGP", "PROTEIN", 50, 53], ["SAA", "PROTEIN", 58, 61], ["previous studies", "TEST", 13, 29], ["AGP and SAA", "PROBLEM", 50, 61], ["rFeIFN\u2010\u03c9 therapy", "TREATMENT", 191, 207], ["good", "OBSERVATION_MODIFIER", 66, 70]]], ["These APPs may be a useful monitoring tool for demonstrating modulation of the innate\u2010immune response.DISCUSSIONFor CRP, with the exception of D65 the three groups of cats were also similar throughout the study.", [["APPs", "GENE_OR_GENE_PRODUCT", 6, 10], ["CRP", "GENE_OR_GENE_PRODUCT", 116, 119], ["cats", "ORGANISM", 167, 171], ["APPs", "PROTEIN", 6, 10], ["CRP", "PROTEIN", 116, 119], ["cats", "SPECIES", 167, 171], ["a useful monitoring tool", "TEST", 18, 42], ["CRP", "TEST", 116, 119], ["D65", "TREATMENT", 143, 146], ["cats", "TREATMENT", 167, 171], ["the study", "TEST", 201, 210]]], ["The particular variation at D65 was due to the fact that FeLV and co\u2010infected cats had higher values than FIV cats.", [["FeLV", "ORGANISM", 57, 61], ["cats", "ORGANISM", 78, 82], ["FIV cats", "ORGANISM", 106, 114], ["cats", "SPECIES", 78, 82], ["cats", "SPECIES", 110, 114], ["FIV cats", "SPECIES", 106, 114], ["FeLV and co\u2010infected cats", "PROBLEM", 57, 82], ["FeLV", "OBSERVATION", 57, 61]]], ["As for AGP at D30, this may have been due to various causes such as sub\u2010clinical uncontrolled infections in the shelter or even a natural progression of retroviral disease.", [["infections", "DISEASE", 94, 104], ["retroviral disease", "DISEASE", 153, 171], ["AGP", "GENE_OR_GENE_PRODUCT", 7, 10], ["retroviral", "ORGANISM", 153, 163], ["AGP", "PROTEIN", 7, 10], ["AGP at D30", "TREATMENT", 7, 17], ["various causes", "PROBLEM", 45, 59], ["sub\u2010clinical uncontrolled infections in the shelter", "PROBLEM", 68, 119], ["retroviral disease", "PROBLEM", 153, 171], ["uncontrolled", "OBSERVATION_MODIFIER", 81, 93], ["infections", "OBSERVATION", 94, 104], ["natural", "OBSERVATION_MODIFIER", 130, 137], ["progression", "OBSERVATION_MODIFIER", 138, 149], ["retroviral disease", "OBSERVATION", 153, 171]]], ["From the beginning (D0) until the end of the treatment (D65) a significant increase of CRP concentrations was noted.", [["CRP", "GENE_OR_GENE_PRODUCT", 87, 90], ["CRP", "PROTEIN", 87, 90], ["the treatment (D65", "TREATMENT", 41, 59], ["CRP concentrations", "PROBLEM", 87, 105], ["significant", "OBSERVATION_MODIFIER", 63, 74], ["increase", "OBSERVATION_MODIFIER", 75, 83], ["CRP concentrations", "OBSERVATION", 87, 105]]], ["Although CRP has not been considered as a useful biomarker of inflammation in cats, this study shows that this APP behaves similarly to SAA and AGP.", [["inflammation", "DISEASE", 62, 74], ["CRP", "GENE_OR_GENE_PRODUCT", 9, 12], ["cats", "ORGANISM", 78, 82], ["APP", "GENE_OR_GENE_PRODUCT", 111, 114], ["SAA", "GENE_OR_GENE_PRODUCT", 136, 139], ["AGP", "GENE_OR_GENE_PRODUCT", 144, 147], ["CRP", "PROTEIN", 9, 12], ["APP", "PROTEIN", 111, 114], ["SAA", "PROTEIN", 136, 139], ["AGP", "PROTEIN", 144, 147], ["CRP", "TEST", 9, 12], ["inflammation in cats", "PROBLEM", 62, 82], ["this study", "TEST", 84, 94], ["SAA", "TEST", 136, 139], ["AGP", "TEST", 144, 147], ["inflammation", "OBSERVATION", 62, 74]]], ["Therefore, in contrast with previous studies, CRP may also have value as a biomarker of feline inflammation, being increased in a similar magnitude to the other APPs measured.DISCUSSIONA recent study described the evolution of different APPs, namely SAA and AGP, in FIV and non\u2010FIV cats following Mycoplasma haemofelis and Candidatus Mycoplasma \u2010Haemominutum infections (Korman et al. 2012).", [["inflammation", "DISEASE", 95, 107], ["Mycoplasma haemofelis", "DISEASE", 297, 318], ["Haemominutum infections", "DISEASE", 346, 369], ["CRP", "GENE_OR_GENE_PRODUCT", 46, 49], ["feline", "ORGANISM", 88, 94], ["APPs", "GENE_OR_GENE_PRODUCT", 161, 165], ["APPs", "GENE_OR_GENE_PRODUCT", 237, 241], ["SAA", "GENE_OR_GENE_PRODUCT", 250, 253], ["AGP", "GENE_OR_GENE_PRODUCT", 258, 261], ["FIV", "ORGANISM", 266, 269], ["FIV cats", "ORGANISM", 278, 286], ["Mycoplasma haemofelis", "ORGANISM", 297, 318], ["Mycoplasma \u2010Haemominutum", "ORGANISM", 334, 358], ["CRP", "PROTEIN", 46, 49], ["APPs", "PROTEIN", 161, 165], ["APPs", "PROTEIN", 237, 241], ["SAA", "PROTEIN", 250, 253], ["AGP", "PROTEIN", 258, 261], ["cats", "SPECIES", 282, 286], ["Mycoplasma haemofelis", "SPECIES", 297, 318], ["Mycoplasma \u2010Haemominutum", "SPECIES", 334, 358], ["FIV", "SPECIES", 266, 269], ["FIV", "SPECIES", 278, 281], ["Mycoplasma haemofelis", "SPECIES", 297, 318], ["previous studies", "TEST", 28, 44], ["CRP", "TEST", 46, 49], ["feline inflammation", "PROBLEM", 88, 107], ["recent study", "TEST", 187, 199], ["different APPs", "PROBLEM", 227, 241], ["AGP", "TEST", 258, 261], ["FIV cats", "TREATMENT", 278, 286], ["Mycoplasma haemofelis", "PROBLEM", 297, 318], ["Candidatus Mycoplasma", "PROBLEM", 323, 344], ["Haemominutum infections", "PROBLEM", 346, 369], ["feline", "OBSERVATION_MODIFIER", 88, 94], ["inflammation", "OBSERVATION", 95, 107], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["Mycoplasma haemofelis", "OBSERVATION", 297, 318], ["Candidatus Mycoplasma", "OBSERVATION", 323, 344]]], ["This study revealed that \u2010pre\u2010existing FIV infection did not significantly affect the APR to mycoplasma.", [["FIV infection", "DISEASE", 39, 52], ["mycoplasma", "DISEASE", 93, 103], ["FIV", "ORGANISM", 39, 42], ["FIV", "SPECIES", 39, 42], ["This study", "TEST", 0, 10], ["\u2010pre\u2010existing FIV infection", "PROBLEM", 25, 52], ["mycoplasma", "PROBLEM", 93, 103], ["infection", "OBSERVATION", 43, 52]]], ["Despite remaining within the RI, FIV positive cats demonstrated lower concentrations of AGP than non\u2010FIV cats.", [["FIV", "ORGANISM", 33, 36], ["cats", "ORGANISM", 46, 50], ["AGP", "GENE_OR_GENE_PRODUCT", 88, 91], ["FIV cats", "ORGANISM", 101, 109], ["AGP", "PROTEIN", 88, 91], ["cats", "SPECIES", 46, 50], ["cats", "SPECIES", 105, 109], ["FIV", "SPECIES", 33, 36], ["FIV", "SPECIES", 101, 104], ["FIV positive cats", "TEST", 33, 50], ["lower concentrations of AGP", "PROBLEM", 64, 91], ["positive cats", "OBSERVATION", 37, 50], ["lower concentrations", "OBSERVATION_MODIFIER", 64, 84]]], ["This contrasted with previous studies suggesting that AGP was increased in FIV cats (Duthie et al. 1997).", [["AGP", "GENE_OR_GENE_PRODUCT", 54, 57], ["FIV cats", "ORGANISM", 75, 83], ["AGP", "PROTEIN", 54, 57], ["cats", "SPECIES", 79, 83], ["FIV cats", "SPECIES", 75, 83], ["previous studies", "TEST", 21, 37], ["AGP", "PROBLEM", 54, 57], ["AGP", "OBSERVATION_MODIFIER", 54, 57], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["FIV cats", "OBSERVATION", 75, 83]]], ["Taking all these into account, it seems reasonable to consider that FIV cats are able to develop an efficient acute phase, which may lead to a rise of APPs.", [["FIV cats", "ORGANISM", 68, 76], ["APPs", "GENE_OR_GENE_PRODUCT", 151, 155], ["APPs", "PROTEIN", 151, 155], ["FIV", "SPECIES", 68, 71], ["FIV cats", "TREATMENT", 68, 76], ["a rise of APPs", "PROBLEM", 141, 155]]], ["Regarding the more conventional assessments of the immune system in retroviral infected cats, a previous study concluded that the hyperglobulinaemia commonly observed in FIV cats may be due to hyperactivation of B\u2010cells which is more evident when the disease progresses (Gleich & Hartmann 2009).", [["immune system", "ANATOMY", 51, 64], ["B\u2010cells", "ANATOMY", 212, 219], ["hyperglobulinaemia", "DISEASE", 130, 148], ["immune system", "ANATOMICAL_SYSTEM", 51, 64], ["retroviral", "ORGANISM", 68, 78], ["cats", "ORGANISM", 88, 92], ["hyperglobulinaemia", "CANCER", 130, 148], ["FIV cats", "ORGANISM", 170, 178], ["B\u2010cells", "GENE_OR_GENE_PRODUCT", 212, 219], ["cats", "SPECIES", 88, 92], ["FIV", "SPECIES", 170, 173], ["retroviral infected cats", "TREATMENT", 68, 92], ["a previous study", "TEST", 94, 110], ["the hyperglobulinaemia", "PROBLEM", 126, 148], ["hyperactivation of B\u2010cells", "PROBLEM", 193, 219], ["retroviral", "OBSERVATION", 68, 78], ["infected cats", "OBSERVATION", 79, 92], ["FIV cats", "OBSERVATION", 170, 178], ["may be due to", "UNCERTAINTY", 179, 192], ["hyperactivation", "OBSERVATION", 193, 208]]], ["In contrast, and due to a progressive defect of helper T\u2010cells, FeLV cats do not usually present with hyperglobulinaemia being more prone to have severe cytopenias (Gleich & Hartmann 2009).", [["hyperglobulinaemia", "DISEASE", 102, 120], ["cytopenias", "DISEASE", 153, 163], ["T\u2010cells", "GENE_OR_GENE_PRODUCT", 55, 62], ["FeLV cats", "ORGANISM", 64, 73], ["helper T\u2010cells", "CELL_TYPE", 48, 62], ["a progressive defect of helper T\u2010cells", "PROBLEM", 24, 62], ["FeLV cats", "PROBLEM", 64, 73], ["hyperglobulinaemia", "PROBLEM", 102, 120], ["severe cytopenias", "PROBLEM", 146, 163], ["progressive", "OBSERVATION_MODIFIER", 26, 37], ["defect", "OBSERVATION", 38, 44], ["severe", "OBSERVATION_MODIFIER", 146, 152], ["cytopenias", "OBSERVATION", 153, 163]]], ["According to this study, the increase of APPs was similar in FIV and FeLV, suggesting that the innate\u2010immune stimulation must have the same basis in these two groups.", [["APPs", "GENE_OR_GENE_PRODUCT", 41, 45], ["FIV", "ORGANISM", 61, 64], ["FeLV", "ORGANISM", 69, 73], ["APPs", "PROTEIN", 41, 45], ["FIV", "SPECIES", 61, 64], ["this study", "TEST", 13, 23], ["the increase of APPs", "PROBLEM", 25, 45], ["the innate\u2010immune stimulation", "TREATMENT", 91, 120], ["increase", "OBSERVATION_MODIFIER", 29, 37]]], ["No studies were performed to correlate \u03b3\u2010globulins with APPs in retroviral infected cats, and whether rFeIFN\u2010\u03c9 interferes with serum protein electrophoresis profiles remains unclear.DISCUSSIONIt has been previously demonstrated that rFeIFN\u03c9 results in an overall clinical improvement not only of FIV but also FeLV and co\u2010infected cats (Gil et al. 2013).", [["serum", "ANATOMY", 127, 132], ["retroviral infected", "DISEASE", 64, 83], ["\u03b3\u2010globulins", "GENE_OR_GENE_PRODUCT", 39, 50], ["APPs", "GENE_OR_GENE_PRODUCT", 56, 60], ["retroviral", "ORGANISM", 64, 74], ["cats", "ORGANISM", 84, 88], ["rFeIFN\u2010\u03c9", "GENE_OR_GENE_PRODUCT", 102, 110], ["serum", "ORGANISM_SUBSTANCE", 127, 132], ["rFeIFN\u03c9", "GENE_OR_GENE_PRODUCT", 233, 240], ["FIV", "ORGANISM", 296, 299], ["FeLV", "ORGANISM", 309, 313], ["cats", "ORGANISM", 330, 334], ["\u03b3\u2010globulins", "PROTEIN", 39, 50], ["APPs", "PROTEIN", 56, 60], ["rFeIFN\u2010\u03c9", "PROTEIN", 102, 110], ["rFeIFN\u03c9", "PROTEIN", 233, 240], ["cats", "SPECIES", 84, 88], ["cats", "SPECIES", 330, 334], ["FIV", "SPECIES", 296, 299], ["studies", "TEST", 3, 10], ["APPs", "TEST", 56, 60], ["retroviral infected cats", "TREATMENT", 64, 88], ["serum protein electrophoresis profiles", "TEST", 127, 165]]], ["Clinical signs, evaluated by a score\u2010scale, decreased in the three groups (FIV, FeLV and co\u2010infected) meaning an overall improvement of symptomatic cats.", [["FIV", "ORGANISM", 75, 78], ["FeLV", "ORGANISM", 80, 84], ["cats", "ORGANISM", 148, 152], ["cats", "SPECIES", 148, 152], ["Clinical signs", "TEST", 0, 14], ["symptomatic cats", "PROBLEM", 136, 152], ["decreased", "OBSERVATION_MODIFIER", 44, 53], ["overall", "OBSERVATION_MODIFIER", 113, 120], ["improvement", "OBSERVATION_MODIFIER", 121, 132], ["symptomatic", "OBSERVATION_MODIFIER", 136, 147], ["cats", "OBSERVATION", 148, 152]]], ["In total, 10 of 16 improved their clinical signs while 6 of 16 remained stable.", [["their clinical signs", "TEST", 28, 48], ["stable", "OBSERVATION_MODIFIER", 72, 78]]], ["Furthermore, a significant decrease in excretion of other viruses was also observed concomitantly (Gil et al. 2013).", [["a significant decrease in excretion of other viruses", "PROBLEM", 13, 65], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["decrease", "OBSERVATION_MODIFIER", 27, 35], ["excretion", "OBSERVATION_MODIFIER", 39, 48], ["viruses", "OBSERVATION", 58, 65]]], ["Correlating the APP profile with these previous results, it was observed that APP concentrations increased in cats with concurrently improved clinical signs and reduced viral excretion.", [["APP", "GENE_OR_GENE_PRODUCT", 16, 19], ["APP", "GENE_OR_GENE_PRODUCT", 78, 81], ["cats", "ORGANISM", 110, 114], ["APP", "PROTEIN", 16, 19], ["APP", "PROTEIN", 78, 81], ["cats", "SPECIES", 110, 114], ["the APP profile", "TEST", 12, 27], ["APP concentrations", "PROBLEM", 78, 96], ["reduced viral excretion", "PROBLEM", 161, 184], ["reduced", "OBSERVATION_MODIFIER", 161, 168], ["viral excretion", "OBSERVATION", 169, 184]]], ["This finding was consistent even in cats with low clinical scores and in those where scores remained stable with therapy.", [["cats", "ORGANISM", 36, 40], ["low clinical scores", "PROBLEM", 46, 65], ["therapy", "TREATMENT", 113, 120], ["consistent even", "UNCERTAINTY", 17, 32], ["low", "OBSERVATION_MODIFIER", 46, 49], ["stable", "OBSERVATION_MODIFIER", 101, 107]]], ["Recognising that APPs may be increased in different situations such as chronic infections and severe inflammation (Ceron et al. 2005, Paltrinieri 2008), this concurrent clinical improvement and the decrease in the loads of other viruses reinforce and sustain the hypothesis that rFeIFN\u2010\u03c9 therapy potentiates the immune response and may involve a beneficial APP increase in treated animals.DISCUSSIONIn conclusion, all the measured APPs significantly increased, revealing a potential innate\u2010immune response in naturally infected cats during rFeIFN\u2010\u03c9 therapy.", [["chronic infections", "DISEASE", 71, 89], ["inflammation", "DISEASE", 101, 113], ["rFeIFN", "CHEMICAL", 279, 285], ["rFeIFN\u2010\u03c9", "CHEMICAL", 540, 548], ["APPs", "GENE_OR_GENE_PRODUCT", 17, 21], ["rFeIFN\u2010\u03c9", "GENE_OR_GENE_PRODUCT", 279, 287], ["APP", "GENE_OR_GENE_PRODUCT", 357, 360], ["APPs", "GENE_OR_GENE_PRODUCT", 431, 435], ["cats", "ORGANISM", 528, 532], ["rFeIFN\u2010\u03c9", "SIMPLE_CHEMICAL", 540, 548], ["APPs", "PROTEIN", 17, 21], ["APP", "PROTEIN", 357, 360], ["APPs", "PROTEIN", 431, 435], ["cats", "SPECIES", 528, 532], ["chronic infections", "PROBLEM", 71, 89], ["severe inflammation", "PROBLEM", 94, 113], ["rFeIFN\u2010\u03c9 therapy", "TREATMENT", 279, 295], ["a beneficial APP increase", "TREATMENT", 344, 369], ["a potential innate\u2010immune response", "PROBLEM", 471, 505], ["rFeIFN\u2010\u03c9 therapy", "TREATMENT", 540, 556], ["may be", "UNCERTAINTY", 22, 28], ["increased", "OBSERVATION_MODIFIER", 29, 38], ["chronic", "OBSERVATION_MODIFIER", 71, 78], ["infections", "OBSERVATION", 79, 89], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["inflammation", "OBSERVATION", 101, 113], ["decrease", "OBSERVATION_MODIFIER", 198, 206]]], ["In humans, it has been described that the administration of IL\u20102 in HIV patients induced an increase of CRP, which was positively correlated to an increase of CD4+ cell count (Barbai et al. 2010).", [["CD4+ cell", "ANATOMY", 159, 168], ["humans", "ORGANISM", 3, 9], ["IL\u20102", "GENE_OR_GENE_PRODUCT", 60, 64], ["HIV", "ORGANISM", 68, 71], ["patients", "ORGANISM", 72, 80], ["CRP", "GENE_OR_GENE_PRODUCT", 104, 107], ["CD4", "GENE_OR_GENE_PRODUCT", 159, 162], ["IL\u20102", "PROTEIN", 60, 64], ["CRP", "PROTEIN", 104, 107], ["CD4", "PROTEIN", 159, 162], ["humans", "SPECIES", 3, 9], ["patients", "SPECIES", 72, 80], ["humans", "SPECIES", 3, 9], ["HIV", "SPECIES", 68, 71], ["the administration of IL\u2010", "TREATMENT", 38, 63], ["an increase of CRP", "PROBLEM", 89, 107], ["CD4", "TEST", 159, 162], ["cell count", "TEST", 164, 174], ["increase", "OBSERVATION_MODIFIER", 92, 100], ["increase", "OBSERVATION_MODIFIER", 147, 155]]], ["These findings reported a possible involvement of CRP in the IL2\u2010induced immune stimulation (Barbai et al. 2010).", [["CRP", "GENE_OR_GENE_PRODUCT", 50, 53], ["IL2", "GENE_OR_GENE_PRODUCT", 61, 64], ["CRP", "PROTEIN", 50, 53], ["IL2", "PROTEIN", 61, 64], ["involvement of CRP", "PROBLEM", 35, 53], ["the IL2\u2010induced immune stimulation", "TREATMENT", 57, 91], ["IL2", "ANATOMY", 61, 64]]], ["Conversely, it was previously described that CD4/CD8 ratios do not change in cats under rFeIFN\u2010\u03c9 (Domenech et al. 2011).", [["CD4", "GENE_OR_GENE_PRODUCT", 45, 48], ["CD8", "GENE_OR_GENE_PRODUCT", 49, 52], ["cats", "ORGANISM", 77, 81], ["CD4", "PROTEIN", 45, 48], ["CD8", "PROTEIN", 49, 52], ["CD4/CD8 ratios", "TEST", 45, 59]]], ["Therefore, the true mechanism by which rFeIFN\u2010\u03c9 induces an increase in APP remains unclear.", [["rFeIFN", "CHEMICAL", 39, 45], ["rFeIFN", "CHEMICAL", 39, 45], ["rFeIFN\u2010\u03c9", "GENE_OR_GENE_PRODUCT", 39, 47], ["APP", "GENE_OR_GENE_PRODUCT", 71, 74], ["rFeIFN\u2010\u03c9", "PROTEIN", 39, 47], ["APP", "PROTEIN", 71, 74], ["an increase in APP", "PROBLEM", 56, 74], ["increase", "OBSERVATION_MODIFIER", 59, 67]]], ["To further characterise the immune response during rFeIFN\u2010\u03c9 therapy, further studies are required to correlate these findings with other parameters such as the cytokine profile.", [["rFeIFN\u2010\u03c9", "SIMPLE_CHEMICAL", 51, 59], ["cytokine", "PROTEIN", 160, 168], ["rFeIFN\u2010\u03c9 therapy", "TREATMENT", 51, 67], ["further studies", "TEST", 69, 84], ["other parameters", "TEST", 131, 147], ["the cytokine profile", "TEST", 156, 176]]], ["For now, the results of this study suggest that APPs may be promising predictors of innate\u2010immune stimulation in naturally retroviral infected cats undergoing rFeIFN\u2010\u03c9 therapy.", [["rFeIFN\u2010\u03c9", "CHEMICAL", 159, 167], ["APPs", "GENE_OR_GENE_PRODUCT", 48, 52], ["retroviral", "ORGANISM", 123, 133], ["cats", "ORGANISM", 143, 147], ["rFeIFN\u2010\u03c9", "SIMPLE_CHEMICAL", 159, 167], ["APPs", "PROTEIN", 48, 52], ["cats", "SPECIES", 143, 147], ["this study", "TEST", 24, 34], ["innate\u2010immune stimulation", "TREATMENT", 84, 109], ["naturally retroviral infected cats", "TREATMENT", 113, 147], ["rFeIFN\u2010\u03c9 therapy", "TREATMENT", 159, 175]]], ["In the future, they could be combined together in an APP\u2010panel that may help with the individual monitoring and assessment of rFeIFN\u2010\u03c9 therapy.", [["APP", "GENE_OR_GENE_PRODUCT", 53, 56], ["rFeIFN\u2010\u03c9", "SIMPLE_CHEMICAL", 126, 134], ["APP", "PROTEIN", 53, 56], ["the individual monitoring", "TEST", 82, 107], ["assessment", "TEST", 112, 122], ["rFeIFN\u2010\u03c9 therapy", "TREATMENT", 126, 142]]]], "cf273437f78bebbb0f112e1b9c3d23b89bb0dbb3": [["Dear Editor,We would like to thank Dr Ni\u00f1o and colleagues for their positive and relevant remarks on our guidelines on anaesthetic management during the SARS-CoV-2 pandemic [1] .Dear Editor,We fully agree with the first comment on the interest of a pre-anaesthetic teleconsultation.Dear Editor,It has indeed been proven by several groups that telemedicine in anaesthesia is a feasible practice, appreciated by patients, that is safe and does not lead to more cancellation of surgery than physical consultation [2] .", [["SARS-CoV-2 pandemic", "DISEASE", 153, 172], ["patients", "ORGANISM", 410, 418], ["patients", "SPECIES", 410, 418], ["anaesthetic management", "TREATMENT", 119, 141], ["the SARS", "TEST", 149, 157], ["a pre-anaesthetic teleconsultation", "TREATMENT", 247, 281], ["surgery", "TREATMENT", 475, 482]]], ["At first glance, one might think that the use of telemedicine should be preferred for patients living in rural areas and/or living far from the hospital, but teleconsultation, even in the format of a simple phone call, remains the preferred method for patients regardless of the distance from their place of residence, their co-morbidities, and the cumbersome nature of the planned surgery [3, 4] .", [["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 252, 260], ["telemedicine", "TREATMENT", 49, 61], ["the planned surgery", "TREATMENT", 370, 389]]], ["However, this enthusiasm of patients and certain practitioners for dematerialised consultation techniques should not be the tree that hides the forest.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["dematerialised consultation techniques", "TREATMENT", 67, 105]]], ["Indeed, the transition, even partial, from in-face to teleconsultation must be prepared and a minimum of prerequisites are necessary, such as: the availability of high-performance computer equipment; the availability of a secretariat to organise the call planning and the sending before the teleconsultation of the documents to be prepared by the patient; the use of secure applications to preserve the confidentiality of the medical data exchanged; or the training of anaesthetists in the institutional tools made available.", [["patient", "ORGANISM", 347, 354], ["patient", "SPECIES", 347, 354], ["secure applications", "TREATMENT", 367, 386]]], ["Finally, the regulatory aspect should not be neglected, and it is important to check that a teleconsultation has the same medico-legal value and is reimbursed to the same extent by the national health insurance organisation as a physical consultation.", [["a teleconsultation", "TEST", 90, 108]]], ["In this sense, France is probably late in this area, and the first wave of the COVID-19 pandemic during Spring 2020 was certainly an opportunity to begin to make up for this delay.", [["the COVID", "TEST", 75, 84], ["this delay", "PROBLEM", 169, 179], ["probably", "UNCERTAINTY", 25, 33], ["late", "OBSERVATION_MODIFIER", 34, 38]]], ["Indeed, the travel restrictions required by the health situation and imposed by the government during the lockdown have made it almost compulsory to use teleconsultation to anticipate the resumption of surgical activity after the first wave of the pandemic.", [["teleconsultation", "TREATMENT", 153, 169], ["surgical activity", "TREATMENT", 202, 219], ["the pandemic", "PROBLEM", 244, 256], ["pandemic", "OBSERVATION", 248, 256]]], ["This crisis therefore represented both an opportunity J o u r n a l P r e -p r o o f to implement a technology that was previously used only occasionally, and a constraint at a time when many anaesthetists who were also involved in the management of patients with severe forms of COVID-19 had little time to train in the technique and to organise the first teleconsultations, which inevitably wasted time before gaining time later.", [["COVID", "DISEASE", 280, 285], ["patients", "ORGANISM", 250, 258], ["patients", "SPECIES", 250, 258], ["This crisis", "PROBLEM", 0, 11], ["severe forms of COVID", "PROBLEM", 264, 285]]], ["Thus, although teleconsultation has been set up in many French centres, its success has been variable.", [["teleconsultation", "TEST", 15, 31], ["variable", "OBSERVATION_MODIFIER", 93, 101]]], ["Finally, it should be noted that teleconsultation is sometimes not possible, particularly with elderly patients, those who are not computerliterate or who are visually or hearing impaired, and that in all studies on the subject a small contingent of patients are excluded from teleconsultation groups; patients in whom in-face consultation will always be necessary.Dear Editor,Concerning the place of the SARS-CoV-2 PCR, we would like to point out that our management algorithm does not recommend carrying out a PCR before any scheduled surgery.", [["hearing impaired", "DISEASE", 171, 187], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 250, 258], ["patients", "ORGANISM", 302, 310], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 250, 258], ["patients", "SPECIES", 302, 310], ["hearing impaired", "PROBLEM", 171, 187], ["all studies", "TEST", 201, 212], ["the SARS", "TEST", 401, 409], ["CoV-2 PCR", "TEST", 410, 419], ["a PCR", "TEST", 510, 515], ["any scheduled surgery", "TREATMENT", 523, 544]]], ["We believe that this would be unnecessarily costly, binding for the patient, and would saturate the laboratory testing circuits, even more in the current period when the beginning of the second wave of the pandemic is leading to an increase in the number of PCR testing performed in symptomatic patients.", [["patient", "ORGANISM", 68, 75], ["patients", "ORGANISM", 295, 303], ["patient", "SPECIES", 68, 75], ["patients", "SPECIES", 295, 303], ["the laboratory testing circuits", "TEST", 96, 127], ["PCR testing", "TEST", 258, 269], ["increase", "OBSERVATION_MODIFIER", 232, 240]]], ["We therefore recommend preoperative PCR in the case of a symptomatic patient and/or a patient at risk of a severe form of COVID-19 and/or major surgery with pulmonary and/or systemic inflammatory repercussions and/or surgery at high risk of aerosolisation (R3.1.4 and Figure 1 ).", [["pulmonary", "ANATOMY", 157, 166], ["aerosolisation", "DISEASE", 241, 255], ["patient", "ORGANISM", 69, 76], ["patient", "ORGANISM", 86, 93], ["pulmonary", "ORGAN", 157, 166], ["patient", "SPECIES", 69, 76], ["patient", "SPECIES", 86, 93], ["preoperative PCR", "TEST", 23, 39], ["COVID", "TEST", 122, 127], ["major surgery", "TREATMENT", 138, 151], ["systemic inflammatory repercussions", "TREATMENT", 174, 209], ["surgery", "TREATMENT", 217, 224], ["aerosolisation", "PROBLEM", 241, 255], ["pulmonary", "ANATOMY", 157, 166], ["inflammatory", "OBSERVATION", 183, 195]]], ["As this PCR must be carried out as close as possible to the surgery, we agree that the result cannot be available at the time of the anaesthetic consultation.", [["this PCR", "TEST", 3, 11], ["the surgery", "TREATMENT", 56, 67], ["the anaesthetic consultation", "TEST", 129, 157]]], ["In this sense, it is theoretically possible to equip the consultation staff with N95, NK95 or FFP2 respirators.", [["N95", "TREATMENT", 81, 84], ["FFP2 respirators", "TREATMENT", 94, 110]]], ["Respirators should not be lacking in intensive care units nor in the operating theatre because it would have been used in consultation.", [["Respirators", "TREATMENT", 0, 11]]], ["Moreover, surgical face masks significantly reduced detection of coronavirus virus RNA in respiratory droplets and aerosols and could prevent transmission of human coronaviruses from symptomatic individuals [5] .", [["respiratory droplets", "ANATOMY", 90, 110], ["coronavirus virus", "ORGANISM", 65, 82], ["human", "ORGANISM", 158, 163], ["coronaviruses", "ORGANISM", 164, 177], ["coronavirus virus RNA", "RNA", 65, 86], ["coronavirus virus", "SPECIES", 65, 82], ["human", "SPECIES", 158, 163], ["coronavirus virus", "SPECIES", 65, 82], ["human coronaviruses", "SPECIES", 158, 177], ["surgical face masks", "TREATMENT", 10, 29], ["coronavirus virus RNA", "TREATMENT", 65, 86], ["respiratory droplets", "TREATMENT", 90, 110], ["aerosols", "TREATMENT", 115, 123], ["human coronaviruses", "PROBLEM", 158, 177], ["symptomatic individuals", "PROBLEM", 183, 206], ["coronavirus virus", "OBSERVATION", 65, 82], ["respiratory droplets", "OBSERVATION", 90, 110]]], ["Finally, equipping the consultation staff with respirators is more expensive, more difficult to bear over a working day, and is probably an exaggerated precaution, provided that any symptomatic patient is immediately referred to the laboratory for COVID-19 testing, ideally before coming to the consultation area by a telephone call the day before, J o u r n a l P r e -p r o o f and at the latest as soon as he or she arrives at the consultation reception desk by filling in a self-questionnaire (R3.1.2 and R6.1.1 + Figure 3 ).", [["patient", "ORGANISM", 194, 201], ["patient", "SPECIES", 194, 201], ["an exaggerated precaution", "TREATMENT", 137, 162], ["COVID", "TEST", 248, 253]]], ["In this sense, this recommendation follows the recommendations of the French government and scientific societies, which stipulate that \"the use of FFP2 type masks should only be used for invasive medical procedures or for manoeuvres on the respiratory tract in COVID-19 patients, in any highly suspicious patient or in patients with proven contact with a COVID-19 patient, whether this procedure is carried out by a doctor, a non-physician caregiver, a dentist or a physiotherapist\" [6, 7] .", [["respiratory tract", "ANATOMY", 240, 257], ["respiratory tract", "ORGANISM_SUBDIVISION", 240, 257], ["patients", "ORGANISM", 270, 278], ["patient", "ORGANISM", 305, 312], ["patients", "ORGANISM", 319, 327], ["patient", "ORGANISM", 364, 371], ["patients", "SPECIES", 270, 278], ["patient", "SPECIES", 305, 312], ["patients", "SPECIES", 319, 327], ["patient", "SPECIES", 364, 371], ["FFP2 type masks", "TREATMENT", 147, 162], ["invasive medical procedures", "TREATMENT", 187, 214], ["manoeuvres", "TREATMENT", 222, 232], ["the respiratory tract", "TREATMENT", 236, 257], ["this procedure", "TREATMENT", 381, 395]]], ["In other cases (i.e. non-aerosol-generating care and no prolonged contact within one metre), the wearing of a simple surgical mask is recommended, including for the care of a proven COVID-19 patient.Dear Editor,J o u r n a l P r e -p r o o f", [["patient", "ORGANISM", 191, 198], ["patient", "SPECIES", 191, 198], ["a simple surgical mask", "TREATMENT", 108, 130]]]], "PMC7125519": [["IntroductionHerpesviruses are widespread among humans and may cause many diseases.", [["Herpesviruses", "DISEASE", 12, 25], ["Herpesviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["humans", "ORGANISM", 47, 53], ["humans", "SPECIES", 47, 53], ["humans", "SPECIES", 47, 53], ["many diseases", "PROBLEM", 68, 81], ["may cause", "UNCERTAINTY", 58, 67], ["many", "OBSERVATION_MODIFIER", 68, 72], ["diseases", "OBSERVATION", 73, 81]]], ["The primary infection is usually followed by a life-long latency of the virus and its reactivation usually occurs during immunosuppression of the host.", [["primary infection", "DISEASE", 4, 21], ["The primary infection", "PROBLEM", 0, 21], ["the virus", "PROBLEM", 68, 77], ["its reactivation", "PROBLEM", 82, 98], ["primary", "OBSERVATION_MODIFIER", 4, 11], ["infection", "OBSERVATION", 12, 21]]], ["Infection with varicella-zoster virus (VZV) results in varicella (chickenpox) which usually takes a mild course in children but may be more severe in adults.", [["varicella-zoster virus", "DISEASE", 15, 37], ["VZV", "DISEASE", 39, 42], ["varicella", "DISEASE", 55, 64], ["chickenpox", "DISEASE", 66, 76], ["varicella-zoster virus", "ORGANISM", 15, 37], ["VZV", "ORGANISM", 39, 42], ["children", "ORGANISM", 115, 123], ["varicella-zoster virus", "SPECIES", 15, 37], ["children", "SPECIES", 115, 123], ["varicella-zoster virus", "SPECIES", 15, 37], ["VZV", "SPECIES", 39, 42], ["Infection", "PROBLEM", 0, 9], ["varicella-zoster virus", "PROBLEM", 15, 37], ["VZV", "PROBLEM", 39, 42], ["varicella (chickenpox)", "PROBLEM", 55, 77], ["varicella", "OBSERVATION", 15, 24], ["zoster virus", "OBSERVATION", 25, 37], ["mild", "OBSERVATION_MODIFIER", 100, 104], ["may be", "UNCERTAINTY", 128, 134], ["more severe", "OBSERVATION_MODIFIER", 135, 146]]], ["Later on, after establishing latency in neural tissues, the virus can reactivate causing herpes zoster (shingles) which is often accompanied by neuralgic pain and can lead to post-herpetic neuralgia (PHN) as well as other complications such as loss of vision (zoster ophthalmicus) [1], [2].IntroductionIn most cases immunocompetent patients infected by herpesviruses do not require antiviral therapy.", [["neural tissues", "ANATOMY", 40, 54], ["herpes zoster", "DISEASE", 89, 102], ["shingles", "DISEASE", 104, 112], ["pain", "DISEASE", 154, 158], ["post-herpetic neuralgia", "DISEASE", 175, 198], ["PHN", "DISEASE", 200, 203], ["loss of vision (zoster ophthalmicus", "DISEASE", 244, 279], ["neural tissues", "TISSUE", 40, 54], ["herpes zoster", "ORGANISM", 89, 102], ["patients", "ORGANISM", 332, 340], ["herpesviruses", "ORGANISM", 353, 366], ["herpes zoster", "SPECIES", 89, 102], ["patients", "SPECIES", 332, 340], ["latency in neural tissues", "PROBLEM", 29, 54], ["the virus", "PROBLEM", 56, 65], ["herpes zoster", "PROBLEM", 89, 102], ["shingles", "PROBLEM", 104, 112], ["neuralgic pain", "PROBLEM", 144, 158], ["post-herpetic neuralgia (PHN)", "PROBLEM", 175, 204], ["other complications", "PROBLEM", 216, 235], ["loss of vision (zoster ophthalmicus", "PROBLEM", 244, 279], ["herpesviruses", "PROBLEM", 353, 366], ["antiviral therapy", "TREATMENT", 382, 399], ["neural tissues", "ANATOMY", 40, 54], ["post-herpetic", "OBSERVATION_MODIFIER", 175, 188], ["neuralgia", "OBSERVATION", 189, 198], ["antiviral therapy", "OBSERVATION", 382, 399]]], ["However, reactivation of the virus is of significant concern in immunocompromised individuals, e.g. recipients of solid-organ and hematopoietic stem cell transplant, patients under aggressive chemotherapy or individuals with acquired immunodeficiency syndrome (AIDS).", [["solid-organ", "ANATOMY", 114, 125], ["hematopoietic stem cell", "ANATOMY", 130, 153], ["acquired immunodeficiency syndrome", "DISEASE", 225, 259], ["AIDS", "DISEASE", 261, 265], ["organ", "ORGAN", 120, 125], ["hematopoietic stem cell", "CELL", 130, 153], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["the virus", "PROBLEM", 25, 34], ["immunocompromised individuals", "PROBLEM", 64, 93], ["solid-organ", "PROBLEM", 114, 125], ["hematopoietic stem cell transplant", "TREATMENT", 130, 164], ["aggressive chemotherapy", "TREATMENT", 181, 204], ["acquired immunodeficiency syndrome", "PROBLEM", 225, 259], ["virus", "OBSERVATION", 29, 34], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["immunocompromised", "OBSERVATION", 64, 81], ["organ", "ANATOMY", 120, 125], ["hematopoietic stem cell transplant", "OBSERVATION", 130, 164]]], ["Under these circumstances, efficient antiviral drugs are of crucial importance.", [["efficient antiviral drugs", "TREATMENT", 27, 52], ["antiviral drugs", "OBSERVATION", 37, 52]]], ["Effective treatments of herpesviridae species, including herpes simplex virus (HSV), VZV and human cytomegalovirus (HCMV) [3], [4] are available but they are hampered by emergence of drug resistance and significant drug toxicities for some anti-herpesvirus agents (such as ganciclovir, foscavir and cidofovir).", [["herpes simplex virus (HSV), VZV and human cytomegalovirus", "DISEASE", 57, 114], ["toxicities", "DISEASE", 220, 230], ["ganciclovir", "CHEMICAL", 273, 284], ["foscavir", "CHEMICAL", 286, 294], ["cidofovir", "CHEMICAL", 299, 308], ["ganciclovir", "CHEMICAL", 273, 284], ["foscavir", "CHEMICAL", 286, 294], ["cidofovir", "CHEMICAL", 299, 308], ["herpesviridae species", "ORGANISM", 24, 45], ["herpes simplex virus", "ORGANISM", 57, 77], ["HSV", "ORGANISM", 79, 82], ["VZV", "ORGANISM", 85, 88], ["human cytomegalovirus", "ORGANISM", 93, 114], ["HCMV", "ORGANISM", 116, 120], ["anti-herpesvirus agents", "SIMPLE_CHEMICAL", 240, 263], ["ganciclovir", "SIMPLE_CHEMICAL", 273, 284], ["foscavir", "SIMPLE_CHEMICAL", 286, 294], ["cidofovir", "SIMPLE_CHEMICAL", 299, 308], ["herpes simplex virus", "SPECIES", 57, 77], ["VZV", "SPECIES", 85, 88], ["human", "SPECIES", 93, 98], ["cytomegalovirus", "SPECIES", 99, 114], ["herpes simplex virus", "SPECIES", 57, 77], ["HSV", "SPECIES", 79, 82], ["VZV", "SPECIES", 85, 88], ["human cytomegalovirus", "SPECIES", 93, 114], ["HCMV", "SPECIES", 116, 120], ["herpesviridae species", "PROBLEM", 24, 45], ["herpes simplex virus", "PROBLEM", 57, 77], ["HSV", "PROBLEM", 79, 82], ["VZV", "PROBLEM", 85, 88], ["human cytomegalovirus", "PROBLEM", 93, 114], ["drug resistance", "PROBLEM", 183, 198], ["significant drug toxicities", "PROBLEM", 203, 230], ["some anti-herpesvirus agents", "TREATMENT", 235, 263], ["ganciclovir", "TREATMENT", 273, 284], ["foscavir", "TREATMENT", 286, 294], ["cidofovir", "TREATMENT", 299, 308], ["herpesviridae species", "OBSERVATION", 24, 45], ["significant", "OBSERVATION_MODIFIER", 203, 214], ["drug toxicities", "OBSERVATION", 215, 230]]], ["Four compounds are currently licensed for the treatment of VZV infections, namely acyclovir, valaciclovir, famciclovir and brivudin [5], [6].", [["VZV infections", "DISEASE", 59, 73], ["acyclovir", "CHEMICAL", 82, 91], ["valaciclovir", "CHEMICAL", 93, 105], ["famciclovir", "CHEMICAL", 107, 118], ["brivudin", "CHEMICAL", 123, 131], ["acyclovir", "CHEMICAL", 82, 91], ["valaciclovir", "CHEMICAL", 93, 105], ["famciclovir", "CHEMICAL", 107, 118], ["brivudin", "CHEMICAL", 123, 131], ["VZV", "ORGANISM", 59, 62], ["acyclovir", "SIMPLE_CHEMICAL", 82, 91], ["valaciclovir", "SIMPLE_CHEMICAL", 93, 105], ["famciclovir", "SIMPLE_CHEMICAL", 107, 118], ["brivudin [5]", "SIMPLE_CHEMICAL", 123, 135], ["[6]", "SIMPLE_CHEMICAL", 137, 140], ["VZV", "SPECIES", 59, 62], ["VZV infections", "PROBLEM", 59, 73], ["acyclovir", "TREATMENT", 82, 91], ["valaciclovir", "TREATMENT", 93, 105], ["famciclovir", "TREATMENT", 107, 118], ["brivudin", "TREATMENT", 123, 131], ["VZV infections", "OBSERVATION", 59, 73]]], ["Regrettably, AIDS patients often do not respond well to acyclovir therapy or other antiviral drugs due to the emergence of thymidine kinase-deficient or thymidine kinase-altered mutations of VZV [7], [8].", [["AIDS", "DISEASE", 13, 17], ["acyclovir", "CHEMICAL", 56, 65], ["thymidine", "CHEMICAL", 123, 132], ["thymidine", "CHEMICAL", 153, 162], ["acyclovir", "CHEMICAL", 56, 65], ["thymidine", "CHEMICAL", 123, 132], ["thymidine", "CHEMICAL", 153, 162], ["patients", "ORGANISM", 18, 26], ["acyclovir", "SIMPLE_CHEMICAL", 56, 65], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 123, 139], ["thymidine kinase", "SIMPLE_CHEMICAL", 153, 169], ["VZV", "ORGANISM", 191, 194], ["thymidine kinase", "PROTEIN", 123, 139], ["thymidine kinase", "PROTEIN", 153, 169], ["patients", "SPECIES", 18, 26], ["acyclovir therapy", "TREATMENT", 56, 73], ["other antiviral drugs", "TREATMENT", 77, 98], ["thymidine kinase", "TREATMENT", 123, 139], ["thymidine kinase", "TEST", 153, 169], ["altered mutations of VZV", "PROBLEM", 170, 194]]], ["Therefore, the extensive search for new anti-VZV agents with superior efficacy compared to currently approved drugs is of high importance.IntroductionNumerous structurally diversified compounds have already been synthesized and tested as new potential anti-VZV agents including bicyclic nucleoside analogues, non-nucleoside DNA polymerase inhibitors and N-(\u03b1-methylbenzyl)-N-arylthiourea analogues (Fig. 1) [9], [10], [11], [12], [13], [14], [15], [16], [17], [18].IntroductionOn the other hand, the antiviral activity of several 1,3-disubstituted quinazoline-2,4-diones (Fig. 2) has been discovered in recent years [19].", [["nucleoside", "CHEMICAL", 287, 297], ["N-(\u03b1-methylbenzyl)-N-arylthiourea", "CHEMICAL", 354, 387], ["1,3-disubstituted quinazoline-2,4-diones", "CHEMICAL", 530, 570], ["nucleoside", "CHEMICAL", 287, 297], ["N-(\u03b1-methylbenzyl)-N-arylthiourea", "CHEMICAL", 354, 387], ["1,3-disubstituted quinazoline-2,4-diones", "CHEMICAL", 530, 570], ["anti-VZV agents", "SIMPLE_CHEMICAL", 40, 55], ["anti-VZV agents", "SIMPLE_CHEMICAL", 252, 267], ["bicyclic nucleoside analogues", "SIMPLE_CHEMICAL", 278, 307], ["non-nucleoside DNA", "SIMPLE_CHEMICAL", 309, 327], ["N-(\u03b1-methylbenzyl)-N-arylthiourea analogues", "SIMPLE_CHEMICAL", 354, 397], ["Fig. 1) [9]", "SIMPLE_CHEMICAL", 399, 410], ["[10], [11], [12], [13], [14], [15], [16], [17], [18]", "SIMPLE_CHEMICAL", 412, 464], ["1,3-disubstituted quinazoline-2,4-diones", "SIMPLE_CHEMICAL", 530, 570], ["anti-VZV", "SPECIES", 40, 48], ["new anti-VZV agents", "TREATMENT", 36, 55], ["drugs", "TREATMENT", 110, 115], ["new potential anti-VZV agents", "TREATMENT", 238, 267], ["bicyclic nucleoside analogues", "TREATMENT", 278, 307], ["non-nucleoside DNA polymerase inhibitors", "TREATMENT", 309, 349], ["N-(\u03b1-methylbenzyl)", "TREATMENT", 354, 372], ["N-arylthiourea analogues", "TEST", 373, 397], ["disubstituted quinazoline", "TREATMENT", 534, 559]]], ["A 3-benzylquinazolin-2,4-dione derivative 1 was reported to posses the anti-HIV-1 activity in MT-4 cells and inhibited the recombinant RT in vitro [20].", [["MT-4 cells", "ANATOMY", 94, 104], ["3-benzylquinazolin-2,4-dione", "CHEMICAL", 2, 30], ["3-benzylquinazolin-2,4-dione", "CHEMICAL", 2, 30], ["3-benzylquinazolin-2,4-dione", "SIMPLE_CHEMICAL", 2, 30], ["anti-HIV-1", "GENE_OR_GENE_PRODUCT", 71, 81], ["MT-4 cells", "CELL", 94, 104], ["MT-4 cells", "CELL_LINE", 94, 104], ["A 3-benzylquinazolin-2,4-dione derivative", "TREATMENT", 0, 41], ["the anti-HIV", "TREATMENT", 67, 79], ["the recombinant RT in vitro", "TREATMENT", 119, 146]]], ["A quinazolinone-2,4-dione 2 was a potent inhibitor of RSV-induced cytopathic effect (EC50 = 2.14 \u03bcM) [21].", [["quinazolinone-2,4-dione", "CHEMICAL", 2, 25], ["quinazolinone-2,4-dione", "CHEMICAL", 2, 25], ["quinazolinone-2,4-dione 2", "SIMPLE_CHEMICAL", 2, 27], ["RSV", "ORGANISM", 54, 57], ["RSV", "SPECIES", 54, 57], ["A quinazolinone", "TREATMENT", 0, 15], ["dione", "TREATMENT", 20, 25], ["a potent inhibitor", "TREATMENT", 32, 50], ["RSV", "PROBLEM", 54, 57], ["cytopathic effect", "PROBLEM", 66, 83], ["EC50", "TEST", 85, 89], ["cytopathic", "OBSERVATION_MODIFIER", 66, 76]]], ["Several other analogues, namely 3\u20135, proved to be very active toward Respiratory Syncytial Virus (RSV) [21].", [["Respiratory Syncytial Virus", "DISEASE", 69, 96], ["3\u20135", "SIMPLE_CHEMICAL", 32, 35], ["Respiratory Syncytial Virus", "ORGANISM", 69, 96], ["RSV", "ORGANISM", 98, 101], ["Respiratory Syncytial Virus", "SPECIES", 69, 96], ["RSV", "SPECIES", 98, 101], ["Several other analogues", "PROBLEM", 0, 23], ["very active", "PROBLEM", 50, 61], ["Respiratory Syncytial Virus", "PROBLEM", 69, 96]]], ["Recently, the N3-benzoylquinazolinonedione moiety was successfully incorporated as a nucleobase mimetic into the 1,2,3-triazole analogues of nucleotides 6[22] and 7[23].", [["N3-benzoylquinazolinonedione", "CHEMICAL", 14, 42], ["1,2,3-triazole", "CHEMICAL", 113, 127], ["N3-benzoylquinazolinonedione", "CHEMICAL", 14, 42], ["1,2,3-triazole", "CHEMICAL", 113, 127], ["nucleotides", "CHEMICAL", 141, 152], ["N3-benzoylquinazolinonedione moiety", "SIMPLE_CHEMICAL", 14, 49], ["1,2,3-triazole", "SIMPLE_CHEMICAL", 113, 127], ["the N3-benzoylquinazolinonedione moiety", "TREATMENT", 10, 49], ["a nucleobase mimetic into the 1,2,3-triazole analogues of nucleotides", "TREATMENT", 83, 152]]], ["While the compound 6 showed a moderate activity against both herpes simplex viruses (HSV-1 and HSV-2) (EC50 = 17 \u03bcM) as well as feline herpes virus (EC50 = 24 \u03bcM), its dihydroxylated derivative (1R,2S)-7 proved to be even more potent (EC50 = 2.9, 4 and 4 \u03bcM toward HSV-1, HSV-2 and feline herpes virus, respectively), while the enantiomer (1S,2S)-16 was inactive [23].", [["herpes simplex viruses", "DISEASE", 61, 83], ["feline herpes virus", "DISEASE", 128, 147], ["1R,2S)-7", "CHEMICAL", 195, 203], ["feline herpes virus", "DISEASE", 282, 301], ["1S,2S)-16", "CHEMICAL", 340, 349], ["herpes simplex viruses", "ORGANISM", 61, 83], ["HSV-1", "ORGANISM", 85, 90], ["HSV-2", "ORGANISM", 95, 100], ["feline", "ORGANISM", 128, 134], ["herpes virus", "ORGANISM", 135, 147], ["1R,2S)-7", "SIMPLE_CHEMICAL", 195, 203], ["HSV-1", "ORGANISM", 265, 270], ["HSV-2", "ORGANISM", 272, 277], ["feline herpes virus", "ORGANISM", 282, 301], ["1S,2S)-16", "SIMPLE_CHEMICAL", 340, 349], ["herpes simplex viruses", "SPECIES", 61, 83], ["HSV-1", "SPECIES", 85, 90], ["HSV-2", "SPECIES", 95, 100], ["feline herpes virus", "SPECIES", 128, 147], ["HSV-1", "SPECIES", 265, 270], ["feline herpes virus", "SPECIES", 282, 301], ["herpes simplex viruses", "SPECIES", 61, 83], ["HSV-1", "SPECIES", 85, 90], ["HSV-2", "SPECIES", 95, 100], ["feline herpes virus", "SPECIES", 128, 147], ["HSV-1", "SPECIES", 265, 270], ["HSV-2", "SPECIES", 272, 277], ["feline herpes virus", "SPECIES", 282, 301], ["a moderate activity", "PROBLEM", 28, 47], ["both herpes simplex viruses", "PROBLEM", 56, 83], ["HSV", "TEST", 85, 88], ["HSV", "TEST", 95, 98], ["EC50", "TEST", 103, 107], ["feline herpes virus", "PROBLEM", 128, 147], ["EC50", "TEST", 149, 153], ["its dihydroxylated derivative", "TEST", 164, 193], ["EC50", "TEST", 235, 239], ["HSV", "TEST", 265, 268], ["HSV", "TEST", 272, 275], ["feline herpes virus", "PROBLEM", 282, 301], ["moderate", "OBSERVATION_MODIFIER", 30, 38], ["activity", "OBSERVATION_MODIFIER", 39, 47], ["herpes simplex viruses", "OBSERVATION", 61, 83]]], ["From several functionalized quinazoline-2,4-diones studied as allosteric inhibitors of the NS5B polymerase compounds 8\u201310 exhibited the highest affinity to the enzyme [24].", [["quinazoline-2,4-diones", "CHEMICAL", 28, 50], ["8\u201310", "CHEMICAL", 117, 121], ["quinazoline-2,4-diones", "CHEMICAL", 28, 50], ["quinazoline-2,4-diones", "SIMPLE_CHEMICAL", 28, 50], ["8\u201310", "SIMPLE_CHEMICAL", 117, 121], ["several functionalized quinazoline", "TREATMENT", 5, 39], ["allosteric inhibitors", "TREATMENT", 62, 83], ["the NS5B polymerase compounds", "TEST", 87, 116], ["the enzyme", "TEST", 156, 166]]], ["On the basis of these observations one may conclude that for the antiviral activity of quinazoline-2,4-diones substitution at N3 with aryl, benzyl or benzoyl groups is beneficial.Chemistry ::: Results and discussionRecently, we successfully accomplished the syntheses of homonucleoside analogues 11 which proved inactive against a broad spectrum of DNA and RNA viruses while some of them appeared slightly cytostatic toward several cancerous cell lines [25].", [["cancerous cell lines", "ANATOMY", 432, 452], ["quinazoline-2,4-diones", "CHEMICAL", 87, 109], ["N3", "CHEMICAL", 126, 128], ["aryl, benzyl", "CHEMICAL", 134, 146], ["benzoyl", "CHEMICAL", 150, 157], ["homonucleoside", "CHEMICAL", 271, 285], ["quinazoline-2,4-diones", "CHEMICAL", 87, 109], ["N3", "CHEMICAL", 126, 128], ["aryl", "CHEMICAL", 134, 138], ["benzyl", "CHEMICAL", 140, 146], ["benzoyl", "CHEMICAL", 150, 157], ["homonucleoside", "CHEMICAL", 271, 285], ["quinazoline-2,4-diones", "SIMPLE_CHEMICAL", 87, 109], ["N3", "SIMPLE_CHEMICAL", 126, 128], ["aryl", "SIMPLE_CHEMICAL", 134, 138], ["benzyl", "SIMPLE_CHEMICAL", 140, 146], ["benzoyl", "SIMPLE_CHEMICAL", 150, 157], ["homonucleoside analogues", "SIMPLE_CHEMICAL", 271, 295], ["DNA", "CELLULAR_COMPONENT", 349, 352], ["cancerous cell lines", "CELL", 432, 452], ["cancerous cell lines", "CELL_LINE", 432, 452], ["the antiviral activity of quinazoline", "TREATMENT", 61, 98], ["diones substitution", "TREATMENT", 103, 122], ["aryl, benzyl or benzoyl groups", "TREATMENT", 134, 164], ["the syntheses of homonucleoside analogues", "TREATMENT", 254, 295], ["DNA", "PROBLEM", 349, 352], ["RNA viruses", "PROBLEM", 357, 368], ["slightly cytostatic", "PROBLEM", 397, 416], ["several cancerous cell lines", "PROBLEM", 424, 452], ["RNA viruses", "OBSERVATION", 357, 368], ["slightly", "OBSERVATION_MODIFIER", 397, 405], ["cytostatic", "OBSERVATION_MODIFIER", 406, 416], ["cancerous cell lines", "OBSERVATION", 432, 452]]], ["However, later on they were additionally screened for inhibition of VZV and HCMV replication and two compounds 11a (B = N-benzoyluracil) and 12a (R = benzoyl, R\u2032 = methyl) showed noticeable activity toward VZV (Table 3).", [["B = N-benzoyluracil", "CHEMICAL", 116, 135], ["12a (R = benzoyl, R\u2032 = methyl", "CHEMICAL", 141, 170], ["N-benzoyluracil", "CHEMICAL", 120, 135], ["benzoyl", "CHEMICAL", 150, 157], ["methyl", "CHEMICAL", 164, 170], ["VZV", "ORGANISM", 68, 71], ["HCMV", "ORGANISM", 76, 80], ["B = N-benzoyluracil", "SIMPLE_CHEMICAL", 116, 135], ["12a (R = benzoyl, R\u2032 = methyl", "SIMPLE_CHEMICAL", 141, 170], ["VZV", "ORGANISM", 206, 209], ["VZV", "SPECIES", 68, 71], ["HCMV", "SPECIES", 76, 80], ["VZV", "SPECIES", 206, 209], ["VZV", "PROBLEM", 68, 71], ["HCMV replication", "TREATMENT", 76, 92], ["B = N-benzoyluracil)", "TREATMENT", 116, 136], ["benzoyl", "TREATMENT", 150, 157]]], ["Based on this discovery we designed a new series of analogues (Scheme 1) installing at N3 of the quinazoline-2,4-dione skeleton either substituted benzoyl groups (compounds 2 and 3) or substituted benzyl residues (compounds 14 and 15).Chemistry ::: Results and discussionAs previously reported [25], N1-allyl-N3-benzoylquinazoline-2,4-dione 18a was obtained in three steps in 20% overall yield starting from quinazoline-2,4-dione employing bis-N1,N3-benzoylation with benzoyl chloride followed by the selective N1-debenzoylation and subsequent allylation.", [["N3 of the quinazoline-2,4-dione", "CHEMICAL", 87, 118], ["benzoyl", "CHEMICAL", 147, 154], ["benzyl", "CHEMICAL", 197, 203], ["N1-allyl-N3-benzoylquinazoline-2,4-dione 18a", "CHEMICAL", 300, 344], ["quinazoline-2,4-dione", "CHEMICAL", 408, 429], ["bis-N1,N3-benzoylation", "CHEMICAL", 440, 462], ["benzoyl chloride", "CHEMICAL", 468, 484], ["N1-debenzoylation", "CHEMICAL", 511, 528], ["quinazoline-2,4-dione", "CHEMICAL", 97, 118], ["benzoyl", "CHEMICAL", 147, 154], ["benzyl", "CHEMICAL", 197, 203], ["N1-allyl-N3-benzoylquinazoline-2,4-dione", "CHEMICAL", 300, 340], ["quinazoline-2,4-dione", "CHEMICAL", 408, 429], ["bis-N1", "CHEMICAL", 440, 446], ["N3", "CHEMICAL", 447, 449], ["benzoyl chloride", "CHEMICAL", 468, 484], ["quinazoline-2,4-dione", "SIMPLE_CHEMICAL", 97, 118], ["substituted benzoyl groups", "SIMPLE_CHEMICAL", 135, 161], ["compounds 2 and 3) or substituted benzyl residues", "SIMPLE_CHEMICAL", 163, 212], ["[25]", "SIMPLE_CHEMICAL", 294, 298], ["N1-allyl-N3-benzoylquinazoline-2,4-dione 18a", "SIMPLE_CHEMICAL", 300, 344], ["quinazoline-2,4-dione", "SIMPLE_CHEMICAL", 408, 429], ["bis-N1,N3-benzoylation", "SIMPLE_CHEMICAL", 440, 462], ["benzoyl chloride", "SIMPLE_CHEMICAL", 468, 484], ["N1-debenzoylation", "SIMPLE_CHEMICAL", 511, 528], ["analogues (Scheme", "TREATMENT", 52, 69], ["the quinazoline", "TREATMENT", 93, 108], ["2,4-dione skeleton", "TREATMENT", 109, 127], ["substituted benzoyl groups", "TREATMENT", 135, 161], ["substituted benzyl residues", "TREATMENT", 185, 212], ["discussionAs", "TEST", 261, 273], ["N1", "TEST", 300, 302], ["allyl", "TEST", 303, 308], ["benzoylquinazoline", "TREATMENT", 312, 330], ["quinazoline", "TREATMENT", 408, 419], ["bis", "TEST", 440, 443], ["N1", "TREATMENT", 444, 446], ["N3", "TREATMENT", 447, 449], ["benzoylation", "TREATMENT", 450, 462], ["benzoyl chloride", "TREATMENT", 468, 484], ["the selective N1-debenzoylation", "TREATMENT", 497, 528], ["subsequent allylation", "TREATMENT", 533, 554]]], ["However, this procedure appeared tedious and the N1-debenzylation step was the least effective.", [["this procedure", "TREATMENT", 9, 23], ["the N1-debenzylation step", "TREATMENT", 45, 70]]], ["For this reason another strategy for the syntheses of N1-allyl-N3-benzoylquinazoline-2,4-diones 18a-18d was designed which relied on N-allylation of the commercially available isatoic anhydride 20 followed by a subsequent condensation of compound 21 with urea [26], [27] and concluded with N3-benzoylation of the resulted N-allylquinazoline-2,4-dione 22 with selected benzoyl chlorides (Scheme 2).", [["N1-allyl-N3-benzoylquinazoline-2,4-diones 18a-18d", "CHEMICAL", 54, 103], ["N-allylation", "CHEMICAL", 133, 145], ["isatoic anhydride", "CHEMICAL", 176, 193], ["urea", "CHEMICAL", 255, 259], ["N3-benzoylation", "CHEMICAL", 290, 305], ["N-allylquinazoline-2,4-dione", "CHEMICAL", 322, 350], ["benzoyl chlorides", "CHEMICAL", 368, 385], ["N1-allyl-N3-benzoylquinazoline-2,4-diones", "CHEMICAL", 54, 95], ["N", "CHEMICAL", 133, 134], ["isatoic anhydride", "CHEMICAL", 176, 193], ["urea", "CHEMICAL", 255, 259], ["N3", "CHEMICAL", 290, 292], ["N-allylquinazoline-2,4-dione", "CHEMICAL", 322, 350], ["benzoyl chlorides", "CHEMICAL", 368, 385], ["N1-allyl-N3-benzoylquinazoline-2,4-diones 18a-18d", "SIMPLE_CHEMICAL", 54, 103], ["isatoic anhydride 20", "SIMPLE_CHEMICAL", 176, 196], ["urea [26]", "SIMPLE_CHEMICAL", 255, 264], ["[27]", "SIMPLE_CHEMICAL", 266, 270], ["N3-benzoylation", "SIMPLE_CHEMICAL", 290, 305], ["N-allylquinazoline-2,4-dione 22", "SIMPLE_CHEMICAL", 322, 353], ["benzoyl chlorides", "SIMPLE_CHEMICAL", 368, 385], ["the syntheses", "TEST", 37, 50], ["N1-allyl", "TREATMENT", 54, 62], ["benzoylquinazoline", "TREATMENT", 66, 84], ["isatoic anhydride", "TREATMENT", 176, 193], ["N3-benzoylation", "TREATMENT", 290, 305], ["allylquinazoline", "TREATMENT", 324, 340], ["selected benzoyl chlorides", "TREATMENT", 359, 385]]], ["Moreover, under these circumstances compounds 19a-d could be obtained in one step by benzylation of allylquinazoline-2,4-dione 22 (Scheme 2).Chemistry ::: Results and discussion1,3-Dipolar cycloadditions of nitrones 16 (R\u2032 = Me) or 7 (R\u2032 = Bn) with the respective N1-allyl-N3-benzoylquinazoline-2,4-diones 18a-d were carried out at 60 \u00b0C in toluene or toluene-ethanol mixtures as solvents and afforded mixtures of diastereoisomeric isoxazolidines trans-12 and cis-12 or trans-13 and cis-13 (Scheme 3, Table 1) with the trans-isomer predominating.", [["19a", "CHEMICAL", 46, 49], ["allylquinazoline-2,4-dione", "CHEMICAL", 100, 126], ["nitrones", "CHEMICAL", 207, 215], ["Me", "CHEMICAL", 225, 227], ["N1-allyl-N3-benzoylquinazoline-2,4-diones", "CHEMICAL", 264, 305], ["toluene", "CHEMICAL", 341, 348], ["toluene", "CHEMICAL", 352, 359], ["ethanol", "CHEMICAL", 360, 367], ["isoxazolidines", "CHEMICAL", 432, 446], ["allylquinazoline-2,4-dione", "CHEMICAL", 100, 126], ["1,3-Dipolar", "CHEMICAL", 177, 188], ["nitrones", "CHEMICAL", 207, 215], ["Me", "CHEMICAL", 225, 227], ["N1-allyl-N3-benzoylquinazoline-2,4-diones", "CHEMICAL", 264, 305], ["toluene", "CHEMICAL", 341, 348], ["toluene", "CHEMICAL", 352, 359], ["ethanol", "CHEMICAL", 360, 367], ["isoxazolidines", "CHEMICAL", 432, 446], ["19a-d", "SIMPLE_CHEMICAL", 46, 51], ["allylquinazoline-2,4-dione 22", "SIMPLE_CHEMICAL", 100, 129], ["1,3-Dipolar cycloadditions", "SIMPLE_CHEMICAL", 177, 203], ["nitrones 16 (R\u2032 = Me)", "SIMPLE_CHEMICAL", 207, 228], ["7 (R\u2032 = Bn)", "SIMPLE_CHEMICAL", 232, 243], ["N1-allyl-N3-benzoylquinazoline-2,4-diones 18a-d", "SIMPLE_CHEMICAL", 264, 311], ["toluene", "SIMPLE_CHEMICAL", 341, 348], ["toluene-ethanol", "SIMPLE_CHEMICAL", 352, 367], ["diastereoisomeric isoxazolidines trans-12", "SIMPLE_CHEMICAL", 414, 455], ["cis-12", "SIMPLE_CHEMICAL", 460, 466], ["trans-13", "SIMPLE_CHEMICAL", 470, 478], ["cis-13 (Scheme 3, Table 1)", "SIMPLE_CHEMICAL", 483, 509], ["trans-isomer", "SIMPLE_CHEMICAL", 519, 531], ["allylquinazoline", "TREATMENT", 100, 116], ["discussion", "TEST", 167, 177], ["Dipolar cycloadditions of nitrones", "TREATMENT", 181, 215], ["the respective N1", "TREATMENT", 249, 266], ["allyl", "TEST", 267, 272], ["benzoylquinazoline", "TREATMENT", 276, 294], ["ethanol mixtures", "TREATMENT", 360, 376], ["diastereoisomeric isoxazolidines trans", "TREATMENT", 414, 452], ["cis", "TEST", 460, 463]]], ["The cis/trans ratios of diastereoisomeric products were determined on the basis of the 31P NMR spectral data.", [["31P", "CHEMICAL", 87, 90], ["31P", "SIMPLE_CHEMICAL", 87, 90], ["diastereoisomeric products", "PROTEIN", 24, 50], ["diastereoisomeric products", "TREATMENT", 24, 50], ["the 31P NMR spectral data", "TEST", 83, 108]]], ["The reactions proceeded with moderate diastereoselectivities (d.e.", [["The reactions", "PROBLEM", 0, 13]]], ["The isolation of pure isomers was successfully accomplished chromatographically for major isomers trans-12a, trans-12b, trans-12c, trans-12d, trans-13c and trans-13d but also for minor isomers cis-12a, cis-12d and cis-13a.Chemistry ::: Results and discussionTo eliminate rigidity within the substituted quinazoline-2,4-dione moiety benzoyl substituents at N3 were replaced by the functionalized benzyl residues.", [["trans-12a, trans-12b, trans-12c, trans-12d, trans-13c and trans-13d", "CHEMICAL", 98, 165], ["rigidity", "DISEASE", 271, 279], ["quinazoline-2,4-dione", "CHEMICAL", 303, 324], ["benzoyl substituents", "CHEMICAL", 332, 352], ["N3", "CHEMICAL", 356, 358], ["benzyl", "CHEMICAL", 395, 401], ["quinazoline-2,4-dione", "CHEMICAL", 303, 324], ["benzoyl", "CHEMICAL", 332, 339], ["N3", "CHEMICAL", 356, 358], ["benzyl", "CHEMICAL", 395, 401], ["trans-12a", "SIMPLE_CHEMICAL", 98, 107], ["trans-12b", "SIMPLE_CHEMICAL", 109, 118], ["trans-12c", "SIMPLE_CHEMICAL", 120, 129], ["trans-12d", "SIMPLE_CHEMICAL", 131, 140], ["trans-13c", "SIMPLE_CHEMICAL", 142, 151], ["trans-13d", "SIMPLE_CHEMICAL", 156, 165], ["cis-12a", "SIMPLE_CHEMICAL", 193, 200], ["cis-12d", "SIMPLE_CHEMICAL", 202, 209], ["cis-13a", "SIMPLE_CHEMICAL", 214, 221], ["quinazoline-2,4-dione moiety benzoyl substituents", "SIMPLE_CHEMICAL", 303, 352], ["N3", "SIMPLE_CHEMICAL", 356, 358], ["cis-12d and cis-13a", "DNA", 202, 221], ["The isolation of pure isomers", "TREATMENT", 0, 29], ["cis", "TEST", 193, 196], ["cis", "TEST", 202, 205], ["cis", "TEST", 214, 217], ["rigidity", "PROBLEM", 271, 279], ["the substituted quinazoline", "TREATMENT", 287, 314], ["2,4-dione moiety benzoyl substituents at N3", "TREATMENT", 315, 358], ["the functionalized benzyl residues", "TREATMENT", 376, 410]]], ["1,3-Dipolar cycloadditions of nitrones 16 (R\u2032 = Me) or 7 (R\u2032 = Bn) with the respective N1-allyl-N3-benzylquinazoline-2,4-diones 19a-d were carried out under conditions already described for compounds 18.", [["1,3-Dipolar", "CHEMICAL", 0, 11], ["nitrones", "CHEMICAL", 30, 38], ["Me", "CHEMICAL", 48, 50], ["N1-allyl-N3-benzylquinazoline-2,4-diones", "CHEMICAL", 87, 127], ["nitrones", "CHEMICAL", 30, 38], ["Me", "CHEMICAL", 48, 50], ["N1-allyl-N3-benzylquinazoline-2,4-diones", "CHEMICAL", 87, 127], ["1,3-Dipolar cycloadditions", "SIMPLE_CHEMICAL", 0, 26], ["nitrones 16 (R\u2032 = Me)", "SIMPLE_CHEMICAL", 30, 51], ["7 (R\u2032 = Bn)", "SIMPLE_CHEMICAL", 55, 66], ["N1-allyl-N3-benzylquinazoline-2,4-diones 19a-d", "SIMPLE_CHEMICAL", 87, 133], ["Dipolar cycloadditions of nitrones", "TREATMENT", 4, 38], ["the respective N1", "TREATMENT", 72, 89], ["benzylquinazoline", "TREATMENT", 99, 116]]], ["Diastereoisomeric cycloadducts trans-14 and cis-14 or trans-15 and cis-15 (Scheme 4, Table 2) were formed in good to excellent overall yields and with moderate diastereoselectivities (d.e.", [["trans-14 and cis-14", "CHEMICAL", 31, 50], ["Diastereoisomeric cycloadducts trans-14", "SIMPLE_CHEMICAL", 0, 39], ["cis-14", "SIMPLE_CHEMICAL", 44, 50], ["trans-15", "SIMPLE_CHEMICAL", 54, 62], ["cis-15 (Scheme 4, Table 2)", "SIMPLE_CHEMICAL", 67, 93], ["Diastereoisomeric cycloadducts trans", "TEST", 0, 36], ["cis", "TEST", 44, 47], ["trans", "TEST", 54, 59], ["cis", "TEST", 67, 70]]], ["28\u201360%) which were slightly higher for reactions of the nitrone 7 (R\u2032 = Bn).", [["nitrone", "CHEMICAL", 56, 63], ["nitrone", "CHEMICAL", 56, 63], ["R\u2032 = Bn", "CHEMICAL", 67, 74], ["R\u2032 = Bn", "SIMPLE_CHEMICAL", 67, 74], ["the nitrone", "TREATMENT", 52, 63]]], ["Chromatographic isolation of pure isomers was achieved for trans-14a, cis-14b, trans-14b, trans-14c and trans-14d.Antiviral and cytostatic evaluation ::: Results and discussionThe pure isomers of quinazoline-2,4-dione - conjugates [trans-11a, cis-11a, trans-12a, cis-12a, trans-13a, cis-13a, trans-12b, trans-12c, trans-13c, trans-12d, cis-12d, trans-13d, trans-14a, trans-14b, cis-14b, trans-15b, trans-14c, trans-14d] and the respective mixtures of cis/trans isomers [cis-12b/trans-12b (87:13), trans-13b/cis-13b (90:10), cis-2c/trans-2c (94:6), cis-13c/trans-13c (86:14), cis-13d/trans-13d (85:15), cis-14a/trans-14a (75:25), trans-15a/cis-15a (90:10), cis-15a/trans-15a (50:50), cis-15b/trans-15b (87:13), cis-14c/trans-14c (97:3), trans-15c/cis-15c (90:10), cis-15c/trans-15c (80:20), cis-14d/trans-14d (75:25), trans-15d/cis-15d (95:5), cis-15d/trans-15d (75:52)] were screened as inhibitors of a wide variety of DNA and RNA viruses using the following cell-based assays: (a) human embryonic lung (HEL) cells: herpes simplex virus-1 (KOS strain), herpes simplex virus-2 (G strain), thymidine kinase deficient (acyclovir resistant) herpes simplex virus-1 (TK\u2013 KOS ACVr strain), vaccinia virus, adenovirus-2, vesicular stomatitis virus, human coronavirus (229E), cytomegalovirus (AD-169 strain and Davis strain), varicella-zoster virus (TK+ VZV Oka strain and TK\u2212 VZV 07-1 strain); (b) HeLa cell cultures: vesicular stomatitis virus, Coxsackie virus B4 and respiratory syncytial virus; (c) Vero cell cultures: parainfluenza virus 3, reovirus-1, Sindbis virus, Coxsackie virus B4, Punta Toro virus, yellow fever virus; (e) Crandell-Rees feline kidney (CRFK) cell cultures: feline corona virus (FIPV) and feline herpes virus (FHV) and (d) Madin Darby canine kidney (MDCK) cell cultures: influenza A virus (H1N1 and H3N2 subtypes) and influenza B virus.", [["cell", "ANATOMY", 959, 963], ["embryonic lung (HEL) cells", "ANATOMY", 988, 1014], ["HeLa cell cultures", "ANATOMY", 1390, 1408], ["cell", "ANATOMY", 1499, 1503], ["kidney", "ANATOMY", 1647, 1653], ["CRFK) cell cultures", "ANATOMY", 1655, 1674], ["kidney", "ANATOMY", 1760, 1766], ["MDCK) cell cultures", "ANATOMY", 1768, 1787], ["trans-14a, cis-14b, trans-14b, trans-14c and trans-14d", "CHEMICAL", 59, 113], ["quinazoline-2,4-dione", "CHEMICAL", 196, 217], ["trans-11a, cis-11a, trans-12a, cis-12a", "CHEMICAL", 232, 270], ["trans-15b, trans-14c, trans-14d", "CHEMICAL", 387, 418], ["cis-12b/trans-12b (87:13), trans-13b/cis-13b", "CHEMICAL", 470, 514], ["cis-2c/trans-2c", "CHEMICAL", 524, 539], ["cis-15d/trans-15d", "CHEMICAL", 843, 860], ["herpes simplex", "DISEASE", 1016, 1030], ["herpes simplex", "DISEASE", 1053, 1067], ["thymidine", "CHEMICAL", 1088, 1097], ["acyclovir", "CHEMICAL", 1116, 1125], ["herpes simplex", "DISEASE", 1137, 1151], ["vesicular stomatitis", "DISEASE", 1213, 1233], ["varicella-zoster", "DISEASE", 1317, 1333], ["vesicular stomatitis", "DISEASE", 1410, 1430], ["respiratory syncytial virus", "DISEASE", 1461, 1488], ["yellow fever", "DISEASE", 1602, 1614], ["feline herpes virus", "DISEASE", 1707, 1726], ["influenza A", "DISEASE", 1789, 1800], ["influenza B", "DISEASE", 1836, 1847], ["quinazoline-2,4-dione", "CHEMICAL", 196, 217], ["trans-11a, cis-11a, trans-12a, cis-12a, trans-13a, cis-13a, trans-12b, trans-12c, trans-13c, trans-12d, cis-12d, trans-13d, trans-14a, trans-14b, cis-14b, trans-15b, trans-14c, trans-14d", "CHEMICAL", 232, 418], ["cis-12b/trans-12b", "CHEMICAL", 470, 487], ["trans-13b/cis-13b", "CHEMICAL", 497, 514], ["cis-", "CHEMICAL", 524, 528], ["cis-13c/trans-13c", "CHEMICAL", 548, 565], ["cis-13d/trans-13d", "CHEMICAL", 575, 592], ["cis-14a/trans-14a", "CHEMICAL", 602, 619], ["trans-15a/cis-15a", "CHEMICAL", 629, 646], ["cis-15a/trans-15a", "CHEMICAL", 656, 673], ["cis-15b/trans-15b", "CHEMICAL", 683, 700], ["cis-14c/trans-14c", "CHEMICAL", 710, 727], ["trans-15c/cis-15c", "CHEMICAL", 736, 753], ["cis-15c/trans-15c (80:20), cis-14d/trans-14d", "CHEMICAL", 763, 807], ["trans-15d/cis-15d", "CHEMICAL", 817, 834], ["cis-15d/trans-15d", "CHEMICAL", 843, 860], ["thymidine", "CHEMICAL", 1088, 1097], ["acyclovir", "CHEMICAL", 1116, 1125], ["trans-14a", "SIMPLE_CHEMICAL", 59, 68], ["cis-14b", "SIMPLE_CHEMICAL", 70, 77], ["trans-14b", "SIMPLE_CHEMICAL", 79, 88], ["trans-14c", "SIMPLE_CHEMICAL", 90, 99], ["trans-14d", "SIMPLE_CHEMICAL", 104, 113], ["quinazoline-2,4-dione - conjugates", "SIMPLE_CHEMICAL", 196, 230], ["trans-11a", "SIMPLE_CHEMICAL", 232, 241], ["cis-11a", "SIMPLE_CHEMICAL", 243, 250], ["trans-12a", "SIMPLE_CHEMICAL", 252, 261], ["cis-12a", "SIMPLE_CHEMICAL", 263, 270], ["trans-13a", "SIMPLE_CHEMICAL", 272, 281], ["cis-13a", "SIMPLE_CHEMICAL", 283, 290], ["trans-12b", "SIMPLE_CHEMICAL", 292, 301], ["trans-12c", "SIMPLE_CHEMICAL", 303, 312], ["trans-13c", "SIMPLE_CHEMICAL", 314, 323], ["trans-12d", "SIMPLE_CHEMICAL", 325, 334], ["cis-12d", "SIMPLE_CHEMICAL", 336, 343], ["trans-13d", "SIMPLE_CHEMICAL", 345, 354], ["trans-14a", "SIMPLE_CHEMICAL", 356, 365], ["trans-14b", "SIMPLE_CHEMICAL", 367, 376], ["cis-14b", "SIMPLE_CHEMICAL", 378, 385], ["trans-15b", "SIMPLE_CHEMICAL", 387, 396], ["trans-14c", "SIMPLE_CHEMICAL", 398, 407], ["trans-14d", "SIMPLE_CHEMICAL", 409, 418], ["cis/trans isomers", "SIMPLE_CHEMICAL", 451, 468], ["cis-12b", "SIMPLE_CHEMICAL", 470, 477], ["trans-12b", "SIMPLE_CHEMICAL", 478, 487], ["87:13)", "SIMPLE_CHEMICAL", 489, 495], ["trans-13b", "SIMPLE_CHEMICAL", 497, 506], ["cis-13b", "SIMPLE_CHEMICAL", 507, 514], ["90:10)", "SIMPLE_CHEMICAL", 516, 522], ["cis-2c/trans-2c (94:6)", "SIMPLE_CHEMICAL", 524, 546], ["cis-13c", "SIMPLE_CHEMICAL", 548, 555], ["trans-13c", "SIMPLE_CHEMICAL", 556, 565], ["86:14)", "SIMPLE_CHEMICAL", 567, 573], ["cis-13d", "SIMPLE_CHEMICAL", 575, 582], ["trans-13d", "SIMPLE_CHEMICAL", 583, 592], ["85:15)", "SIMPLE_CHEMICAL", 594, 600], ["cis-14a", "SIMPLE_CHEMICAL", 602, 609], ["trans-14a", "SIMPLE_CHEMICAL", 610, 619], ["75:25)", "SIMPLE_CHEMICAL", 621, 627], ["trans-15a", "SIMPLE_CHEMICAL", 629, 638], ["cis-15a", "SIMPLE_CHEMICAL", 639, 646], ["90:10)", "SIMPLE_CHEMICAL", 648, 654], ["cis-15a", "SIMPLE_CHEMICAL", 656, 663], ["trans-15a", "SIMPLE_CHEMICAL", 664, 673], ["50:50)", "SIMPLE_CHEMICAL", 675, 681], ["cis-15b", "SIMPLE_CHEMICAL", 683, 690], ["trans-15b", "SIMPLE_CHEMICAL", 691, 700], ["87:13)", "SIMPLE_CHEMICAL", 702, 708], ["cis-14c", "SIMPLE_CHEMICAL", 710, 717], ["trans-14c", "SIMPLE_CHEMICAL", 718, 727], ["97:3)", "SIMPLE_CHEMICAL", 729, 734], ["trans-15c", "SIMPLE_CHEMICAL", 736, 745], ["cis-15c", "SIMPLE_CHEMICAL", 746, 753], ["90:10)", "SIMPLE_CHEMICAL", 755, 761], ["cis-15c", "SIMPLE_CHEMICAL", 763, 770], ["trans-15c", "SIMPLE_CHEMICAL", 771, 780], ["80:20)", "SIMPLE_CHEMICAL", 782, 788], ["cis-14d", "SIMPLE_CHEMICAL", 790, 797], ["trans-14d", "SIMPLE_CHEMICAL", 798, 807], ["75:25)", "SIMPLE_CHEMICAL", 809, 815], ["trans-15d", "SIMPLE_CHEMICAL", 817, 826], ["cis-15d", "SIMPLE_CHEMICAL", 827, 834], ["cis-15d", "SIMPLE_CHEMICAL", 843, 850], ["trans-15d (75:52)", "SIMPLE_CHEMICAL", 851, 868], ["DNA", "CELLULAR_COMPONENT", 919, 922], ["cell", "CELL", 959, 963], ["human", "ORGANISM", 982, 987], ["embryonic lung", "CELL", 988, 1002], ["HEL) cells", "CELL", 1004, 1014], ["herpes simplex virus-1", "ORGANISM", 1016, 1038], ["KOS strain", "ORGANISM", 1040, 1050], ["herpes simplex virus-2", "ORGANISM", 1053, 1075], ["G strain", "ORGANISM", 1077, 1085], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 1088, 1104], ["acyclovir resistant)", "ORGANISM", 1116, 1136], ["herpes simplex virus-1", "ORGANISM", 1137, 1159], ["TK\u2013 KOS ACVr strain", "ORGANISM", 1161, 1180], ["vaccinia virus", "ORGANISM", 1183, 1197], ["adenovirus-2", "ORGANISM", 1199, 1211], ["vesicular stomatitis virus", "ORGANISM", 1213, 1239], ["human coronavirus", "ORGANISM", 1241, 1258], ["cytomegalovirus", "ORGANISM", 1267, 1282], ["AD-169 strain", "ORGANISM", 1284, 1297], ["Davis strain", "ORGANISM", 1302, 1314], ["varicella-zoster virus", "ORGANISM", 1317, 1339], ["TK+ VZV Oka strain", "ORGANISM", 1341, 1359], ["TK\u2212 VZV 07-1 strain", "ORGANISM", 1364, 1383], ["HeLa cell cultures", "CELL", 1390, 1408], ["vesicular stomatitis virus", "ORGANISM", 1410, 1436], ["Coxsackie virus B4", "ORGANISM", 1438, 1456], ["respiratory syncytial virus", "ORGANISM", 1461, 1488], ["Vero cell cultures", "CELL", 1494, 1512], ["parainfluenza virus 3", "ORGANISM", 1514, 1535], ["reovirus-1", "ORGANISM", 1537, 1547], ["Sindbis virus", "ORGANISM", 1549, 1562], ["Coxsackie virus B4", "ORGANISM", 1564, 1582], ["Punta Toro virus", "ORGANISM", 1584, 1600], ["yellow fever virus", "ORGANISM", 1602, 1620], ["Crandell-Rees feline", "ORGANISM", 1626, 1646], ["kidney", "ORGAN", 1647, 1653], ["CRFK) cell cultures", "CELL", 1655, 1674], ["feline corona virus", "ORGANISM", 1676, 1695], ["FIPV", "ORGANISM", 1697, 1701], ["feline herpes virus", "ORGANISM", 1707, 1726], ["FHV", "ORGANISM", 1728, 1731], ["Madin Darby canine kidney", "ORGANISM", 1741, 1766], ["MDCK) cell cultures", "CELL", 1768, 1787], ["influenza A virus", "ORGANISM", 1789, 1806], ["H1N1 and H3N2 subtypes", "ORGANISM", 1808, 1830], ["influenza B virus", "ORGANISM", 1836, 1853], ["trans-14b, trans-14c and trans-14d", "DNA", 79, 113], ["cis", "DNA", 827, 830], ["cis-15d", "DNA", 843, 850], ["human embryonic lung (HEL) cells", "CELL_TYPE", 982, 1014], ["thymidine kinase", "PROTEIN", 1088, 1104], ["HeLa cell cultures", "CELL_LINE", 1390, 1408], ["Madin Darby canine kidney (MDCK) cell cultures", "CELL_LINE", 1741, 1787], ["human", "SPECIES", 982, 987], ["herpes simplex virus-1", "SPECIES", 1016, 1038], ["herpes simplex virus-2", "SPECIES", 1053, 1075], ["herpes simplex virus-1", "SPECIES", 1137, 1159], ["vaccinia virus", "SPECIES", 1183, 1197], ["vesicular stomatitis virus", "SPECIES", 1213, 1239], ["human", "SPECIES", 1241, 1246], ["coronavirus", "SPECIES", 1247, 1258], ["varicella-zoster virus", "SPECIES", 1317, 1339], ["vesicular stomatitis virus", "SPECIES", 1410, 1436], ["Coxsackie virus B4", "SPECIES", 1438, 1456], ["respiratory syncytial virus", "SPECIES", 1461, 1488], ["parainfluenza virus 3", "SPECIES", 1514, 1535], ["reovirus-1", "SPECIES", 1537, 1547], ["Sindbis virus", "SPECIES", 1549, 1562], ["Coxsackie virus B4", "SPECIES", 1564, 1582], ["Punta Toro virus", "SPECIES", 1584, 1600], ["yellow fever virus", "SPECIES", 1602, 1620], ["feline", "SPECIES", 1640, 1646], ["feline corona virus", "SPECIES", 1676, 1695], ["feline herpes virus", "SPECIES", 1707, 1726], ["influenza A virus", "SPECIES", 1789, 1806], ["H1N1 and H3N2", "SPECIES", 1808, 1821], ["influenza B virus", "SPECIES", 1836, 1853], ["human", "SPECIES", 982, 987], ["herpes simplex virus-1", "SPECIES", 1016, 1038], ["herpes simplex virus-2", "SPECIES", 1053, 1075], ["herpes simplex virus-1", "SPECIES", 1137, 1159], ["TK\u2013 KOS ACVr strain", "SPECIES", 1161, 1180], ["vaccinia virus", "SPECIES", 1183, 1197], ["stomatitis virus", "SPECIES", 1223, 1239], ["human coronavirus", "SPECIES", 1241, 1258], ["varicella-zoster virus", "SPECIES", 1317, 1339], ["VZV", "SPECIES", 1345, 1348], ["TK\u2212 VZV 07-1", "SPECIES", 1364, 1376], ["stomatitis virus", "SPECIES", 1420, 1436], ["Coxsackie virus B4", "SPECIES", 1438, 1456], ["respiratory syncytial virus", "SPECIES", 1461, 1488], ["parainfluenza virus", "SPECIES", 1514, 1533], ["reovirus-1", "SPECIES", 1537, 1547], ["Sindbis virus", "SPECIES", 1549, 1562], ["Coxsackie virus B4", "SPECIES", 1564, 1582], ["Punta Toro virus", "SPECIES", 1584, 1600], ["yellow fever virus", "SPECIES", 1602, 1620], ["feline corona virus", "SPECIES", 1676, 1695], ["FIPV", "SPECIES", 1697, 1701], ["feline herpes virus", "SPECIES", 1707, 1726], ["FHV", "SPECIES", 1728, 1731], ["canine", "SPECIES", 1753, 1759], ["influenza A virus", "SPECIES", 1789, 1806], ["influenza B virus", "SPECIES", 1836, 1853], ["Chromatographic isolation of pure isomers", "TREATMENT", 0, 41], ["cis", "TEST", 70, 73], ["trans", "TEST", 79, 84], ["Antiviral and cytostatic evaluation", "TEST", 114, 149], ["quinazoline", "TREATMENT", 196, 207], ["cis", "TEST", 243, 246], ["cis", "TEST", 263, 266], ["cis", "TEST", 283, 286], ["trans", "TEST", 292, 297], ["trans", "TEST", 303, 308], ["trans", "TEST", 314, 319], ["trans", "TEST", 325, 330], ["cis", "TEST", 336, 339], ["trans", "TEST", 345, 350], ["trans", "TEST", 367, 372], ["cis", "TEST", 378, 381], ["trans", "TEST", 387, 392], ["trans", "TEST", 398, 403], ["trans", "TEST", 409, 414], ["cis", "TEST", 451, 454], ["trans isomers", "TEST", 455, 468], ["cis", "TEST", 470, 473], ["trans", "TEST", 497, 502], ["cis", "TEST", 507, 510], ["cis-", "TEST", 524, 528], ["trans", "TEST", 531, 536], ["cis", "TEST", 548, 551], ["trans", "TEST", 556, 561], ["cis", "TEST", 575, 578], ["cis", "TEST", 602, 605], ["cis", "TEST", 656, 659], ["cis-", "TEST", 683, 687], ["cis-", "TEST", 710, 714], ["trans", "TEST", 718, 723], ["trans", "TEST", 736, 741], ["cis", "TEST", 746, 749], ["cis", "TEST", 763, 766], ["cis-", "TEST", 790, 794], ["trans", "TEST", 817, 822], ["cis", "TEST", 827, 830], ["cis-", "TEST", 843, 847], ["a wide variety of DNA", "PROBLEM", 901, 922], ["RNA viruses", "PROBLEM", 927, 938], ["a) human embryonic lung (HEL) cells", "TEST", 979, 1014], ["herpes simplex virus", "TEST", 1016, 1036], ["KOS strain", "TEST", 1040, 1050], ["herpes simplex virus", "TEST", 1053, 1073], ["G strain", "TEST", 1077, 1085], ["thymidine kinase deficient", "TEST", 1088, 1114], ["acyclovir resistant) herpes simplex virus", "PROBLEM", 1116, 1157], ["TK\u2013 KOS ACVr strain", "TEST", 1161, 1180], ["vaccinia virus", "PROBLEM", 1183, 1197], ["adenovirus", "TEST", 1199, 1209], ["vesicular stomatitis virus", "PROBLEM", 1213, 1239], ["human coronavirus", "PROBLEM", 1241, 1258], ["cytomegalovirus", "PROBLEM", 1267, 1282], ["AD", "TEST", 1284, 1286], ["Davis strain", "TEST", 1302, 1314], ["varicella", "PROBLEM", 1317, 1326], ["zoster virus", "PROBLEM", 1327, 1339], ["TK", "TEST", 1341, 1343], ["VZV Oka strain", "TEST", 1345, 1359], ["TK", "TEST", 1364, 1366], ["VZV", "TEST", 1368, 1371], ["HeLa cell cultures", "TEST", 1390, 1408], ["vesicular stomatitis virus", "PROBLEM", 1410, 1436], ["Coxsackie virus B4", "PROBLEM", 1438, 1456], ["respiratory syncytial virus", "PROBLEM", 1461, 1488], ["Vero cell cultures", "TEST", 1494, 1512], ["parainfluenza virus", "PROBLEM", 1514, 1533], ["reovirus", "TEST", 1537, 1545], ["Sindbis virus", "PROBLEM", 1549, 1562], ["Coxsackie virus B4", "TEST", 1564, 1582], ["Punta Toro virus", "PROBLEM", 1584, 1600], ["yellow fever virus", "PROBLEM", 1602, 1620], ["Crandell", "TEST", 1626, 1634], ["Rees feline kidney (CRFK", "TEST", 1635, 1659], ["cell cultures", "TEST", 1661, 1674], ["feline corona virus", "PROBLEM", 1676, 1695], ["feline herpes virus", "PROBLEM", 1707, 1726], ["Darby canine kidney (MDCK) cell cultures", "TEST", 1747, 1787], ["influenza A virus", "PROBLEM", 1789, 1806], ["H1N1", "PROBLEM", 1808, 1812], ["H3N2 subtypes", "PROBLEM", 1817, 1830], ["influenza B virus", "PROBLEM", 1836, 1853], ["lung", "ANATOMY", 998, 1002], ["vesicular stomatitis", "ANATOMY", 1213, 1233], ["varicella", "ANATOMY", 1317, 1326], ["zoster virus", "OBSERVATION", 1327, 1339], ["vesicular stomatitis", "ANATOMY", 1410, 1430], ["respiratory syncytial", "ANATOMY", 1461, 1482], ["parainfluenza virus", "OBSERVATION", 1514, 1533], ["kidney", "ANATOMY", 1647, 1653], ["kidney", "ANATOMY", 1760, 1766]]], ["Ganciclovir, cidofovir, acyclovir, brivudin, zalcitabine, zanamivir, alovudine, amantadine, rimantadine, ribavirin, dextran sulfate (molecular weight 10000, DS-10000), mycophenolic acid, Hippeastrum hybrid agglutinin (HHA) and Urtica dioica agglutinin (UDA) were used as the reference compounds.", [["Ganciclovir", "CHEMICAL", 0, 11], ["cidofovir", "CHEMICAL", 13, 22], ["acyclovir", "CHEMICAL", 24, 33], ["brivudin", "CHEMICAL", 35, 43], ["zalcitabine", "CHEMICAL", 45, 56], ["zanamivir", "CHEMICAL", 58, 67], ["alovudine", "CHEMICAL", 69, 78], ["amantadine", "CHEMICAL", 80, 90], ["rimantadine", "CHEMICAL", 92, 103], ["ribavirin", "CHEMICAL", 105, 114], ["dextran sulfate", "CHEMICAL", 116, 131], ["weight 10000, DS-10000", "CHEMICAL", 143, 165], ["mycophenolic acid", "CHEMICAL", 168, 185], ["Hippeastrum", "CHEMICAL", 187, 198], ["HHA", "CHEMICAL", 218, 221], ["UDA", "CHEMICAL", 253, 256], ["Ganciclovir", "CHEMICAL", 0, 11], ["cidofovir", "CHEMICAL", 13, 22], ["acyclovir", "CHEMICAL", 24, 33], ["brivudin", "CHEMICAL", 35, 43], ["zalcitabine", "CHEMICAL", 45, 56], ["zanamivir", "CHEMICAL", 58, 67], ["alovudine", "CHEMICAL", 69, 78], ["amantadine", "CHEMICAL", 80, 90], ["rimantadine", "CHEMICAL", 92, 103], ["ribavirin", "CHEMICAL", 105, 114], ["dextran sulfate", "CHEMICAL", 116, 131], ["mycophenolic acid", "CHEMICAL", 168, 185], ["Ganciclovir", "SIMPLE_CHEMICAL", 0, 11], ["cidofovir", "SIMPLE_CHEMICAL", 13, 22], ["acyclovir", "SIMPLE_CHEMICAL", 24, 33], ["brivudin", "SIMPLE_CHEMICAL", 35, 43], ["zalcitabine", "SIMPLE_CHEMICAL", 45, 56], ["zanamivir", "SIMPLE_CHEMICAL", 58, 67], ["alovudine", "SIMPLE_CHEMICAL", 69, 78], ["amantadine", "SIMPLE_CHEMICAL", 80, 90], ["rimantadine", "SIMPLE_CHEMICAL", 92, 103], ["ribavirin", "SIMPLE_CHEMICAL", 105, 114], ["dextran sulfate", "SIMPLE_CHEMICAL", 116, 131], ["DS-10000", "SIMPLE_CHEMICAL", 157, 165], ["mycophenolic acid", "SIMPLE_CHEMICAL", 168, 185], ["Hippeastrum hybrid agglutinin", "SIMPLE_CHEMICAL", 187, 216], ["HHA", "SIMPLE_CHEMICAL", 218, 221], ["Urtica dioica agglutinin", "ORGANISM", 227, 251], ["UDA", "SIMPLE_CHEMICAL", 253, 256], ["Urtica dioica", "SPECIES", 227, 240], ["Urtica dioica", "SPECIES", 227, 240], ["Ganciclovir", "TREATMENT", 0, 11], ["cidofovir", "TREATMENT", 13, 22], ["acyclovir", "TREATMENT", 24, 33], ["brivudin", "TREATMENT", 35, 43], ["zalcitabine", "TREATMENT", 45, 56], ["zanamivir", "TREATMENT", 58, 67], ["alovudine", "TREATMENT", 69, 78], ["amantadine", "TREATMENT", 80, 90], ["rimantadine", "TREATMENT", 92, 103], ["ribavirin", "TREATMENT", 105, 114], ["dextran sulfate", "TREATMENT", 116, 131], ["DS", "TEST", 157, 159], ["mycophenolic acid", "TREATMENT", 168, 185], ["Hippeastrum hybrid agglutinin", "TREATMENT", 187, 216], ["Urtica dioica agglutinin (UDA)", "TREATMENT", 227, 257]]], ["The antiviral activity was expressed as the EC50: the compound concentration required to reduce virus plaque formation (VZV) by 50% or to reduce virus-induced cytopathogenicity by 50% (other viruses).Antiviral and cytostatic evaluation ::: Results and discussionSeveral synthesized quinazoline-2,4-diones inhibited the replication of both TK+ and TK\u2212 VZV strains (Table 3).", [["plaque", "ANATOMY", 102, 108], ["cytopathogenicity", "DISEASE", 159, 176], ["quinazoline-2,4-diones", "CHEMICAL", 282, 304], ["quinazoline-2,4-diones", "CHEMICAL", 282, 304], ["VZV", "ORGANISM", 120, 123], ["quinazoline-2,4-diones", "SIMPLE_CHEMICAL", 282, 304], ["VZV", "ORGANISM", 351, 354], ["VZV", "SPECIES", 120, 123], ["VZV", "SPECIES", 351, 354], ["the compound concentration", "TREATMENT", 50, 76], ["virus plaque formation", "PROBLEM", 96, 118], ["virus", "PROBLEM", 145, 150], ["induced cytopathogenicity", "PROBLEM", 151, 176], ["Antiviral and cytostatic evaluation", "TEST", 200, 235], ["discussionSeveral synthesized quinazoline", "TREATMENT", 252, 293], ["diones", "TREATMENT", 298, 304], ["TK", "TEST", 339, 341], ["VZV strains", "PROBLEM", 351, 362], ["antiviral activity", "OBSERVATION", 4, 22]]], ["A 95:5 trans-15d/cis-15d mixture and a 87:13 cis-15b/trans-15b mixture emerged as the most active derivatives with EC50's of, respectively, 4.7 \u03bcM and 3 \u03bcM (VZV TK+ strain) and of 3.6 \u03bcM and 5.1 \u03bcM (VZV TK\u2212 strain).", [["trans-15d/cis-15d", "CHEMICAL", 7, 24], ["87:13 cis-15b/trans-15b", "CHEMICAL", 39, 62], ["95:5 trans-15d", "SIMPLE_CHEMICAL", 2, 16], ["cis-15d", "SIMPLE_CHEMICAL", 17, 24], ["87:13 cis-15b", "SIMPLE_CHEMICAL", 39, 52], ["trans-15b", "SIMPLE_CHEMICAL", 53, 62], ["cis", "TEST", 17, 20], ["cis", "TEST", 45, 48], ["EC50's", "TEST", 115, 121], ["VZV TK", "TEST", 157, 163], ["strain", "TEST", 165, 171], ["\u03bcM", "TEST", 184, 186], ["\u03bcM", "TEST", 195, 197], ["VZV TK\u2212 strain)", "PROBLEM", 199, 214]]], ["These two quinazoline-2,4-diones were 4\u20136-fold less active against the TK+ virus but proved to be 10\u201314-fold more active against the TK\u2013 strain when compared to the reference drug acyclovir.", [["quinazoline-2,4-diones", "CHEMICAL", 10, 32], ["acyclovir", "CHEMICAL", 180, 189], ["quinazoline-2,4-diones", "CHEMICAL", 10, 32], ["acyclovir", "CHEMICAL", 180, 189], ["quinazoline-2,4-diones", "SIMPLE_CHEMICAL", 10, 32], ["4\u20136", "SIMPLE_CHEMICAL", 38, 41], ["TK+ virus", "ORGANISM", 71, 80], ["acyclovir", "SIMPLE_CHEMICAL", 180, 189], ["TK+ virus", "SPECIES", 71, 80], ["These two quinazoline", "TREATMENT", 0, 21], ["diones", "TREATMENT", 26, 32], ["the TK+ virus", "PROBLEM", 67, 80], ["the TK\u2013 strain", "PROBLEM", 129, 143], ["the reference drug acyclovir", "TREATMENT", 161, 189]]], ["These data clearly indicate that these novel derivatives do not require activation by the viral TK.", [["these novel derivatives", "PROBLEM", 33, 56], ["the viral TK", "TEST", 86, 98], ["viral TK", "OBSERVATION", 90, 98]]], ["Although these quinazoline-2,4-diones did not significantly altered the morphology of cells in the antiviral assays, they showed considerable cytostatic activity (in the same range as the antiviral activity).Antiviral and cytostatic evaluation ::: Results and discussionCompounds trans-13c, a 86:14 cis-13c/trans-13c mixture, trans-13d, and a 85:15 cis-13d/trans-13d mixture inhibited both VZV TK+ and TK\u2013 viruses with EC50's in the range of 6.0\u20138.5 \u03bcM.", [["cells", "ANATOMY", 86, 91], ["quinazoline-2,4-diones", "CHEMICAL", 15, 37], ["trans-13c", "CHEMICAL", 280, 289], ["86:14 cis-13c/trans-13c", "CHEMICAL", 293, 316], ["trans-13d", "CHEMICAL", 326, 335], ["85:15 cis-13d/trans-13d", "CHEMICAL", 343, 366], ["quinazoline-2,4-diones", "CHEMICAL", 15, 37], ["quinazoline-2,4-diones", "SIMPLE_CHEMICAL", 15, 37], ["cells", "CELL", 86, 91], ["trans-13c", "SIMPLE_CHEMICAL", 280, 289], ["86:14 cis-13c", "SIMPLE_CHEMICAL", 293, 306], ["trans-13c", "SIMPLE_CHEMICAL", 307, 316], ["trans-13d", "SIMPLE_CHEMICAL", 326, 335], ["85:15 cis-13d", "SIMPLE_CHEMICAL", 343, 356], ["trans-13d", "SIMPLE_CHEMICAL", 357, 366], ["VZV", "ORGANISM", 390, 393], ["TK\u2013 viruses", "ORGANISM", 402, 413], ["VZV", "SPECIES", 390, 393], ["these quinazoline", "TREATMENT", 9, 26], ["the antiviral assays", "TEST", 95, 115], ["considerable cytostatic activity", "PROBLEM", 129, 161], ["the antiviral activity", "TREATMENT", 184, 206], ["Antiviral and cytostatic evaluation", "TEST", 208, 243], ["cis", "TEST", 299, 302], ["cis", "TEST", 349, 352], ["VZV TK", "TEST", 390, 396], ["TK\u2013 viruses", "PROBLEM", 402, 413], ["EC50's", "TEST", 419, 425], ["considerable", "OBSERVATION_MODIFIER", 129, 141], ["cytostatic activity", "OBSERVATION", 142, 161], ["VZV TK", "ANATOMY", 390, 396]]], ["Compounds trans-12a, cis-12a, cis-13a, trans-12d and a 50:50 cis-15a/trans-15a mixture also proved active against VZV TK+ strain (EC50's of 6.9\u20137.5 \u03bcM) and VZV TK\u2212 strain (EC50's of 10\u201314 \u03bcM), slightly exceeding in potency against VZV TK\u2212 strains the reference drugs acyclovir and brivudin (EC50 = 50.3 \u03bcM and 22.7, respectively).", [["trans-12a, cis-12a, cis-13a, trans-12d", "CHEMICAL", 10, 48], ["cis-15a/trans-15a", "CHEMICAL", 61, 78], ["acyclovir", "CHEMICAL", 267, 276], ["brivudin", "CHEMICAL", 281, 289], ["acyclovir", "CHEMICAL", 267, 276], ["brivudin", "CHEMICAL", 281, 289], ["trans-12a", "SIMPLE_CHEMICAL", 10, 19], ["cis-12a", "SIMPLE_CHEMICAL", 21, 28], ["cis-13a", "SIMPLE_CHEMICAL", 30, 37], ["trans-12d", "SIMPLE_CHEMICAL", 39, 48], ["50:50 cis-15a", "SIMPLE_CHEMICAL", 55, 68], ["trans-15a", "SIMPLE_CHEMICAL", 69, 78], ["VZV", "ORGANISM", 114, 117], ["TK+ strain", "ORGANISM", 118, 128], ["VZV", "ORGANISM", 156, 159], ["VZV", "ORGANISM", 231, 234], ["TK\u2212 strains", "ORGANISM", 235, 246], ["acyclovir", "SIMPLE_CHEMICAL", 267, 276], ["brivudin", "SIMPLE_CHEMICAL", 281, 289], ["VZV", "SPECIES", 114, 117], ["VZV TK\u2212 strain", "SPECIES", 156, 170], ["VZV", "SPECIES", 231, 234], ["cis", "TEST", 21, 24], ["cis", "TEST", 30, 33], ["VZV TK", "TEST", 114, 120], ["strain", "PROBLEM", 122, 128], ["EC50's", "TEST", 130, 136], ["VZV TK\u2212 strain", "PROBLEM", 156, 170], ["EC50's", "TEST", 172, 178], ["VZV TK", "TEST", 231, 237], ["acyclovir", "TREATMENT", 267, 276], ["brivudin", "TREATMENT", 281, 289], ["EC50", "TEST", 291, 295], ["VZV TK", "ANATOMY", 156, 162]]], ["However, majority of the studied compounds exhibited significant cytotoxicity and the 95:5 trans-15d/cis-15d mixture reduced cell growth (CC50) at concentration as low as 6.6 \u03bcM which was almost two orders of magnitude lower than that for acyclovir (CC50 = 440 \u03bcM).Antiviral and cytostatic evaluation ::: Results and discussionAmong the investigated quinazoline-2,4-diones, the N3-benzoylated compounds (cis- and trans-12/13) were found inactive toward both human cytomegalovirus (HCMV) strains.", [["cell", "ANATOMY", 125, 129], ["trans-15d/cis-15d", "CHEMICAL", 91, 108], ["acyclovir", "CHEMICAL", 239, 248], ["quinazoline-2,4-diones", "CHEMICAL", 350, 372], ["acyclovir", "CHEMICAL", 239, 248], ["quinazoline-2,4-diones", "CHEMICAL", 350, 372], ["N3-benzoylated", "CHEMICAL", 378, 392], ["95:5 trans-15d", "SIMPLE_CHEMICAL", 86, 100], ["cis-15d", "SIMPLE_CHEMICAL", 101, 108], ["cell", "CELL", 125, 129], ["acyclovir", "SIMPLE_CHEMICAL", 239, 248], ["quinazoline-2,4-diones", "SIMPLE_CHEMICAL", 350, 372], ["N3-benzoylated compounds", "SIMPLE_CHEMICAL", 378, 402], ["cis-", "SIMPLE_CHEMICAL", 404, 408], ["trans-12/13", "SIMPLE_CHEMICAL", 413, 424], ["human", "ORGANISM", 458, 463], ["cytomegalovirus", "ORGANISM", 464, 479], ["HCMV", "ORGANISM", 481, 485], ["human", "SPECIES", 458, 463], ["human cytomegalovirus", "SPECIES", 458, 479], ["HCMV", "SPECIES", 481, 485], ["the studied compounds", "PROBLEM", 21, 42], ["significant cytotoxicity", "PROBLEM", 53, 77], ["cis", "TEST", 101, 104], ["acyclovir", "TREATMENT", 239, 248], ["Antiviral and cytostatic evaluation", "TEST", 265, 300], ["quinazoline", "TEST", 350, 361], ["both human cytomegalovirus (HCMV) strains", "PROBLEM", 453, 494], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["cytotoxicity", "OBSERVATION", 65, 77], ["cytomegalovirus", "OBSERVATION", 464, 479]]], ["On the other hand, isoxazolidine phosphonates having benzyl substituents both at N3 of the quinazoline-2,4-dione skeleton and at N2 of the isoxazolidine ring (cis- and trans-15) showed weak antiviral activity with EC50 in the range of \u22653\u2013\u226514.5 \u03bcM (Table 4).Antiviral and cytostatic evaluation ::: Results and discussionPreliminary structure-activity relationship observations revealed a lack of significant differences in activity of cis vs. trans isoxazolidines and higher potency of isoxazolidines carrying N-benzyl substituents in comparison with their N-methyl counterparts especially well pronounced for the N3-benzylquinazoline-2,4-diones 15.", [["isoxazolidine phosphonates", "CHEMICAL", 19, 45], ["benzyl substituents", "CHEMICAL", 53, 72], ["N3 of the quinazoline-2,4-dione", "CHEMICAL", 81, 112], ["isoxazolidine", "CHEMICAL", 139, 152], ["cis- and trans-15", "CHEMICAL", 159, 176], ["isoxazolidines", "CHEMICAL", 448, 462], ["isoxazolidines", "CHEMICAL", 485, 499], ["N-benzyl substituents", "CHEMICAL", 509, 530], ["N-methyl", "CHEMICAL", 556, 564], ["N3-benzylquinazoline-2,4-diones", "CHEMICAL", 613, 644], ["isoxazolidine phosphonates", "CHEMICAL", 19, 45], ["benzyl", "CHEMICAL", 53, 59], ["quinazoline-2,4-dione", "CHEMICAL", 91, 112], ["N2", "CHEMICAL", 129, 131], ["isoxazolidine", "CHEMICAL", 139, 152], ["isoxazolidines", "CHEMICAL", 448, 462], ["isoxazolidines", "CHEMICAL", 485, 499], ["N-benzyl", "CHEMICAL", 509, 517], ["N-methyl", "CHEMICAL", 556, 564], ["N3-benzylquinazoline-2,4-diones", "CHEMICAL", 613, 644], ["isoxazolidine phosphonates", "SIMPLE_CHEMICAL", 19, 45], ["benzyl substituents", "SIMPLE_CHEMICAL", 53, 72], ["quinazoline-2,4-dione", "SIMPLE_CHEMICAL", 91, 112], ["isoxazolidine ring", "SIMPLE_CHEMICAL", 139, 157], ["cis-", "SIMPLE_CHEMICAL", 159, 163], ["trans-15", "SIMPLE_CHEMICAL", 168, 176], ["trans isoxazolidines", "SIMPLE_CHEMICAL", 442, 462], ["isoxazolidines", "SIMPLE_CHEMICAL", 485, 499], ["N-benzyl substituents", "SIMPLE_CHEMICAL", 509, 530], ["N3-benzylquinazoline-2,4-diones 15", "SIMPLE_CHEMICAL", 613, 647], ["isoxazolidine phosphonates", "TREATMENT", 19, 45], ["benzyl substituents", "TREATMENT", 53, 72], ["the quinazoline", "TREATMENT", 87, 102], ["the isoxazolidine ring", "TREATMENT", 135, 157], ["weak antiviral activity", "PROBLEM", 185, 208], ["EC50", "TEST", 214, 218], ["Antiviral and cytostatic evaluation", "TEST", 257, 292], ["significant differences in activity of cis", "PROBLEM", 395, 437], ["trans isoxazolidines", "TREATMENT", 442, 462], ["isoxazolidines carrying N-benzyl substituents", "TREATMENT", 485, 530], ["benzylquinazoline", "TREATMENT", 616, 633], ["skeleton", "ANATOMY", 113, 121], ["antiviral activity", "OBSERVATION", 190, 208]]], ["For the active compounds the introduction of a fluorine atom into the benzene ring either in benzyl or benzoyl residues did not improve their efficacy.", [["fluorine", "CHEMICAL", 47, 55], ["benzene", "CHEMICAL", 70, 77], ["benzyl", "CHEMICAL", 93, 99], ["benzoyl", "CHEMICAL", 103, 110], ["fluorine", "CHEMICAL", 47, 55], ["benzene", "CHEMICAL", 70, 77], ["benzyl", "CHEMICAL", 93, 99], ["benzoyl", "CHEMICAL", 103, 110], ["fluorine atom", "SIMPLE_CHEMICAL", 47, 60], ["benzene ring", "SIMPLE_CHEMICAL", 70, 82], ["benzyl", "SIMPLE_CHEMICAL", 93, 99], ["benzoyl", "SIMPLE_CHEMICAL", 103, 110], ["a fluorine atom", "TREATMENT", 45, 60], ["the benzene ring", "TREATMENT", 66, 82], ["benzyl", "TREATMENT", 93, 99], ["benzoyl residues", "TREATMENT", 103, 119], ["active", "OBSERVATION_MODIFIER", 8, 14], ["compounds", "OBSERVATION", 15, 24]]], ["While the quinazoline-2,4-diones substituted at N3 with benzoyl and benzyl moieties were found effective against VZV, only those carrying substituted benzyl components proved active toward HMCV.Antiviral and cytostatic evaluation ::: Results and discussionAll synthesized isoxazolidine phosphonates were also subjected to antiviral screening with other viruses, but only compound trans-12d appeared slightly active against other herpesviruses, adenovirus-2 and human Coronavirus (Table 5).Cytostatic activity ::: Results and discussionThe 50% cytostatic inhibitory concentration (IC50) causing a 50% decrease in cell proliferation was determined against murine leukemia L1210, human lymphocyte CEM, human cervix carcinoma HeLa and immortalized human dermal microvacsular endothelial cells (HMEC-1) (Table 6).", [["cell", "ANATOMY", 612, 616], ["leukemia L1210", "ANATOMY", 661, 675], ["lymphocyte CEM", "ANATOMY", 683, 697], ["cervix carcinoma HeLa", "ANATOMY", 705, 726], ["dermal microvacsular endothelial cells", "ANATOMY", 750, 788], ["HMEC-1", "ANATOMY", 790, 796], ["quinazoline-2,4-diones", "CHEMICAL", 10, 32], ["N3", "CHEMICAL", 48, 50], ["benzoyl", "CHEMICAL", 56, 63], ["benzyl", "CHEMICAL", 68, 74], ["benzyl", "CHEMICAL", 150, 156], ["isoxazolidine phosphonates", "CHEMICAL", 272, 298], ["trans-12d", "CHEMICAL", 380, 389], ["leukemia L1210", "DISEASE", 661, 675], ["cervix carcinoma", "DISEASE", 705, 721], ["quinazoline-2,4-diones", "CHEMICAL", 10, 32], ["N3", "CHEMICAL", 48, 50], ["benzoyl", "CHEMICAL", 56, 63], ["benzyl", "CHEMICAL", 68, 74], ["benzyl", "CHEMICAL", 150, 156], ["isoxazolidine phosphonates", "CHEMICAL", 272, 298], ["quinazoline-2,4-diones", "SIMPLE_CHEMICAL", 10, 32], ["N3", "SIMPLE_CHEMICAL", 48, 50], ["benzoyl", "SIMPLE_CHEMICAL", 56, 63], ["benzyl moieties", "SIMPLE_CHEMICAL", 68, 83], ["VZV", "ORGANISM", 113, 116], ["benzyl components", "SIMPLE_CHEMICAL", 150, 167], ["HMCV", "SIMPLE_CHEMICAL", 189, 193], ["isoxazolidine phosphonates", "SIMPLE_CHEMICAL", 272, 298], ["trans-12d", "SIMPLE_CHEMICAL", 380, 389], ["herpesviruses", "ORGANISM", 429, 442], ["adenovirus-2", "ORGANISM", 444, 456], ["human", "ORGANISM", 461, 466], ["cell", "CELL", 612, 616], ["murine", "ORGANISM", 654, 660], ["leukemia L1210", "CELL", 661, 675], ["human", "ORGANISM", 677, 682], ["lymphocyte CEM", "CELL", 683, 697], ["human", "ORGANISM", 699, 704], ["cervix carcinoma HeLa", "CELL", 705, 726], ["human", "ORGANISM", 744, 749], ["dermal microvacsular endothelial cells", "CELL", 750, 788], ["HMEC-1", "CELL", 790, 796], ["murine leukemia L1210", "CELL_LINE", 654, 675], ["human lymphocyte CEM", "CELL_LINE", 677, 697], ["human cervix carcinoma HeLa", "CELL_LINE", 699, 726], ["immortalized human dermal microvacsular endothelial cells", "CELL_LINE", 731, 788], ["HMEC-1", "CELL_LINE", 790, 796], ["human", "SPECIES", 461, 466], ["murine", "SPECIES", 654, 660], ["human", "SPECIES", 677, 682], ["human", "SPECIES", 699, 704], ["human", "SPECIES", 744, 749], ["VZV", "SPECIES", 113, 116], ["human", "SPECIES", 461, 466], ["human", "SPECIES", 677, 682], ["human", "SPECIES", 699, 704], ["human", "SPECIES", 744, 749], ["the quinazoline", "TREATMENT", 6, 21], ["diones", "TREATMENT", 26, 32], ["benzoyl", "TREATMENT", 56, 63], ["benzyl moieties", "TREATMENT", 68, 83], ["VZV", "PROBLEM", 113, 116], ["substituted benzyl components", "TREATMENT", 138, 167], ["Antiviral and cytostatic evaluation", "TEST", 194, 229], ["All synthesized isoxazolidine phosphonates", "TREATMENT", 256, 298], ["antiviral screening", "TEST", 322, 341], ["other viruses", "PROBLEM", 347, 360], ["slightly active", "PROBLEM", 399, 414], ["other herpesviruses", "PROBLEM", 423, 442], ["adenovirus", "TEST", 444, 454], ["The 50% cytostatic inhibitory concentration", "TREATMENT", 535, 578], ["a 50% decrease in cell proliferation", "PROBLEM", 594, 630], ["murine leukemia L1210", "PROBLEM", 654, 675], ["human lymphocyte CEM", "TEST", 677, 697], ["human cervix carcinoma HeLa", "PROBLEM", 699, 726], ["immortalized human dermal microvacsular endothelial cells", "TREATMENT", 731, 788], ["HMEC", "TEST", 790, 794], ["slightly", "OBSERVATION_MODIFIER", 399, 407], ["active", "OBSERVATION", 408, 414], ["cell proliferation", "OBSERVATION", 612, 630], ["leukemia L1210", "OBSERVATION", 661, 675], ["lymphocyte CEM", "OBSERVATION", 683, 697], ["cervix carcinoma", "OBSERVATION", 705, 721], ["microvacsular endothelial cells", "OBSERVATION", 757, 788]]], ["Among all tested compounds only quinazoline-2,4-diones trans-15/cis-15 having benzyl substituents at N3 in the quinazolinone core and the benzyl group at N2 of the isoxazolidine unit showed significant cytostatic activity toward the tested cell lines.", [["cell lines", "ANATOMY", 240, 250], ["quinazoline-2,4-diones trans-15/cis-15", "CHEMICAL", 32, 70], ["benzyl substituents", "CHEMICAL", 78, 97], ["N3", "CHEMICAL", 101, 103], ["quinazolinone", "CHEMICAL", 111, 124], ["benzyl", "CHEMICAL", 138, 144], ["isoxazolidine", "CHEMICAL", 164, 177], ["quinazoline-2,4-diones", "CHEMICAL", 32, 54], ["benzyl", "CHEMICAL", 78, 84], ["N3", "CHEMICAL", 101, 103], ["quinazolinone", "CHEMICAL", 111, 124], ["benzyl", "CHEMICAL", 138, 144], ["N2", "CHEMICAL", 154, 156], ["isoxazolidine", "CHEMICAL", 164, 177], ["quinazoline-2,4-diones trans-15/cis-15", "SIMPLE_CHEMICAL", 32, 70], ["benzyl substituents", "SIMPLE_CHEMICAL", 78, 97], ["N3", "SIMPLE_CHEMICAL", 101, 103], ["quinazolinone", "SIMPLE_CHEMICAL", 111, 124], ["benzyl", "SIMPLE_CHEMICAL", 138, 144], ["isoxazolidine", "SIMPLE_CHEMICAL", 164, 177], ["cell lines", "CELL", 240, 250], ["tested cell lines", "CELL_LINE", 233, 250], ["quinazoline", "TREATMENT", 32, 43], ["cis", "TEST", 64, 67], ["benzyl substituents", "TREATMENT", 78, 97], ["the quinazolinone core", "TREATMENT", 107, 129], ["the benzyl group", "TREATMENT", 134, 150], ["the isoxazolidine unit", "TREATMENT", 160, 182], ["significant cytostatic activity", "PROBLEM", 190, 221], ["significant", "OBSERVATION_MODIFIER", 190, 201], ["cytostatic activity", "OBSERVATION", 202, 221], ["tested cell lines", "OBSERVATION", 233, 250]]], ["For the CEM cell line, these derivatives were as active as the reference drug 5-fluorouracil.", [["CEM cell line", "ANATOMY", 8, 21], ["5-fluorouracil", "CHEMICAL", 78, 92], ["5-fluorouracil", "CHEMICAL", 78, 92], ["CEM cell line", "CELL", 8, 21], ["5-fluorouracil", "SIMPLE_CHEMICAL", 78, 92], ["CEM cell line", "CELL_LINE", 8, 21], ["the CEM cell line", "TREATMENT", 4, 21], ["these derivatives", "TREATMENT", 23, 40], ["fluorouracil", "TREATMENT", 80, 92], ["CEM cell line", "OBSERVATION", 8, 21]]], ["It was noticed that the replacement of the benzyl component within the isoxazolidine moiety for the methyl group (trans-15/cis-15 vs. the respective trans-14/cis-14) resulted in decrease in potency by roughly an order of magnitude.ConclusionsSeveral series of {5-(2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl-2-methylisoxazolidin-3-yl})phosphonates (cis-12/trans-12 and cis-14/trans-14) and {5-(2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl-2-benzylisoxazolidin-3-yl})phosphonates (cis-13/trans-13 and cis-15/trans-15) modified at N3 in the quinazoline-2,4-dione moiety have been obtained by the 1,3-dipolar cycloaddition of N-substituted (C-diethoxyphosphoryl)nitrones 16 (R=Me) and 17 (R=Bn) and the respective N1-allylated quinazoline-2,4-diones substituted at N3 with benzoyl (compounds 18) or benzyl groups (compounds 19).ConclusionsThe synthesized isoxazolidine phosphonates were evaluated against a variety of DNA and RNA viruses and several derivatives appeared to be active against varicella-zoster virus and human cytomegalovirus.", [["benzyl", "CHEMICAL", 43, 49], ["isoxazolidine", "CHEMICAL", 71, 84], ["methyl", "CHEMICAL", 100, 106], ["{5-(2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl-2-methylisoxazolidin-3-yl}", "CHEMICAL", 260, 338], ["phosphonates", "CHEMICAL", 339, 351], ["{5-(2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl-2-benzylisoxazolidin-3-yl}", "CHEMICAL", 394, 472], ["phosphonates", "CHEMICAL", 473, 485], ["cis-13", "CHEMICAL", 487, 493], ["N3", "CHEMICAL", 536, 538], ["quinazoline-2,4-dione", "CHEMICAL", 546, 567], ["N-substituted (C-diethoxyphosphoryl)nitrones", "CHEMICAL", 630, 674], ["N1-allylated quinazoline-2,4-diones", "CHEMICAL", 718, 753], ["N3", "CHEMICAL", 769, 771], ["benzoyl", "CHEMICAL", 777, 784], ["benzyl", "CHEMICAL", 803, 809], ["isoxazolidine phosphonates", "CHEMICAL", 859, 885], ["varicella-zoster", "DISEASE", 996, 1012], ["benzyl", "CHEMICAL", 43, 49], ["isoxazolidine", "CHEMICAL", 71, 84], ["methyl", "CHEMICAL", 100, 106], ["{5-(2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl-2-methylisoxazolidin-3-yl})phosphonates", "CHEMICAL", 260, 351], ["cis-12", "CHEMICAL", 353, 359], ["cis-14", "CHEMICAL", 373, 379], ["{5-(2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl-2-benzylisoxazolidin-3-yl})phosphonates", "CHEMICAL", 394, 485], ["cis-13", "CHEMICAL", 487, 493], ["cis-15", "CHEMICAL", 507, 513], ["N3", "CHEMICAL", 536, 538], ["quinazoline-2,4-dione", "CHEMICAL", 546, 567], ["N-substituted (C-diethoxyphosphoryl)nitrones", "CHEMICAL", 630, 674], ["Me", "CHEMICAL", 681, 683], ["N1-allylated quinazoline-2,4-diones", "CHEMICAL", 718, 753], ["N3", "CHEMICAL", 769, 771], ["benzoyl", "CHEMICAL", 777, 784], ["benzyl", "CHEMICAL", 803, 809], ["isoxazolidine phosphonates", "CHEMICAL", 859, 885], ["benzyl", "SIMPLE_CHEMICAL", 43, 49], ["isoxazolidine moiety", "SIMPLE_CHEMICAL", 71, 91], ["methyl", "SIMPLE_CHEMICAL", 100, 106], ["trans-15", "SIMPLE_CHEMICAL", 114, 122], ["cis-15", "SIMPLE_CHEMICAL", 123, 129], ["trans-14/cis-14", "SIMPLE_CHEMICAL", 149, 164], ["{5-(2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl-2-methylisoxazolidin-3-yl})phosphonates", "SIMPLE_CHEMICAL", 260, 351], ["cis-12/trans-12", "SIMPLE_CHEMICAL", 353, 368], ["cis-14/trans-14)", "SIMPLE_CHEMICAL", 373, 389], ["{5-(2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl-2-benzylisoxazolidin-3-yl})phosphonates", "SIMPLE_CHEMICAL", 394, 485], ["cis-13/trans-13", "SIMPLE_CHEMICAL", 487, 502], ["cis-15/trans-15", "SIMPLE_CHEMICAL", 507, 522], ["quinazoline-2,4-dione moiety", "SIMPLE_CHEMICAL", 546, 574], ["1,3-dipolar", "SIMPLE_CHEMICAL", 601, 612], ["N-substituted (C-diethoxyphosphoryl)nitrones 16 (R=Me)", "SIMPLE_CHEMICAL", 630, 684], ["17 (R=Bn)", "SIMPLE_CHEMICAL", 689, 698], ["N1-allylated quinazoline-2,4-diones", "SIMPLE_CHEMICAL", 718, 753], ["N3", "SIMPLE_CHEMICAL", 769, 771], ["benzoyl (compounds 18) or benzyl groups", "SIMPLE_CHEMICAL", 777, 816], ["isoxazolidine phosphonates", "SIMPLE_CHEMICAL", 859, 885], ["DNA", "CELLULAR_COMPONENT", 922, 925], ["varicella-zoster virus", "ORGANISM", 996, 1018], ["human", "ORGANISM", 1023, 1028], ["cytomegalovirus", "ORGANISM", 1029, 1044], ["varicella-zoster virus", "SPECIES", 996, 1018], ["human", "SPECIES", 1023, 1028], ["varicella-zoster virus", "SPECIES", 996, 1018], ["human cytomegalovirus", "SPECIES", 1023, 1044], ["the benzyl component", "TREATMENT", 39, 59], ["the isoxazolidine moiety", "TREATMENT", 67, 91], ["the methyl group", "TREATMENT", 96, 112], ["cis", "TEST", 123, 126], ["Several series", "TEST", 242, 256], ["{5", "TEST", 260, 262], ["dioxo", "TEST", 268, 273], ["methyl", "TREATMENT", 305, 311], ["phosphonates (cis", "TREATMENT", 339, 356], ["dioxo", "TEST", 402, 407], ["dihydroquinazolin", "TREATMENT", 412, 429], ["methyl", "TREATMENT", 439, 445], ["benzylisoxazolidin-3", "TREATMENT", 448, 468], ["phosphonates", "TREATMENT", 473, 485], ["cis", "TEST", 487, 490], ["the quinazoline", "TREATMENT", 542, 557], ["dione moiety", "TREATMENT", 562, 574], ["dipolar cycloaddition of N-substituted (C-diethoxyphosphoryl)nitrones", "TREATMENT", 605, 674], ["the respective N1", "TREATMENT", 703, 720], ["allylated quinazoline", "TREATMENT", 721, 742], ["diones", "TREATMENT", 747, 753], ["benzoyl (compounds", "TREATMENT", 777, 795], ["benzyl groups", "TREATMENT", 803, 816], ["The synthesized isoxazolidine phosphonates", "TREATMENT", 843, 885], ["DNA", "PROBLEM", 922, 925], ["RNA viruses", "PROBLEM", 930, 941], ["several derivatives", "PROBLEM", 946, 965], ["varicella-zoster virus", "PROBLEM", 996, 1018], ["human cytomegalovirus", "PROBLEM", 1023, 1044], ["decrease", "OBSERVATION_MODIFIER", 178, 186], ["RNA viruses", "OBSERVATION", 930, 941], ["zoster virus", "OBSERVATION", 1006, 1018]]], ["Among all tested compounds, a 95:5 trans-15d/cis-15d (95:5) (EC50 = 3.0 \u03bcM) and a cis-15b/trans-15b (87:13) (EC50 = 4.7 \u03bcM) showed the highest activity toward TK+ VZV strain.", [["95:5 trans-15d/cis-15d", "CHEMICAL", 30, 52], ["cis-15b/trans-15b", "CHEMICAL", 82, 99], ["cis-15b", "CHEMICAL", 82, 89], ["95:5 trans-15d", "SIMPLE_CHEMICAL", 30, 44], ["cis-15d", "SIMPLE_CHEMICAL", 45, 52], ["trans-15b", "SIMPLE_CHEMICAL", 90, 99], ["VZV", "ORGANISM", 163, 166], ["VZV", "SPECIES", 163, 166], ["cis", "TEST", 45, 48], ["EC50", "TEST", 61, 65], ["a cis-15b/trans", "TEST", 80, 95], ["EC50", "TEST", 109, 113], ["TK", "TEST", 159, 161], ["VZV strain", "PROBLEM", 163, 173], ["VZV strain", "OBSERVATION", 163, 173]]], ["The potency of these derivatives was 4\u20136 fold lower than that of acyclovir, used as reference drug.ConclusionsOn the other hand, compounds trans-13c, mixture cis-13c/trans-13c (86:14), trans-13d, and a 85:15 mixture of cis-13d/trans-13d exhibited potency not only against TK+ VZV strain but also toward TK\u2212 VZV strain and their anti-TK\u2212 VZV activity was significantly higher than that of the reference drugs acyclovir and brivudin (EC50 = 50.3 and 22.7 \u03bcM, respectively).", [["acyclovir", "CHEMICAL", 65, 74], ["trans-13c, mixture cis-13c/trans-13c (86:14), trans-13d", "CHEMICAL", 139, 194], ["cis-13d/trans-13d", "CHEMICAL", 219, 236], ["acyclovir", "CHEMICAL", 408, 417], ["brivudin", "CHEMICAL", 422, 430], ["acyclovir", "CHEMICAL", 65, 74], ["acyclovir", "CHEMICAL", 408, 417], ["brivudin", "CHEMICAL", 422, 430], ["acyclovir", "SIMPLE_CHEMICAL", 65, 74], ["trans-13c", "SIMPLE_CHEMICAL", 139, 148], ["cis-13c", "SIMPLE_CHEMICAL", 158, 165], ["trans-13c", "SIMPLE_CHEMICAL", 166, 175], ["86:14)", "SIMPLE_CHEMICAL", 177, 183], ["trans-13d", "SIMPLE_CHEMICAL", 185, 194], ["cis-13d/trans-13d", "SIMPLE_CHEMICAL", 219, 236], ["TK+ VZV", "ORGANISM", 272, 279], ["TK\u2212 VZV", "ORGANISM", 303, 310], ["anti-TK\u2212 VZV", "ORGANISM", 328, 340], ["acyclovir", "SIMPLE_CHEMICAL", 408, 417], ["brivudin", "SIMPLE_CHEMICAL", 422, 430], ["VZV", "SPECIES", 276, 279], ["TK\u2212 VZV", "SPECIES", 303, 310], ["VZV", "SPECIES", 337, 340], ["these derivatives", "TREATMENT", 15, 32], ["acyclovir", "TREATMENT", 65, 74], ["mixture cis", "TEST", 150, 161], ["cis", "TEST", 219, 222], ["TK+ VZV strain", "PROBLEM", 272, 286], ["TK\u2212 VZV strain", "PROBLEM", 303, 317], ["VZV activity", "PROBLEM", 337, 349], ["acyclovir", "TREATMENT", 408, 417], ["brivudin", "TREATMENT", 422, 430], ["EC50", "TEST", 432, 436], ["potency", "OBSERVATION_MODIFIER", 4, 11], ["hand", "ANATOMY", 123, 127], ["VZV", "OBSERVATION", 276, 279], ["VZV strain", "OBSERVATION", 307, 317]]], ["The isoxazolidine phosphonates cis-15a-d/trans-15a-d having benzyl substituents both at N3 of the quinazoline-2,4-dione skeleton and at N2 of the isoxazolidine ring (cis- and trans-5) showed some activity toward human cytomegalovirus (EC50 in the range of \u22653 to \u226514.5 \u03bcM).ConclusionsThe quinazoline-2,4-diones endowed with anti-VZV and anti-HCMV activity did not alter the morphology of cells used in the antiviral assays up to a concentration of 100 \u03bcM.", [["cells", "ANATOMY", 387, 392], ["isoxazolidine", "CHEMICAL", 4, 17], ["cis-15a-d/trans-15a-d", "CHEMICAL", 31, 52], ["benzyl substituents", "CHEMICAL", 60, 79], ["N3 of the quinazoline-2,4-dione", "CHEMICAL", 88, 119], ["isoxazolidine", "CHEMICAL", 146, 159], ["cis- and trans-5", "CHEMICAL", 166, 182], ["quinazoline-2,4-diones", "CHEMICAL", 287, 309], ["isoxazolidine phosphonates", "CHEMICAL", 4, 30], ["benzyl", "CHEMICAL", 60, 66], ["quinazoline-2,4-dione", "CHEMICAL", 98, 119], ["N2", "CHEMICAL", 136, 138], ["isoxazolidine", "CHEMICAL", 146, 159], ["quinazoline-2,4-diones", "CHEMICAL", 287, 309], ["isoxazolidine phosphonates cis-15a-d", "SIMPLE_CHEMICAL", 4, 40], ["trans-15a-d", "SIMPLE_CHEMICAL", 41, 52], ["benzyl substituents", "SIMPLE_CHEMICAL", 60, 79], ["N3", "SIMPLE_CHEMICAL", 88, 90], ["quinazoline-2,4-dione skeleton", "SIMPLE_CHEMICAL", 98, 128], ["isoxazolidine ring", "SIMPLE_CHEMICAL", 146, 164], ["cis-", "SIMPLE_CHEMICAL", 166, 170], ["trans-5)", "SIMPLE_CHEMICAL", 175, 183], ["human", "ORGANISM", 212, 217], ["cytomegalovirus", "ORGANISM", 218, 233], ["quinazoline-2,4-diones", "SIMPLE_CHEMICAL", 287, 309], ["anti-VZV", "SIMPLE_CHEMICAL", 323, 331], ["anti-HCMV", "SIMPLE_CHEMICAL", 336, 345], ["cells", "CELL", 387, 392], ["human", "SPECIES", 212, 217], ["human cytomegalovirus", "SPECIES", 212, 233], ["anti-VZV", "SPECIES", 323, 331], ["The isoxazolidine phosphonates cis", "TREATMENT", 0, 34], ["benzyl substituents", "TREATMENT", 60, 79], ["the quinazoline", "TREATMENT", 94, 109], ["the isoxazolidine ring", "TREATMENT", 142, 164], ["human cytomegalovirus", "PROBLEM", 212, 233], ["EC50", "TEST", 235, 239], ["The quinazoline", "TREATMENT", 283, 298], ["anti-VZV", "TREATMENT", 323, 331], ["anti-HCMV activity", "TREATMENT", 336, 354], ["skeleton", "ANATOMY", 120, 128], ["cytomegalovirus", "OBSERVATION", 218, 233]]], ["However, these derivatives showed considerable cytostatic activity.", [["these derivatives", "TEST", 9, 26], ["considerable cytostatic activity", "PROBLEM", 34, 66], ["considerable", "OBSERVATION_MODIFIER", 34, 46], ["cytostatic activity", "OBSERVATION", 47, 66]]], ["Cytostatic activity of the obtained compounds was also evaluated on L1210, CEM, HeLa and HMEC-1 cells.", [["L1210", "ANATOMY", 68, 73], ["CEM", "ANATOMY", 75, 78], ["HeLa", "ANATOMY", 80, 84], ["HMEC-1 cells", "ANATOMY", 89, 101], ["L1210", "CELL", 68, 73], ["CEM", "CELL", 75, 78], ["HeLa", "CELL", 80, 84], ["HMEC-1 cells", "CELL", 89, 101], ["L1210", "CELL_LINE", 68, 73], ["CEM", "CELL_LINE", 75, 78], ["HeLa", "CELL_LINE", 80, 84], ["HMEC-1 cells", "CELL_LINE", 89, 101], ["Cytostatic activity", "PROBLEM", 0, 19], ["L1210", "TEST", 68, 73], ["CEM", "TEST", 75, 78], ["HeLa", "TEST", 80, 84], ["HMEC", "TEST", 89, 93], ["HeLa", "ANATOMY", 80, 84]]], ["Among all tested compounds, only quinazoline-2,4-diones (trans-15/cis-15) bearing benzyl substituents at N3 in the quinazolinone core and the benzyl group at N2 of the isoxazolidine unit showed significant (IC50 = 10\u201398 \u03bcM) activity toward tested cell lines.General ::: Experimental", [["cell lines", "ANATOMY", 247, 257], ["quinazoline-2,4-diones", "CHEMICAL", 33, 55], ["trans-15/cis-15", "CHEMICAL", 57, 72], ["benzyl substituents", "CHEMICAL", 82, 101], ["N3", "CHEMICAL", 105, 107], ["quinazolinone", "CHEMICAL", 115, 128], ["benzyl", "CHEMICAL", 142, 148], ["isoxazolidine", "CHEMICAL", 168, 181], ["quinazoline-2,4-diones", "CHEMICAL", 33, 55], ["benzyl", "CHEMICAL", 82, 88], ["N3", "CHEMICAL", 105, 107], ["quinazolinone", "CHEMICAL", 115, 128], ["benzyl", "CHEMICAL", 142, 148], ["N2", "CHEMICAL", 158, 160], ["isoxazolidine", "CHEMICAL", 168, 181], ["quinazoline-2,4-diones", "SIMPLE_CHEMICAL", 33, 55], ["trans-15/cis-15)", "SIMPLE_CHEMICAL", 57, 73], ["benzyl substituents", "SIMPLE_CHEMICAL", 82, 101], ["N3", "SIMPLE_CHEMICAL", 105, 107], ["quinazolinone", "SIMPLE_CHEMICAL", 115, 128], ["benzyl", "SIMPLE_CHEMICAL", 142, 148], ["isoxazolidine", "SIMPLE_CHEMICAL", 168, 181], ["cell lines", "CELL", 247, 257], ["cell lines", "CELL_LINE", 247, 257], ["quinazoline", "TREATMENT", 33, 44], ["bearing benzyl substituents", "TREATMENT", 74, 101], ["the quinazolinone core", "TREATMENT", 111, 133], ["the benzyl group", "TREATMENT", 138, 154], ["the isoxazolidine unit", "TREATMENT", 164, 186], ["IC50", "TEST", 207, 211], ["cell lines", "OBSERVATION", 247, 257]]]], "PMC7319616": [], "e3c64e982187fc7d41bd555c9aae1898faf09729": [["increasing throughout the study period, except for benzene, which continuously decreased.", [["benzene", "CHEMICAL", 51, 58], ["benzene", "CHEMICAL", 51, 58], ["benzene", "SIMPLE_CHEMICAL", 51, 58], ["benzene", "PROBLEM", 51, 58], ["decreased", "OBSERVATION_MODIFIER", 79, 88]]]]}